| Excerpt | Reference |
|---|
| "Colorectal cancer is a common and devastating disease." | ( Flareau, BJ; Oldenski, RJ, 1992) |
| "Since human colorectal tumors are insensitive to most chemotherapeutic agents, there is a need for the discovery of new drugs that would show activity against this disease." | ( Beaune, PH; Chabot, GG; de Waziers, I; Gouyette, A; Janot, F; Massaad, L; Morizet, J; Ribrag, V, 1992) |
| "Diagnosis for colorectal cancer is commonly made using either colonoscopy or double contrast barium enema techniques." | ( Chamberlain, JO; Hardcastle, JD; Walker, AR; Whynes, DK, 1991) |
| "As colorectal cancer is less sensitive than other tissues to various chemotherapeutic agents, we recommend that MMC and CQ be prescribed to treat patients with these malignant lesions." | ( Emi, Y; Kohnoe, S; Kusumoto, T; Maehara, Y; Sakaguchi, Y; Sugimachi, K, 1991) |
| "The causes of colorectal cancer are complex and in most cases obscure, making primary prevention impossible at present." | ( Kronborg, O, 1991) |
| "The diagnosis of colorectal carcinoma is based on double-contrast barium enema and endoscopy." | ( Deininger, HK; Gaa, J, 1990) |
| "Screening for colorectal cancer is optional." | ( Eddy, DM, 1990) |
| "Colorectal cancer is the second most common cause of cancer in the United States." | ( Browning, TH; Cooper, JN; Fleischer, DE; Friedman, E; Goldberg, SB; Goldner, FH; Keeffe, EB; Smith, LE, 1989) |
| "Colorectal cancer is the second most common cancer in the Western world, and yet the survival after potentially curative excisional surgery has improved little over the last half century." | ( Leicester, RJ; Mansi, JL; Rayter, Z, 1995) |
| "Most deaths from colorectal carcinoma are due to metastases." | ( Higgs, D; Leathem, A; Loizidou, M; Pickering, R; Schumacher, U; Taylor, I, 1994) |
| "Colorectal cancer is the second most common cause of overall cancer mortality in the United States." | ( Ferrucci, JT, 1993) |
| "Colorectal carcinoma is the second most common cancer that occurs in women and men." | ( Ott, DJ, 1993) |
| "Colorectal cancer is second only to lung cancer in the number of lives it claims annually, yet it is a curable cancer." | ( Burhenne, HJ; Donald, JJ, 1993) |
| "Colorectal cancer is a disease of elderly subjects." | ( de Haan, AF; Hopman, WP; Jansen, JB; Nagengast, FM; Salemans, JM; Tangerman, A; van Schaik, A, 1993) |
| "Metastatic colorectal cancer is generally incurable." | ( Abbruzzese, JL; Brown, BW; Gross, HM; Jones, DV; Levin, B; Levy, LB; Pendergrass, KB; Pugh, RP; Wade, JL; Winn, RJ, 1995) |
| "bcl-2 expression in colorectal carcinomas is associated with a better clinical course." | ( Baretton, GB; Christoforis, G; Diebold, J; Dopfer, K; Löhrs, U; Müller, C; Schmidt, M; Schneiderbanger, K; Vogt, M, 1996) |
| "Colorectal cancer is one of the major malignant diseases and, recently, its incidence appears to be increasing." | ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996) |
| "Colorectal cancer is the second leading cause of death from cancer in the United States." | ( Beauchamp, RD; DuBois, RN; Shao, J; Sheng, H; Tsujii, M, 1996) |
| "Colorectal cancer is one of the tumors most refractory to treatment by chemotherapy." | ( Hotta, T; Ishimoto, K; Iwahashi, M; Murakami, K; Nakamori, M; Noguchi, K; Tani, M; Tanimura, H; Yamaue, H, 1996) |
| "Many patients with colorectal cancer are not amenable to curative resection at the time of presentation." | ( Chia, YW; Tai, LS, 1996) |
| "Colorectal cancer is a common cancer and a common cause of death." | ( Bleiberg, H, 1996) |
| "Colorectal cancer is a major disease of Western civilizations and diet may account for approximately 35% of cases." | ( Owen, RW, 1997) |
| "Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy." | ( Beuzeboc, P; Deffontaines, D; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, S, 1996) |
| "Colorectal cancer is the third leading cause of cancer mortality for men and women in the United States." | ( O'Reilly, S; Rowinsky, EK, 1997) |
| "Colorectal cancer is a prevalent and mortal disease, resulting in nearly 55,000 deaths in the United States annually." | ( Ong, J; Stabile, B; Stamos, M; Stuntz, M; Wilmoth, G, 1997) |
| "Colorectal carcinoma is the third leading cause of cancer-related death." | ( Machover, D, 1997) |
| "Colorectal cancer is the second most common cancer in the Western world and nearly two-thirds of patients will require palliative treatment." | ( Kerr, DJ; O'Connor, KM, 1997) |
| "Advanced colorectal cancer is currently treated with 5-fluorouracil, generally in combination with other agents such as leucovorin." | ( Judson, IR, 1997) |
| "Colorectal cancer is one of the most frequent cancers in western countries." | ( Bleiberg, H; Gerard, B, 1997) |
| "Colorectal cancer is the third most common cause of cancer-related death in both men and women." | ( Creemers, GJ, 1997) |
| "Colorectal cancer is the second leading cause of cancer death in western countries." | ( Borner, M; Maurer, C, 1998) |
| "Colorectal cancer is the third leading cause of cancer-related mortality and a significant public health problem in the United States." | ( Singh, AK; Trotman, BW, 1998) |
| "Colorectal cancer is one of the most frequent cancers in the western world." | ( Kamm, YJ; Punt, CJ; Rietjens, IM; Wagener, DJ, 1998) |
| "Colorectal cancer is the second most lethal cancer in the United States." | ( Inger, DB, 1999) |
| "Colorectal cancer is the fourth most common cancer and the second leading cause of cancer death in the United States." | ( Grodstein, F; Newcomb, PA; Stampfer, MJ, 1999) |
| "Breast and colorectal cancer are main causes of death in industrialized countries." | ( de Deckere, EA, 1999) |
| "Colorectal carcinoma is an important cause of cancer morbidity and mortality." | ( Adjei, AA, 1999) |
| "Colorectal cancer is one of the most common internal malignancies in Western society." | ( de Kok, TM; van Maanen, JM, 2000) |
| "Liver metastases of colorectal cancer is present in more than 20% of new diagnosed patients and in 40-60% of relapsed patients." | ( Cariello, A; Dazzi, C; De Giorgi, U; Fiorentini, G; Giovanis, P; Guglielminetti, D; Latino, W; Leoni, M; Marangolo, M; Poddie, DB; Turci, D, 2000) |
| "Colorectal cancer is widely treated with 5-FU, which leads to thymidylate synthase inhibition; this accounts for increased dUTP intracellular pools and subsequent uracil incorporation into DNA." | ( Dusseau, C; Keenan, RA; Krokan, HE; McLeod, HL; Murray, GI; O'Kelly, T, 2001) |
| "Gene therapy for colorectal cancer is still in the early stages of development, and fundamental research in the molecular and cellular biology will improve the therapy." | ( Kaibara, N; Nakamura, S, 2001) |
| "Colorectal cancer is one of the leading causes of cancer death." | ( Rothenberg, ML, 2000) |
| "Colorectal carcinoma is one of the most common malignancies in the western world, and although fluorouracil (5-FU) has been used in its treatment for almost 40 years, new agents with significant activity have been introduced recently." | ( Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D, 2001) |
| "Colorectal cancer is usually diagnosed in patients around 70 years of age." | ( Aapro, M; Bokemeyer, C; Bontke, N; Grothey, A; Köhne, CH, 2001) |
| "Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death." | ( Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G, 2001) |
| "Colorectal cancer is a leading cause of cancer mortality in Western countries." | ( Chen, MJ; Chung-Faye, GA; Kerr, DJ; Searle, PF; Young, LS, 2001) |
| "Colorectal cancer is the second most frequent cause of death from cancer in western countries." | ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
| "Colorectal carcinoma is uncommon in Egypt, but a high proportion of cases occurs before age 40 years and in the rectum." | ( Amos, CI; Bayoumy, S; Bondy, ML; Chan, AO; Eissa, S; El-Badawy, SA; Hamilton, SR; Houlihan, PS; Levin, B; Lukish, JR; Mokhtar, N; Seifeldin, IA; Soliman, AS; Watanabe, T; Zhu, D, 2001) |
| "Colorectal cancer is still a majorhealth and social problem." | ( Beretta, GD; Labianca, RF; Pessi, MA, 2001) |
| "Colorectal cancer is the third most incident cancer in the United States and is second only to lung cancer as a cause of cancer-related mortality." | ( Gwyn, K; Sinicrope, FA, 2002) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | ( Holen, KD; Saltz, LB, 2001) |
| "DCC (deleted in colorectal cancer) is a candidate tumor suppressor gene." | ( Chen, YQ; Finley, RL; Liu, J; Morgan, M; Thorburn, A; Wu, R; Yao, F, 2002) |
| "In Japan, colorectal cancer is the third most common cause of death from cancer." | ( Ito, K; Kato, T, 2002) |
| "Colorectal cancer is one of the most common tumors worldwide." | ( Bazzoli, F; Ricciardiello, L, 2002) |
| "Colorectal cancer is a significant contributor to morbidity and mortality in the United States." | ( Levin, B; Pignone, M, 2002) |
| "Colorectal cancer is one of the leading causes of cancer deaths in the Western world." | ( Chauhan, DP, 2002) |
| "Although colorectal cancer is often considered as a single entity, it is being increasingly recognised that colon and rectal cancers are distinct disease groups and separate therapeutic strategies should be considered for each." | ( Kumar, D; Prabhudesai, AG, 2002) |
| "Colorectal cancer is the commonest malignancy encountered in Singapore." | ( Ang, P; Ang, PT; Au, E; Koo, WH; See, HT, 2002) |
| "Colorectal cancer is the second most common cause of cancer-related mortality in Europe and North America." | ( Chau, I; Cunningham, D, 2002) |
| "Advanced colorectal carcinoma is a major cause of morbidity and mortality in the United States and other developed countries." | ( Benson, AB; O'dwyer, PJ, 2002) |
| "Colorectal cancer is the second leading cause of cancer death but is largely preventable." | ( Rex, DK, 2002) |
| "The risk of colorectal cancer is increased in ulcerative colitis and Crohn's colitis." | ( Bernstein, CN; Eaden, J; Gordon, PH; Munkholm, P; Steinhart, AH, 2002) |
| "Metastatic colorectal cancer is a major cause of cancer-related mortality." | ( Goldberg, RM; Hobday, TJ, 2002) |
| "Colorectal cancer is often diagnosed at a later stage in blacks." | ( Reker, DM; Richards, RJ, 2002) |
| "Advanced colorectal cancer is a leading cause of cancer-related morbidity and mortality." | ( Hochster, H, 2002) |
| "Colorectal cancer is one of the most common cancers in the elderly." | ( Daniele, B; De Maio, E; Gallo, C; Iaffaioli, RV; Manzione, L; Ottaiano, A; Perrone, F; Pignata, S; Rosati, G; Rossi, A; Tambaro, R, 2003) |
| "Colorectal cancer is the second leading cause of cancer-related death in the United States." | ( , 2003) |
| "Colorectal cancer is the second leading cause of cancer death in the United States, and the number of new cases annually is approximately equal for men and women." | ( Giovannucci, E, 2003) |
| "Colorectal cancer is one of the most frequent human malignancies." | ( Douglass, EC, 2003) |
| "Colorectal cancer is the second most common cause of cancer-related mortality in the west." | ( Huls, G; Kleibeuker, JH; Koornstra, JJ, 2003) |
| "Colorectal cancer is one of the leading causes of cancer death." | ( Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y, 2003) |
| "Colorectal cancer is a leading cause of cancer death world-wide." | ( Gill, S; Goldberg, RM; Thomas, RR, 2003) |
| "Colorectal carcinoma is a leading cause of cancer related death worldwide." | ( Adel-Alvarez, LA; Alvarez, OR; Broaddus, R; Das, S; Jones, R, 2003) |
| "Colorectal cancer is a disease with a high mortality at present, due to the late stage at which many cases present." | ( Courtney, ED; Leicester, RJ; Melville, DM, 2004) |
| "Colorectal cancer is a frequent cause of mortality in Western countries, including Italy, where a definite screening policy has not yet been adopted." | ( Annibale, B; Bevilacqua, S; Capurso, G; Chiriatti, A; Delle Fave, G; Giovannetti, P; Impinna, S; Panzuto, F; Pistilli, F; Russo, G, 2003) |
| "Advanced colorectal cancer is a significant cause of worldwide cancer-related mortality." | ( Gill, S; Goldberg, RM, 2004) |
| "Colorectal cancer is responsible for over 500 000 deaths annually world-wide." | ( Atkin, W; Lieberman, DA, 2004) |
| "Colorectal cancer is a multistep process caused by genetic alterations in cell growth regulatory genes such as K-ras and B-raf." | ( Dimberg, J; Fransén, K; Monstein, HJ; Söderkvist, P, 2004) |
| "Colorectal cancer is one of the leading causes of cancer deaths in the industrialized nations." | ( Agaba, EA, 2004) |
| "The incidence of colorectal cancer is at least 30% lower in women than in men in the United States." | ( Adlercreutz, H; Armbrecht, HJ; Cross, HS; Gerdenitsch, W; Kállay, E; Lechner, D, 2004) |
| "Although colorectal cancer is one of the most preventable forms of cancer, it remains the second leading cause of cancer death worldwide." | ( Herszényi, L; Juhász, M; Prónai, L; Tulassay, Z, 2004) |
| "Colorectal cancer is the second most common cause of cancer-related death in the United States." | ( Goldberg, RM; Penland, SK, 2004) |
| "Colorectal carcinoma is a human malignant tumor, which is very resistant to currently available methods of treatment." | ( Chen, YC; Chow, JM; Ko, CH; Shen, SC; Tseng, SW, 2004) |
| "Colorectal cancer is a leading cause of cancer death worldwide." | ( Gill, S; Goldberg, RM, 2004) |
| "Colorectal carcinoma is the second cause of death for tumour after lung cancer." | ( Beretta, GD; Labianca, R; Milesi, L; Mosconi, S, 2004) |
| "Colorectal cancer is a leading cause of death and the third most common cancer in Canada." | ( Barkun, AN; Cousineau, G; Dubé, S; Jobin, G; Lahaie, R; Paré, P; Stein, B; Wassef, R, 2004) |
| "Colorectal carcinoma is one of the most common malignancies in the Western world." | ( Damjanovic, D; Findlay, MP; Thompson, P, 2004) |
| "Colorectal cancer is one of the leading causes of cancer-associated death in the United States and United Kingdom." | ( Eremin, O; Takhar, AS; Watson, SA, 2004) |
| "Colorectal cancer is a major cause of cancer death in Western countries." | ( Benamouzig, R, 2004) |
| "Colorectal Cancer is one of the leading causes for cancer related death in the industrialized world." | ( Andre, N; Graeven, U; Schmiegel, W, 2004) |
| "Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years." | ( Iqbal, S; Lenz, HJ, 2004) |
| "Colorectal cancer is the second leading cause of mortality in the United States." | ( Hawk, ET; Levin, B, 2005) |
| "Colorectal cancer is the third leading cause of cancer deaths in American men and women." | ( Bond, VC; Bumpers, HL; Grizzle, WE; Huang, MB; Lillard, JW; Okoli, J; Powell, M, 2005) |
| "Colorectal cancer is one of the most common carcinomas observed in humans." | ( Bulut, T; Durlanik, O; Kanbağli, O; Ozdemirler Erata, G; Toker, G; Uysal, M, 2005) |
| "Colorectal carcinoma is a leading cause of human mortality due to its high metastatic ability." | ( Chen, YC; Ko, CH; Lee, TJ; Shen, SC, 2005) |
| "Colorectal cancer is a leading cancer in many countries." | ( Kuang, A; Tang, G, 2005) |
| "Since colorectal cancer is the second most prevalent cancer worldwide, its treatment remains a major challenge for researchers, gastroenterologists and oncologists." | ( Galle, PR; Moehler, M; Teufel, A, 2005) |
| "Colorectal cancers are classically revealed by a low digestive bleeding, which can be occult or exteriorized." | ( Spano, JP; Vignot, S, 2005) |
| "Metastatic colorectal cancer is the second most common cause of cancer mortality." | ( Cai, SR; Church, RD; Culverhouse, R; Garbow, JR; McLeod, HL; Shannon, WD; Zhang, W, 2005) |
| "Worldwide, colorectal cancer is a common cancer and a major cause of morbidity and mortality." | ( Jefford, M; Khamly, K; Michael, M; Zalcberg, J, 2005) |
| "Colorectal cancer is a frequently occurring malignancy in the western world." | ( Punt, CJ, 2005) |
| "Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude." | ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005) |
| "Most colorectal cancers are diagnosed after the onset of symptoms." | ( Hamilton, W; Peters, TJ; Round, A; Sharp, D, 2005) |
| "Colorectal cancer is the second most common malignant human neoplasia." | ( Becker, C; Fantini, MC; Neurath, MF, 2005) |
| "Colorectal cancer is usually diagnosed in elderly patients." | ( Blanco, G; Bordonaro, R; Cordio, S; Manzione, L; Reggiardo, G; Rosati, G; Tucci, A, 2005) |
| "Colorectal cancer is one of the most common forms of gastrointestinal cancer in the world today." | ( Aznan, M; Goh, KL; Hasnida, N; Hilmi, IN; Kwan, KL; Lee, CK; Ong, KT; Quek, KF; Yeo, GT, 2005) |
| "The demography of colorectal cancer is different from western patients." | ( Aznan, M; Goh, KL; Hasnida, N; Hilmi, IN; Kwan, KL; Lee, CK; Ong, KT; Quek, KF; Yeo, GT, 2005) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | ( Fung, A; Viale, PH; Zitella, L, 2005) |
| "Colorectal cancer is a serious complication of inflammatory bowel disease." | ( Esendal, B; Kornbluth, A; Loftus, EV; Mittmann, U; Munkholm, P; Reinacher-Schick, A, 2006) |
| "Colorectal cancer is a major cause of cancer death in Western Europe and United States; the liver is the most common site for colorectal metastases." | ( Erturk, SM; Fujii, H; Ichikawa, T; Ros, PR; Yasuda, S, 2006) |
| "Colorectal cancer is the most commonly diagnosed cancer in the EU." | ( Goyle, S; Maraveyas, A, 2005) |
| "Colorectal cancer is a major cause of cancer death worldwide." | ( Aguilera, O; Ballestar, E; Espada, J; Esteller, M; Fraga, MF; García, JM; González-Sancho, JM; Herranz, M; Muñoz, A; Paz, MF, 2006) |
| "Advanced colorectal cancer is a common disease with an high mortality rate." | ( Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Francini, G; Giorgi, G; Micheli, L; Nencini, C; Torino, F, 2006) |
| "Colorectal cancer is the second most common malignant tumour in Germany with an unfavorable prognosis especially in a locally advanced or metastasizing stage." | ( Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG, 2006) |
| "Progression to colorectal cancer is associated with increased expression in iron import proteins and a block in iron export due to decreased expression and aberrant localisation of HEPH and FPN, respectively." | ( Anderson, GJ; Berx, G; Brookes, MJ; Hotchin, N; Hughes, S; Iqbal, T; Ismail, T; McKie, AT; Reynolds, G; Sharma, N; Tselepis, C; Turner, FE, 2006) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the Western world." | ( Allen, WL; Coyle, VM; Johnston, PG, 2006) |
| "In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer." | ( Grothey, A; Terstriep, S, 2006) |
| "Human sporadic colorectal cancer is the result of a lengthy somatic evolutionary process facilitated by various forms of genomic instability." | ( Alrawi, S; Anderson, GR; Bartos, JD; Brenner, BM; Chen, N; Cummings, KM; Dutt, SS; McQuaid, DA; Natarajan, N; Nowak, NJ; Petrelli, NJ; Rodriguez-Bigas, MA; Shaukat, A; Stoler, DL; Swede, H; Wiseman, SM, 2006) |
| "Colorectal cancer is a major cause of mortality and whilst up to 80% of sporadic colorectal tumours are considered preventable, trends toward increasing obesity suggest the potential for a further increase in its worldwide incidence." | ( Chell, S; Kadi, A; Kaidi, A; Paraskeva, C; Williams, AC, 2006) |
| "Colorectal cancer is a real national healthy problem because of high frequency and high rate of mortality." | ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | ( Eguchi, T; Shirao, K, 2006) |
| "The colorectal cancer is one of the most serious complication of inflammatory bowel disease." | ( Hagymási, K; Tulassay, Z, 2006) |
| "Colorectal cancer is on the third place among all cancer patients in our country." | ( Pavalkis, D; Rimaitis, K, 2006) |
| "Colorectal cancer is the third most common malignancy and the second most common cause of cancer-related mortality worldwide." | ( Fortina, P; Graves, DJ; Hyslop, T; Kricka, LJ; Surrey, S; Waldman, SA, 2006) |
| "Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year." | ( Gyôrffy, B; Tegze, B; Tulassay, Z, 2006) |
| "The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically developed nations." | ( Cunningham, D; Starling, N; Tilden, D; White, J, 2007) |
| "Some colorectal carcinomas are hormone-dependent tumors, and anti-estrogen therapy has no effect on them." | ( Chen, MS; Gui, ZN; Li, GC; Li, LR; Pan, ZZ; Wan, DS; Zhang, HD; Zhang, YQ; Zhou, ZW, 2007) |
| "Colorectal cancer is the second leading cause of cancer mortality in the United States." | ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "Colorectal cancer is a leading cause of cancer-related death globally, though in theory at least, it is eminently preventable in many cases." | ( Luebeck, G; Renehan, AG, 2007) |
| "Colorectal cancer is a common malignancy often requiring adjuvant chemotherapy." | ( Brenner, B; Purim, O; Sulkes, A, 2007) |
| "Colorectal cancer is the third most often cause of morbidity and mortality due to cancer in Poland." | ( Butkiewicz, A; Sierko, E; Sulkowski, S; Tokajuk, P; Wojtukiewicz, MZ; Zimnoch, L, 2005) |
| "Colorectal cancer is a major cause of mortality and treatment costs are considerable." | ( Arber, N; Das, D; Jankowski, JA, 2007) |
| "Colorectal cancer is related to diet, lifestyle, physical inactivity, and obesity." | ( Pool-Zobel, BL; Sauer, J, 2007) |
| "Colorectal cancer is a complication of longstanding inflammatory bowel disease." | ( Henriksen, M; Moum, B, 2007) |
| "Colorectal cancer is a common cancer in the Nordic countries and 50% of the patients develop liver metastases." | ( Høyer, M; Keiding, S; Mortensen, FV; Sørensen, M; Vilstrup, H, 2007) |
| "Colorectal carcinoma is the second most common cause of cancer death in the western world and nearly 50% of patients develop liver metastases." | ( Fawcett, WJ; Karanjia, ND; Lordan, JT; Quiney, N; Worthington, TR, 2009) |
| "Colorectal cancer is one of the most common cancers in developed countries, and its incidence is negatively associated with high dietary fiber intake." | ( Chung, MC; Hew, CL; Lim, TK; Lin, Q; Tan, HT; Tan, S, 2008) |
| "Colorectal cancer is an ideal opportunity for screening programs because of its long period of development." | ( Esser, P; Herber, S; Pohl, C; Rehbein, M; Tepas, T, 2008) |
| "Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death." | ( Mayer, RJ; Wolpin, BM, 2008) |
| "Colorectal cancers are rare in developing countries, but are the second most frequent malignancy in the affluent world." | ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008) |
| "Prostate and colorectal cancers are among the most common cancers and identifying modifiable risk factors are important steps to reduce the burden of these severe diseases." | ( Peters, U; Takata, Y, 2008) |
| "Colorectal cancer is one of the leading causes of malignant death in Taiwan because it often remains undetected until later stages of the disease." | ( Lai, PS; Lin, FH; Lou, PJ; Peng, CL; Shieh, MJ; Wei, MF; Yang, SJ; Yao, CJ; Young, TH, 2009) |
| "The colorectal cancer is the most frequent and clinically significant tumor of the gastrointestinal tract." | ( Deliĭski, T; Ignatov, V; Ivanov, K; Kolev, N; Madzhov, R; Temelkov, T, 2006) |
| "Colorectal cancer is a common malignancy that afflicts many in the western world." | ( Iyer, RB; Vikram, R, 2008) |
| "Colorectal cancer is the second leading cause of cancer death in developed countries." | ( Barrasa, A; Celda, B; López, JA; Monleón, D; Morales, JM; Vázquez, C, 2009) |
| "Colorectal cancer is a leading cause of morbidity and mortality worldwide, and its incidence has been increasing in recent years." | ( Chen, YX; Fang, JY; Lu, R; Sun, DF; Tian, XQ; Wang, X; Zhao, SL, 2008) |
| "Patients with colorectal cancer are frequently anaemic and many receive allogeneic red blood cell transfusions peri and post-operatively." | ( Devon, KM; McLeod, RS, 2009) |
| "Colorectal cancer is a major cause of morbidity and mortality for cancer worldwide." | ( Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Wang, Q; Yuan, CS, 2009) |
| "Colorectal carcinoma is one of the major causes of morbidity and mortality in the Western World." | ( Ball, S; Cen, L; Chen, CL; DeAngelis, S; Fuchs, JR; Hutzen, B; Li, C; Li, PK; Lin, J, 2009) |
| "Colorectal cancer is a most frequent type of gastrointestinal tract cancers." | ( Bian, HB; De, W; Ji, XH; Wang, ZX; Yang, JS, 2009) |
| "Colorectal cancer is one of the leading causes of cancer-related morbidity and mortality." | ( Agarwal, C; Agarwal, R; Deep, G; Katiyar, S; Kaur, M; Tyagi, A; Velmurugan, B, 2009) |
| "MMR-deficient colorectal cancers are classically characterized by right-sided location, multifocality, mucinous histology, and lymphocytic infiltration." | ( Afrasiabi, K; Birnbaumer, L; Edwards, RA; Lipkin, SM; Pham, T; Wang, K; Witherspoon, M, 2009) |
| "Colorectal cancer is more common in the western countries." | ( Dikshit, R; Ganesh, B; Talole, SD, 2009) |
| "The incidence of colorectal cancer is rapidly increasing in Japan." | ( Ishiguro, S; Ishikawa, H; Kawano, A; Matsuura, N; Murakami, Y; Nakamura, T; Okuda, T; Otani, T; Sakai, T; Takeyama, I, 2010) |
| "Colorectal cancer is a serious medical problem." | ( Dziki, Ł; Klimczak, A; Kubiak, K; Malinowska, K, 2009) |
| "Colorectal cancer is one of the leading causes of malignant death and often goes undetected with current colonoscopy practices." | ( Lin, FH; Shieh, MJ; Tsai, HM; Tsai, KC; Wei, MF; Wong, JM; Yang, SJ, 2010) |
| "Colorectal cancer is the third most common form of cancer and hypermethylation has been shown to increase the risk of developing this disease." | ( Guan, M; Li, J; Li, M; Lin, Y; Liu, C; Liu, W; Lu, Y; Ma, W; Su, B, 2010) |
| "Colorectal cancer is the most common form of malignancy in Taiwan and the third leading cause of death from cancer, preceded only by lung and hepatic cancers." | ( Chow, KC; Lin, YL, 2010) |
| "Colorectal cancer is the third most common malignancy in the United States." | ( Agyeman, A; DeVecchio, J; Houghton, JA; Jani, TS; Mazumdar, T, 2010) |
| "Colorectal cancer is commonly diagnosed in the United State and is one of the leading causes of cancer deaths." | ( Shie, P, 2011) |
| "Colorectal cancer is the third-most common form of cancer in the Western world." | ( Ryan, JJ; Waldby, G, 2010) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs." | ( Bodmer, WF; Bracht, K; Liu, Y; Nicholls, AM, 2010) |
| "Colorectal cancer is respectively the third and second most common cancer among men and women in France." | ( Bissonnette, M; Poupon, R; Serfaty, L, 2010) |
| "The majority of colorectal cancers are characterized by a defective DNA mismatch repair (MMR)." | ( Cheng, WH; Lartey, FM; Qi, Y; Schoene, NW, 2010) |
| "Colorectal cancer is often a deadly disease and cannot be cured at metastatic stage." | ( Abo-Ramadan, U; Bauerschmitz, G; Diaconu, I; Escutenaire, S; Halavaara, J; Hemminki, A; Kanerva, A; Lavilla-Alonso, S; Pesonen, S; Tatlisumak, T, 2010) |
| "Advanced colorectal cancer is associated with elevated amounts of hyaluronan of varying size." | ( Bouga, H; Bounias, D; Kyriakopoulou, D; Papageorgakopoulou, N; Stavropoulos, MS; Theocharis, DA; Tsouros, I; Vynios, DH, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| "Colorectal cancer is ranked the third most common cancer worldwide in terms of incidence and the second in terms of mortality." | ( Carru, C; Contini, M; Cossu-Rocca, P; De Miglio, MR; Manca, A; Massarelli, G; Mura, A; Murgia, L; Sotgia, S; Uras, MG; Zinellu, A, 2010) |
| "Colorectal cancer is one of the leading causes of cancer death and often goes undetected with current colonoscopy practices." | ( Chin, HC; Lin, CF; Lin, FH; Shieh, MJ; Tsai, HM; Wong, JM; Yang, SJ, 2011) |
| "Colorectal cancer is one of the major causes of cancer-related mortality in both men and women worldwide." | ( Ho, CT; Lai, CS; Pan, MH; Wu, JC, 2011) |
| "Colorectal cancer is one of the most common cancer types and the third leading cause of cancer-related death in the western world." | ( Beneytout, JL; Cook-Moreau, J; Delage, C; Leger, DY; Liagre, B; Limami, Y; Mousseau, Y; Pinon, A; Simon, A, 2011) |
| "Metastatic colorectal cancer is frequently treated with irinotecan, a topoisomerase-I inhibitor." | ( Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K, 2011) |
| "Colorectal cancer is (CRC) one of the leading causes of mortality and morbidity." | ( Hussain, MU; Khan, MS; Khan, NP; Mudassar, S; Pandith, AA; Wani, KA; Yousuf, A, 2011) |
| "Colorectal carcinoma is a tumour with higher incidence in patients with type 2 diabetes and obesity." | ( Svacina, S, 2011) |
| "Colorectal cancer is the third most common cancer and is associated with significant morbidity and mortality." | ( Deb, J; Dibra, H; Kankipati, CS; Manneh, J; Nicholl, ID; Perry, CJ; Rajan, S; Shan, S, 2011) |
| "Colorectal cancer is the third most common malignancy in the developed countries, and about a quarter of people present with intestinal obstruction or perforation." | ( Landau, D; Qureshi, A; Ross, P; Verma, A, 2010) |
| "Colorectal cancer is common worldwide and chemoprevention has the potential of reducing the number of individuals who may suffer and perish from this disease." | ( Alberts, DS; Blanke, CD; Chu, DZ; Fenoglio-Preiser, CM; Giguere, JK; Goodman, GE; Hussey, MA; Meyskens, FL; Mills, GM; Rivkin, SE, 2011) |
| "Colorectal carcinoma is a major public health concern with its yearly mondial incidence of about one million cases and yearly mortality of 500,000 cases." | ( Geschwind, JF; Pellerin, O, 2011) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the world." | ( Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G, 2011) |
| "Colorectal cancer is the third cause of death in industrialized countries." | ( Albano, F; Barone, M; De Tullio, N; Di Leo, A; Licinio, R; Licino, R; Lofano, K, 2012) |
| "Colorectal tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis." | ( Pauwels, P; Peeters, M; Reutelingsperger, CP; Staelens, S; Van Damme, N; Van de Wiele, C; Vangestel, C, 2011) |
| "Colorectal cancer is the fourth most common cancer in the world." | ( Boghossian, S; Hawash, A, 2012) |
| "Patients with colorectal cancer are characterized by reduced activity of antioxidant enzymes catalase and superoxide dismutase which suggests impaired antioxidant barrier." | ( Dziki, A; Dziki, Ł; Kubiak, K; Langer, E; Majsterek, I; Malinowska, K, 2011) |
| "In a nation where colorectal cancer is on the rise, it is imperative that high volume centers develop specialized units to train future specialist colorectal surgeons." | ( Bodhankar, YD; Goel, M; Ingle, S; Shetty, GS; Shrikhande, SV; Shukla, PJ; Thakkar, RG, 2012) |
| "Colorectal cancer is the commonest cancer among males and the third commonest cancer among women in Malaysia." | ( Amry, AR; Harmy, MY; Noor, NM; Norwati, D, 2011) |
| "Colorectal cancer is the third most common malignancy and the third-leading cause of cancer-related deaths worldwide." | ( Liang, HW; Xing, YN; Xu, HM; Zhao, L, 2011) |
| "Colorectal cancer is one of the deadliest diseases in Western countries." | ( Coco, C; Ferlini, C; Mariani, M; Martinelli, E; Martino, C; Scambia, G; Shahabi, S; Sieber, S; Sioletic, S; Zannoni, GF, 2012) |
| "Colorectal cancer is one of the major neoplasms and a leading cause of cancer death worldwide, and new preventive strategies are needed to lower the burden of this disease." | ( Endo, H; Ezuka, A; Fujisawa, N; Hata, Y; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Matsuhashi, N; Morita, S; Nagase, H; Nakajima, A; Ohkubo, H; Sakai, E; Takahashi, H; Uchiyama, S; Uchiyama, T; Yamada, E; Yamanaka, S, 2012) |
| "Colorectal cancer is a significant source of morbidity and mortality in the United States and other Western countries." | ( Anderson, DG; Guajardo, G; Karagiannis, ED; Langer, RS; Urbanska, AM, 2012) |
| "Colorectal cancer is the leading cause of death from gastrointestinal malignancy in the US." | ( Lenz, HJ; Ning, Y, 2012) |
| "Colorectal cancer is one of the leading causes of cancer-related death throughout the world, and the risk to develop this malignant disease seems to be associated with long-term cigarette smoking." | ( Bizzarri, M; Coluccia, P; Cucina, A; D'Anselmi, F; Dinicola, S; Pasqualato, A; Proietti, S, 2012) |
| "Colorectal carcinoma is rare in the paediatric population but is increasing in incidence." | ( Kennedy, MJ; Larkin, JO; McCormick, P; Mehigan, B; Muldoon, C; Woods, R, 2012) |
| "Colorectal cancer is the third most common cancer worldwide with an annual incidence of ~1 million cases and an annual mortality rate of ~655,000 individuals." | ( Balog, CI; Deelder, AM; Fung, WL; Koeleman, CA; McDonnell, LA; Mesker, WE; Stavenhagen, K; Tollenaar, RA; Verhoeven, A; Wuhrer, M, 2012) |
| "Gastric and colorectal cancers are among the most common cancers worldwide and cause serious cancer mortality." | ( He, C; Hu, X; Huang, X; Kuang, Y; Li, L; Mo, L; Rong, R; Shi, Q; Shu, X; Su, X; Sui, X; Tao, Q, 2013) |
| "Colorectal cancer is a major public health problem in Malaysia." | ( Blazeby, JM; Law, CW; Magaji, BA; Moy, FM; Roslani, AC; Sagap, I; Zakaria, J, 2012) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the United States." | ( Dannenberg, AJ; Karoly, ED; Kopelovich, L; Montrose, DC; Subbaramaiah, K; Yantiss, RK; Zhou, XK, 2012) |
| "Metastatic colorectal cancer is the second leading cause of cancer death in the United States." | ( de Braud, F; Díaz-Rubio, E; Pietrantonio, F, 2012) |
| "In Malaysia, colorectal cancer is the most common cancer in males and the third most common in females." | ( Daud, N; Noor, NM; Rahim, AA; Yusoff, HM, 2012) |
| "Colorectal cancer is the third and second most common cancer among men and women, respectively, in France." | ( Serfaty, L, 2012) |
| "Colorectal cancer is one of the leading causes of cancer deaths." | ( Essapen, S; Khelwatty, SA; Modjtahedi, H; Seddon, AM, 2013) |
| "Colorectal cancer is a leading cause of cancer mortality with a complex carcinogenesis that includes reduced cellular senescence." | ( Du, X; Liu, L; Shi, L; Wang, J; Wang, Z; Zhang, W; Zhang, Y, 2013) |
| "Colorectal cancer is a leading cause of cancer morbidity and mortality worldwide." | ( Ahn, SJ; Choi, HY; Choi, SJ; Jeong, YM; Kim, HS, 2013) |
| "Colorectal cancer is the second leading cause of cancer-related deaths." | ( Gu, Y; Guo, SY; Huo, HZ; Liu, WY; Qin, J; Wang, B, 2013) |
| "The risk of colorectal cancer is reduced among users of oral contraceptives or menopausal hormone therapy, but associations with reproductive characteristics that are markers of a woman's endogenous hormone milieu have not been consistently observed." | ( Brenner, H; Chang-Claude, J; Herpel, E; Hoffmeister, M; Roth, W; Rudolph, A; Schirmacher, P; Toth, C, 2013) |
| "Colorectal cancers are visible on the contrast-enhanced dual-energy CT without bowel preparation or insufflation." | ( Boellaard, TN; Henneman, OD; Nio, CY; Stoker, J; Streekstra, GJ; van Dorth-Rombouts, MC; Venema, HW, 2013) |
| "Colorectal carcinoma is characterized by increased oxidative stress and antioxidant disbalance." | ( Dragutinović, VV; Gajić, MM; Gopčević, KR; Krivokapić, ZV; Rovčanin, BR; Tatić, SB, 2013) |
| "Colorectal cancer is one of the leading causes of cancer-related mortality worldwide." | ( Chen, Z; Fang, Y; Gu, X; Li, Z; Xiang, J, 2013) |
| "Human colorectal cancers are known to possess multiple mutations, though how these mutations interact in tumor development and progression has not been fully investigated." | ( Albrecht, D; Bacher, J; Clipson, L; Deming, DA; Halberg, RB; Leystra, AA; Middlebrooks, M; Miller, D; Nettekoven, L; Sievers, C; Washington, MK; Weichert, J, 2014) |
| "Colorectal cancer is the third most commonly diagnosed type of cancer." | ( Bouga, H; Bounias, D; Kolliopoulos, C; Kyriakopoulou, D; Stavropoulos, M; Vynios, DH, 2013) |
| "Since the risk of colorectal cancer is increasing steadily in Kashmir, India, like in some other corners of Asia, exhaustive efforts are being made to find the association of above given and other risk factors with the development of this gastrointestinal tract cancer." | ( Ganai, BA; Kadla, SA; Rasool, S; Rasool, V, 2013) |
| "Colorectal cancer is the second most common cancer in Malaysia." | ( Dahlui, M; Loh, KW; Majid, HA; Roslani, AC; Su, TT, 2013) |
| "Although colorectal cancer is a major cause of concern in the western population, recent studies are showing the incidence and mortality of colorectal cancer to be rapidly rising in Asia." | ( Banerjee, S; Mukherjee, R; Mukherjee, SK; Paira, SK; Roy, B; Sarkar, S, 2012) |
| "Colorectal cancer is the third most common cancer, with recent advances in the management of unresectable metastatic lesions." | ( Foubert, F; Matysiak-Budnik, T; Touchefeu, Y, 2014) |
| "Colorectal cancer is the third most common malignancy worldwide." | ( Sun, Y; Tian, H; Wang, L; Yang, H, 2013) |
| "Colorectal cancer is the third and fourth leading cause of cancer in males and females, respectively." | ( Ahn, S; Hwang, D; Kim, DW; Koh, D; Lee, YH; Lim, Y; Shin, SY; Yoon, H, 2013) |
| "Colorectal cancer is the third leading cause of cancer death in Japan and the United States and is strongly associated with obesity, especially visceral obesity." | ( Endo, H; Hosono, K; Nakajima, A; Takahashi, H, 2013) |
| "Colorectal carcinoma is one of the most common malignant tumors." | ( Li, T; Liu, Y; Wan, Y; Wang, X; Yin, H; Zhang, Q; Zhu, J, 2014) |
| "Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death." | ( Bi, F; Chen, Q; Ge, XJ; Tang, QL; Xia, HW; Zhang, YC, 2013) |
| "Colorectal cancer is the third most commonly diagnosed cancer worldwide." | ( Cao, Q; Chen, C; Chen, Z; Li, W; Liu, F; Liu, W; Wu, X; Xu, Z; Yao, X, 2014) |
| "Colorectal cancer is one of the most common types of cancer with over fifty percent of patients presenting at an advanced stage." | ( Alnabulsi, A; Blihoghe, D; Brown, GT; Cash, BG; Johansson, P; Murray, GI, 2014) |
| "Colorectal cancer is a lethal disease if not discovered early." | ( Mukherji, D; Shamseddine, A; Temraz, S, 2014) |
| "Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments." | ( Adams, R; Butler, R; Fisher, D; Kaplan, R; Lowdell, C; Madi, A; Maughan, T; Meade, AM; Middleton, G; Pugh, C; Sizer, B; Sydes, B; Wasan, H; Wilson, R, 2014) |
| "Colorectal cancer is the most intensively studied cancer because of its high incidence and mortality rate." | ( Wang, XW; Zhang, YJ, 2014) |
| "Colorectal cancer is the third leading cause of cancer deaths in the United States." | ( Carucci, LR; Cash, BD; Feig, BW; Fowler, KJ; Katz, DS; Kim, DH; Lalani, T; Rosen, MP; Smith, MP; Yaghmai, V; Yee, J, 2014) |
| "Colorectal cancer is highly prevalent, and the vast majority of cases are thought to be sporadic, although few risk factors have been identified." | ( Boca, S; Cross, AJ; Huang, WY; Moore, SC; Sampson, JN; Sinha, R; Stolzenberg-Solomon, R; Xiong, X, 2014) |
| "Colorectal cancer is still the second leading cause of cancer death, for this reason in many countries screening programs have been approved and colonoscopy is considered the golden standard." | ( Allegri, V; Ambrosini, V; Castellucci, P; Fanti, S; Ghedini, P; Grassi, I; Guidalotti, PL; Montini, GC; Nanni, C, 2014) |
| "Colorectal cancer is the third most common cancer worldwide." | ( Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE, 2014) |
| "Colorectal cancer is one of the leading causes of cancer deaths." | ( Cao, H; Cao, X; He, N; Kong, X; Luo, S; Song, S; Wang, B; Wang, S; Xu, M; Yan, F; Zhang, Y, 2014) |
| "Colorectal cancer is the second most frequent cancer in Malaysia." | ( Law, CW; Magaji, BA; Moy, FM; Roslani, AC, 2014) |
| "Colorectal cancer is associated with chronic inflammation and immunosuppression mediated by myeloid-derived suppressor cells (MDSC)." | ( Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M, 2014) |
| "Colorectal cancer is one of the most common tumors worldwide and at least 50 % of patients with this disease develop metastases." | ( Argilés, G; Benavides, M; Feliú, J; García-Alfonso, P; García-Carbonero, R; Grávalos, C; Guillén-Ponce, C; Martínez-Villacampa, M; Pericay, C; Sastre, J, 2014) |
| "Colorectal cancer is one of the most common malignancies in the world, and is generally treated more effectively by chemoradiotherapy rather than radiotherapy or chemotherapy alone." | ( Jung, WG; Kim, EH; Kim, MS, 2014) |
| "Colorectal cancer is the third most common cancer in humans." | ( Kouraklis, G; Nebiker, CA; Tampaki, EC; Tampakis, A, 2014) |
| "Although colorectal cancer is a disease characterized by sequential accumulation of mutations in epithelial cells, mechanisms leading to genomic vulnerability contributing to tumor initiation remain undefined." | ( Girondo, MA; Gong, J; Hyslop, T; Li, P; Lin, JE; Liu, C; Rui, H; Sato, T; Snook, AE; Waldman, SA; Wilson, C, 2014) |
| "Colorectal cancer is one of the world's three most common cancers, and its incidence is rising." | ( Carpen, O; Deelder, AM; Haglund, C; Hagström, J; Heiskanen, A; Hokke, CH; Kaprio, T; Mustonen, H; Saarinen, J; Satomaa, T, 2015) |
| "Colorectal cancer is a leading cause of mortality worldwide." | ( Baron, DM; Bayer, E; Gerner, C; Haudek-Prinz, VJ; Kaindl, U; Marian, B; Röhrl, C, 2014) |
| "Colorectal cancer is the third most common cancer in the world." | ( Chalmers, A; El-Khamisy, SF; Gilbert, DC; Gollins, S; Haley, V; Meisenberg, C; Ward, SE, 2015) |
| "The colorectal cancer is the leading contributor of cancer-related mortality." | ( Chen, MB; Cui, JF; Li, C; Liu, CY; Liu, F; Lu, PH; Zhang, QD; Zou, J, 2015) |
| "Colorectal cancer is one of the most common causes of cancer-associated mortality worldwide, but it is truly a preventable disease." | ( Anguiano, E; Baldwin, N; Boland, CR; Buhrmann, C; Goel, A; Nattamai, D; Okugawa, Y; Shakibaei, M; Toden, S, 2015) |
| "Colorectal cancers are the most common cancers of the gastrointestinal system." | ( Bayhan, Z; Canturk, NZ; Cekmen, M; Ergül, E; Simşek, T; Utkan, NZ, 2014) |
| "Colorectal cancer is a major cause of deaths due to cancer; therefore, research into its etiology is urgently needed." | ( Araki, K; Baba, H; Hirashima, K; Ida, S; Maehara, Y; Miyamoto, Y; Morita, M; Ohmuraya, M; Oki, E; Ozaki, N; Sakamoto, Y; Taki, K; Watanabe, M; Yamamura, K; Zaitsu, Y, 2015) |
| "Colorectal cancer is common." | ( Das, UN; Ni, X; Shen, S; Yu, H; Zhang, C, 2015) |
| "Colorectal cancer is the third most common cancer diagnosed in the USA each year." | ( Anderson, BJ; Peterson, LL, 2016) |
| "Colorectal cancer is the third most frequently diagnosed cancer and the combination of radiation with capecitabine has been shown to achieve only 15% to 25% of pathologic complete response." | ( Li, G; Wan, J; Zhang, Z; Zhu, J, 2016) |
| "Colorectal cancer is a leading cause of cancer-related deaths." | ( Carter, RA; Finkelstein, D; Gilbertson, RJ; Gurung, P; Kanneganti, TD; Karki, R; Li, L; Liu, Z; Malik, A; Malireddi, RK; Man, SM; McGoldrick, DJ; Neale, G; Olsen, SR; Sharma, D; Vogel, P; Wu, G; Zhu, L; Zhu, Q, 2015) |
| "Colorectal cancer is one of the most common malignancies in the Western world." | ( Laurens, ST; Oyen, WJ, 2015) |
| "Colorectal cancer is commonly treated with 5-fluorouracil and 5-formyltetrahydrofolate (leucovorin)." | ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2015) |
| "Colorectal cancer is the third most common cancer worldwide." | ( Agnoli, C; Bendinelli, B; Frasca, G; Grioni, S; Krogh, V; Masala, G; Mattiello, A; Pala, V; Panico, S; Pellegrini, N; Ricceri, F; Sacerdote, C; Sieri, S; Tumino, R; Vece, MM, 2015) |
| "Colorectal cancer is the third most common malignancy in humans and novel therapeutic approaches are urgently needed." | ( Elssner, C; Jaeger, D; Jassowicz, A; Kautz, N; Koehler, BC; Lorenz, S; Radhakrishnan, P; Scherr, AL; Schneider, M; Schulze-Bergkamen, H; Weiss, J, 2015) |
| "Colorectal cancer is the third most common cancer in men and second in women, estimated to cause 694,000 deaths worldwide in 2012." | ( Esin, E; Yalcin, S, 2016) |
| "Colorectal cancer is the third most common type of cancer in both, men and women." | ( Cabeza, L; Hernandez, R; Jimenez-Lopez, J; Jimenez-Luna, C; Leiva, MC; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J; Rama, AR; Zafra, I, 2016) |
| "Colorectal cancer is a common and often fatal malignancy." | ( Eglinton, T; Eteuati, J; Frizelle, F; Hollington, P; Keenan, J; Wakeman, C, 2017) |
| "Colorectal cancer is the second most frequent cancer in Malaysia." | ( Law, CW; Magaji, BA; Moy, FM; Roslani, AC; Sagap, I, 2015) |
| "Colorectal cancer is a clinical condition whose treatment often involves intestinal resection." | ( Havel, E; Hyšpler, R; Kaška, M; Plíšková, L; Tichá, A; Zadák, Z; Žaloudková, L, 2015) |
| "Colorectal cancer is the third of the twentieth most commonly diagnosed cancer." | ( Mahabusarakam, W; Nakamura, Y; Sophonnithiprasert, T; Watanapokasin, R, 2015) |
| "Colorectal cancer is a critical health concern because of its incidence as the third most prevalent cancer in the world." | ( Baskaran, R; Jin, S; Naick, H, 2016) |
| "Colorectal cancer is a very prevalent diagnosed cancer." | ( Kilari, BP; Kotakadi, VS; Penchalaneni, J, 2016) |
| "Colorectal cancer is the fourth most common cancer diagnosed in the United States, and the third most common cause of death from cancer." | ( Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S, 2015) |
| "Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease." | ( Bekaii-Saab, T; Stintzing, S; Sunakawa, Y, 2016) |
| "Colorectal cancer is a common cancer with high mortality rate." | ( Ahmad, J; El-Shemi, AG; Idris, S; Kensara, OA; Mohamed, AM; Refaat, B, 2016) |
| "Colorectal cancer is the fourth worldwide cause of death and even if some dietary habits are consider risk factors, the contribution of food additives including foodgrade titanium dioxide (TiO2), designated as E171, has been poorly investigated." | ( Chirino, YI; Delgado-Buenrostro, NL; Flores-Flores, JO; Freyre-Fonseca, V; Garduño-Balderas, LG; González-Robles, A; Hernández-Pando, R; León-Cabrera, S; Pedraza-Chaverri, J; Rodríguez-Sosa, M; Terrazas, LI; Urrutia-Ortega, IM; van Loveren, H, 2016) |
| "Colorectal cancer is the third most common cancer in the United States." | ( Chen, J; Nadesan, S; Smalligan, RD, 2016) |
| "Colorectal cancer is the most common form of cancer in the world, and the five-year survival rate is estimated to be almost 90% in the early stages." | ( Chen, YM; Chu, PC; Hsiao, ES; Lee, CT; Lee, JC; Liao, PC; Lin, PC; Tyan, YC; Yang, YF, 2016) |
| "Colorectal cancer is the third most common cancer worldwide." | ( Bellora, P; Monni, M; Spinoglio, G, 2016) |
| "In Malaysia, colorectal cancer is the second most common cancer in males and the third most common cancer in females." | ( Abu Hassan, MR; Chaiyakunapruk, N; Ching, SM; Lim, KG; Veettil, SK, 2017) |
| "As MSI colorectal carcinomas are known for their robust immune response, we then aimed to link FABP1 to the immune microenvironment of MSI carcinomas." | ( Brodsky, AS; Friedman, K; Gill, AJ; Karashchuk, G; Lombardo, K; Lu, S; Resnick, MB; Wood, SM; Yang, D, 2017) |
| "Colorectal cancer is the most commonly diagnosed malignancy with high mortality rates worldwide." | ( Chen, W; Chen, X; Dai, X; Feng, C; He, G; Liang, G; Qiu, C; Vinothkumar, R; Wang, Y; Wu, W; Xie, Y; Ye, Q; Zhou, H, 2016) |
| "Colorectal cancer is a common malignancy that most commonly metastasizes to the liver." | ( D'Souza, D; Flanagan, S; Golzarian, J; Young, S, 2017) |
| "Colorectal cancer is the third most common cancer worldwide." | ( Chang, CC; Chang, Y; Cheung, MW; Ho, C; Huang, CP; Lee, WC; Lin, WC; Or, CR; Su, HL, 2016) |
| "Colorectal cancer is third most common malignancy and is the second most common cause of cancer-related death." | ( Ahmad, R; Al-Obaid, O; Alam, M; Hasegawa, M; Kharbanda, S; Kufe, D; Uchida, Y, 2017) |
| "Colorectal cancer is one of the most common cancers in industrialised societies." | ( Aggarwal, A; Bilban, M; Kallay, E; Manhardt, T; Schulz, H; Thakker, RV, 2017) |
| "Colorectal cancer is the second most common cause of cancer death in developed countries." | ( Jiang, R; Lönnerdal, B, 2017) |
| "Colorectal cancer is the third leading cause of cancer-related mortality in most developed countries." | ( Adekoya, D; Chung, SS; Clarke, O; Enenmoh, I; Sarkyssian, M; Vadgama, JV; Wang, P; Wu, Y, 2017) |
| "Colorectal cancer is one of the major causes of death from cancer." | ( Huang, S; Jin, M; Lv, Q; Ma, H; Nie, X; Shen, Q; Wu, G; Zhang, D; Zhang, T; Zhao, L; Zheng, X; Zhou, P, 2017) |
| "Colorectal carcinoma is a major health concern worldwide and its high incidence and mortality require accurate screening methods." | ( Carvalho, S; Gueiral, N; Henrique, R; Nogueira, E; Oliveira, L; Tuchin, VV, 2017) |
| "Colorectal Cancer is the fourth most frequent cause of cancer death worldwide and its incidence increases from 50 years of age." | ( Abbate, I; Casamassima, A; Casamassima, P; Daniele, A; DE Luca, R; Divella, R; Garrisi, VM; Ruggieri, E; Savino, E, 2017) |
| "Colorectal cancer is a global public health issue." | ( Antoniolli-Silva, AC; Cantero, WB; Carreira, CM; Genez, LA; Limeiras, SM; Neves, SC; Ogo, FM; Oliveira, EJ; Oliveira, RJ; Pesarini, JR; Pessatto, LR; Schweich, LC; Silva, RA, 2017) |
| "Colorectal cancer is among the most lethal of malignancies, due to its propensity to metastatic spread and multifactorial-chemoresistance." | ( Avan, A; Ferns, GA; Ghayour-Mobarhan, M; Kazemi, M; Nabinejad, A; Nedaeinia, R; Salehi, R; Sharifi, M, 2017) |
| "Colorectal cancer is one among the most common cancers in the world and a major cause of cancer related deaths." | ( Abida, PS; Babu, TD; Narayanankutty, A; Nazeem, PA; Raghavamenon, AC; Roy, N; Valsala, PA; Valsalan, R, 2018) |
| "Colorectal cancer is a major cancer type worldwide." | ( Deng, Q; Li, L; Li, Y; Liu, L; Wang, L; Wang, S; Zhang, M; Zhou, Z, 2017) |
| "Colorectal cancer is among the most lethal malignancies globally." | ( Avan, A; Bahrami, A; Ferns, GA; Hassanian, SM; Hesari, A; Khazaei, M, 2018) |
| "Colorectal cancer is the third most prevalent cancer type worldwide and contributes to a significant percentage of cancer-related mortality." | ( Li, X; Wang, S; Wang, Z; Xing, J; Yang, X; Yu, E; Zhang, C, 2017) |
| "Colorectal cancer is one of the most common malignancies and is the second-leading cause of cancer-related death world-wide, which is linked to genetic mutations, epigenetic alterations, and oncogenic signaling activation." | ( Bao, Y; Guo, Y; Yang, W, 2017) |
| "Colorectal cancer is a major healthcare concern worldwide." | ( Ohnishi, M; Sakai, H; Shimizu, M; Shirakami, Y; Tanaka, T, 2017) |
| "Colorectal cancer is the third most commonly diagnosed malignancy and the fourth leading cause of cancer-related death globally." | ( Law, CW; Magaji, BA; Moy, FM; Roslani, AC, 2017) |
| "Colorectal cancer is the third most common cancer in men and second most common in women globally." | ( Agarwal, M; Gandhi, JS; Goswami, M; Gupta, G; Gupta, N; Mehta, A; Pasricha, S; Sharma, A; Singh, S; Tanwar, P, 2018) |
| "Colorectal cancer is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature, and drug responsiveness." | ( Chae, J; Cho, SY; Han, JY; Kang, J; Kang, W; Kim, J; Kim, JI; Lee, A; Lee, C; Lee, J; Lee, WS; Min, S; Na, D; Park, H, 2017) |
| "Colorectal cancer is the third leading cause of cancer-related deaths in the United States." | ( Ahmad, T; Ahmed, M; Czejka, M; Fan, Y; Khan, RA; Mansoor, N; Sharib, S; Yang, DH, 2017) |
| "Colorectal cancer is a growing health concern with increasing mortality rates, and resistance to anticancer drugs and radiotherapy is a serious drawback in its treatment." | ( Haddad, F; Iranshahi, M; Moussavi, M; Rassouli, FB; Soleymanifard, S, 2017) |
| "Colorectal cancer is the third most common cancer in the world." | ( El-Maraghy, SA; ElMeshad, AN; Hammam, OA; Motawi, TK; Nady, OM, 2017) |
| "Screening of colorectal cancer is crucial for early stage diagnosis and treatment." | ( Bhattacharyya, D; Kumar, P; Misra, M; Mohanty, SK; Smith, YR, 2017) |
| "Colorectal cancer is an increasingly significant cause of mortality whose risk is linked to diet and inversely correlated with cruciferous vegetable consumption." | ( Bao, Y; Dacosta, C, 2017) |
| "Metastatic colorectal cancer is a common disease encountered in oncology practice and treatment options beyond fluoropyrimidines, irinotecan, oxaliplatin and monoclonal antibodies against epidermal growth factor receptor and vascular endothelium growth factor (VEGF) are limited." | ( Mercier, J; Voutsadakis, IA, 2017) |
| "Colorectal cancer is currently the third leading cause of cancer related deaths." | ( Aparna, JS; Binu, VS; Harikumar, KB; James, S; Lankadasari, MB; Mohammed, S; Paul, AM; Reshmi, G; Santhoshkumar, TR, 2017) |
| "Colorectal cancer is a worldwide public health problem." | ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| "Globally, colorectal cancer is the third most common type of cancer." | ( Bansal, S; Bhat, ZI; Burman, A; Kumar, B; Kumar, GT; Naseem, A; Rizvi, MMA; Saini, S; Saluja, SS; Wahabi, K, 2017) |
| "Colorectal cancer is one of the most common malignancies in the Western world, and even after surgical removal, there is a high recurrence rate." | ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2018) |
| "Colorectal cancer is one of the most common causes of cancer death worldwide." | ( Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H, 2018) |
| "Colorectal carcinoma is a common malignant tumor occurring in the alimentary system." | ( Guo, Z; Liu, Z; Wang, J; Yue, H, 2018) |
| "Colorectal cancer is a common cause of morbidity and mortality in the United States." | ( McMechan, D; Talukder, A; Wilkins, T, 2018) |
| "Mortality for colorectal cancer is mainly due to liver metastases, surgical resection remains the curative treatment and use of neoadjuvant therapy improves resectability of metastases." | ( Bacha, D; Bayar, R; Ben Slama, S; Bouraoui, S; Khadhar, A; Lahmar, A; Sassi, A, 2017) |
| "Colorectal cancer is one of the most common malignancies both in men and women." | ( Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC, 2018) |
| "Colorectal cancer is a leading cause of cancer-related death worldwide." | ( Gu, D; Liu, B; Song, R; Xie, J; Yu, B; Zhang, L; Zhang, X, 2018) |
| "Colorectal cancer is a leading cause of cancer-related death." | ( Hu, M; Liu, L; Yao, W, 2018) |
| "Colorectal cancer is the third leading cause of cancer-related deaths in the word." | ( Han, B; Huang, T; Jiang, P; Li, X; Li, Z; Ye, X; Yu, Y, 2018) |
| "Breast and colorectal cancer are the two most common cancers in Malaysia." | ( Dahlui, M; Donnelly, C; Donnelly, M; Loh, SY; Schliemann, D; Somasundaram, S; Su, TT; Tamin Ibrahim, NSB, 2018) |
| "BACKGROUND Colorectal cancer is one of the leading causes of death in China, and the development of effective drugs is urgently needed." | ( Li, LX; Pan, TJ; Wu, WZ; Yang, YK; Yang, ZS; Zhang, JW, 2018) |
| "Colorectal cancer is one of the most frequently diagnosed cancers worldwide." | ( An, C; Li, H; Mushtaq, N; Shi, Y; Ullah, S; Xu, J; Yang, F; Yuan, L; Zhang, S, 2018) |
| "Colorectal cancer is a heterogeneous group of diseases that result from the accumulation of different sets of genomic alterations, together with epigenomic alterations, and it is influenced by tumor-host interactions, leading to tumor cell growth and glycolytic imbalances." | ( Fu, XL; Gao, J; Guan, R; Shi, F; Sun, Y; Wang, G; Wang, JJ, 2019) |
| "Colorectal cancer is a common type of cancer with reported resistance to treatment, in most cases due to loss of function of apoptotic and cell-cycle proteins." | ( Aguzzoli, C; DA Silva Machado, F; Echeverrigaray, S; Henriques, JAP; Kato, MJ; Moura, S; Munari, FM; Pich, CT; Roesch-Ely, M; Scariot, FJ; Yamaguchi, L, 2018) |
| "Colorectal cancer is the third most common malignancy worldwide, with 1." | ( Almuaili, D; Geoghegan, J; Hand, F; Harmon, C; Hoti, E; Houlihan, DD; Lynch, L; Mentor, K; O'Farrelly, C; Robinson, MW, 2019) |
| "Colorectal cancer is one of the most common malignant disease worldwide with highly metastatic potential." | ( Li, Q; Li, Y; Wang, G; Xie, Y; Yang, F; Yang, S; Ye, T; Zhao, R; Zhou, J, 2019) |
| "Lower incidence of colorectal cancer is associated with increased fibre intake." | ( Biondo, LA; Costa, RGF; Diniz, TA; Mosele, FC; Rosa Neto, JC; Silveira, LS; Souza, CO; Teixeira, AAS, 2019) |
| "Tumor buds in colorectal cancer are hypothesized to undergo a (partial) epithelial-mesenchymal transition (EMT)." | ( Dawson, H; Galván, JA; Lugli, A; Meyer, SN; Sokol, L; Zahnd, S; Zlobec, I, 2019) |
| "Colorectal cancer is one of the most common malignancies worldwide and is associated with high mortality rates." | ( Aparicio, G; Francisco, M; González, ML; Lopes, MTP; Merino, N; Pérez, C; Piloto-Ferrer, J; Rodeiro, I; Sánchez-Lamar, Á, 2019) |
| "Colorectal cancer is one of the most common forms of cancer in the world, with more than half a million new cases annually." | ( Newton, PT, 2019) |
| "Colorectal cancer is one of the primary causes of cancer-related deaths and 5-fluorouracil (5-FU) therapy remains the cornerstone of treatment in these patients." | ( Bachvarov, CH; Bogdanova, MK; Chaushev, BG; Conev, NV; Dimitrova, EG; Donev, IS; Georgiev, KD; Kalchev, KP; Kashlov, YK; Manev, RR; Petrov, DP; Popov, HB; Radanova, MA; Todorov, GN, 2019) |
| "Colorectal cancer is the third most common cancer in men and the second in women." | ( Malheiro, M; Matos, LV; Pissarra, A; Plácido, AN, 2019) |
| "Colorectal cancer is one of the most common causes of cancer death worldwide." | ( Bode, AM; Chen, H; Choi, BY; Dong, Z; Huang, H; Lee, MH; Liu, X; Shim, JH; Song, M; Yin, F; Zhang, M; Zhao, R; Zhou, S, 2019) |
| "Colorectal cancer is the fourth cause of cancer related death." | ( Aravantinos, G; Gazouli, M; Katifelis, H; Lampropoulou, DI; Laschos, K; Lazaris, F; Papadimitriou, C; Theodosopoulos, T, 2019) |
| "Colorectal cancer is a common malignant tumour with a low 5-year survival rate." | ( Hou, R; Li, X; Liang, X; Ma, X; Wang, F; Zhang, X, 2019) |
| "Metastatic colorectal cancer is a stumbling block in colorectal cancer management due to limited treatment approaches and unfavorable prognosis." | ( Hu, Y; Lin, Y; Wang, B; Yang, D; Zhou, P, 2019) |
| "Colorectal cancer is one of the most common cancers worldwide and chemotherapy is the main approach for the treatment of advanced and recurrent cases." | ( Choong, CY; Lee, BH; Lin, LT; Shi, YC; Tai, CJ; Uen, WC, 2019) |
| "Colorectal cancer is one of the most common cancers among the elderly, which is also seen in the forms of hereditary syndromes occurring in younger individuals." | ( Ghazizadeh, S; Gholamzadeh, S; Majidinia, M; Mihanfar, A; Mirza-Aghazadeh-Attari, M; Mohammadzadeh, A; Mostavafi, S; Sadighparvar, S; Yousefi, B, 2020) |
| "Colorectal cancer is a common cancer with metachronous distant metastases still threatening overall survival." | ( Law, HKW; Tam, SY; Wu, VWC, 2019) |
| "Late-stage colorectal cancer is resistant to current treatments." | ( Kibi, M; Kobayashi, T; Kodama, Y; Nishiumi, S; Yoshida, M, 2019) |
| "Colorectal carcinoma is one of the utmost diagnosed cancer with a steep increase in mortality rate." | ( Balasubramanian, B; Liu, W; Manju, V; Natesan, K; Park, S; Thangaraj, K, 2019) |
| "Colorectal cancer is the second most common cause of cancer-related death globally, with marked differences in prognosis by disease stage at diagnosis." | ( Achaintre, D; Bachleitner-Hofmann, T; Baierl, A; Bergmann, MM; Boehm, J; Bours, MJL; Brenner, H; Breukink, SO; Brezina, S; Chang-Claude, J; de Wilt, JHW; Geijsen, AJMR; Gicquiau, A; Gigic, B; Gsur, A; Gumpenberger, T; Habermann, N; Hansson, BME; Herpel, E; Hoffmeister, M; Holowatyj, AN; Kampman, E; Karner-Hanusch, J; Keski-Rahkonen, P; Keulen, ETP; Kok, DE; Koole, JL; Leeb, G; Ose, J; Scalbert, A; Schirmacher, P; Schneider, MA; Schrotz-King, P; Stift, A; Ueland, PM; Ulrich, AB; Ulrich, CM; Ulvik, A; van Duijnhoven, FJB; van Roekel, EH; van Zutphen, M; Vogelaar, FJ; Weijenberg, MP; Wesselink, E, 2020) |
| "Colorectal cancer is the third leading cause of cancer death worldwide." | ( Albert, MS; Davenport, E; Davenport, K; Fox, MS; Li, T; Shepelytskyi, Y, 2019) |
| "Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed." | ( DiPrima, M; Ha, T; Kudlinzki, D; Kwak, H; Maric, D; Sanchez-Martin, D; Schwalbe, H; Terrades-Garcia, N; Tosato, G; Tröster, A; Wang, D, 2019) |
| "Colorectal cancer is a leading cause of death in the world." | ( Cho, EC; Hung, WH; Lee, KC; Zheng, JH, 2019) |
| "Colorectal cancer is one of the common malignant tumors." | ( Chen, S; Lin, M; Qiu, S; Shen, L; Shi, L; Xiang, Y; Xu, L; Zhao, C; Zhu, J; Zuo, Z, 2019) |
| "Colorectal cancer is the third important cause of cancer-associated deaths across the world." | ( Gupta, MK; Sarojamma, V; Vadde, R, 2019) |
| "Colorectal cancer is the fourth cause of cancer-related death." | ( Aravantinos, G; Gazouli, M; Lampropoulou, DI; Laschos, K; Papadimitriou, C; Theodosopoulos, T, 2019) |
| "As colorectal cancer is the fourth most common neoplasia in Europe with 28." | ( Costa, P; de la Fuente, VG; Fernández, J; García, MTF; Ledesma, E; Lombó, F; Martínez-Camblor, P; Millán, E; Monte, J; Villar, CJ, 2019) |
| "Colorectal cancer is a major cause of cancer-related deaths worldwide." | ( Cho, MK; Choi, H; Kim, HM; Lee, HW; Lee, K; Lim, CS; Noh, CK; Shin, SJ, 2019) |
| "Colorectal cancer is a common malignant tumor of the digestive tract, the morbidity rate of which is rising in recent years." | ( Cong, D; Cong, Z; Lei, X; Yang, B; Zhang, X; Zhao, Q; Zhou, Y, 2020) |
| "Colorectal cancer is one of the leading causes of cancer-related death in elderly people." | ( Kuang, Y; Tang, J; Wang, J; Wang, M; Wang, W; Zhang, R, 2020) |
| "Colorectal cancer is the third most commonly diagnosed cancer in the world, causing many deaths every year." | ( Alam, MN; Beale, P; Huq, F; Yu, JQ, 2020) |
| "Colorectal cancer is among the leading causes of death worldwide." | ( Abdel-Rasol, M; El-Beih, NM; El-Sayed, WM; Ismail, MA; Yahya, SMM, 2020) |
| " Colorectal cancer is the second most common malignancy diagnosed globally." | ( Abdelal, H; Alipour, Z; Amidi, E; Chapman, W; Chatterjee, D; Mostafa, A; Mutch, M; Nandy, S; Yang, G; Zhu, Q, 2019) |
| "Currently, colorectal cancer is emerging as the fourth leading cause of death and the third most common malignancy worldwide." | ( Dooghaie Moghadam, A; Eslami, P; Hashemi, MR; Iravani, S; Majidzadeh-A, K; Mansour-Ghanaei, A; Mansour-Ghanaei, F; Mehrvar, A; Moazzami, B, 2020) |
| "Colorectal cancer is the third most commonly diagnosed type of cancer and lacks targeted therapy for RAS or RAF mutation carrying cases." | ( Aigner, C; Baranyi, M; Dank, M; Garay, T; Hegedűs, B; Hegedűs, L; Jalsovszky, I; Molnár, E; Németh, A; Rittler, D; Shirasawa, S; Tímár, J; Tóvári, J; Varga, IK, 2020) |
| "The majority of colorectal cancers are resistant to cancer immune checkpoint inhibitors." | ( Allen, BG; Callaghan, C; Caster, JM; Hasibuzzaman, MM; Kalen, AL; Mapuskar, KA; Mott, SL; Petronek, MS; Pham, V; Seyedin, SN; Spitz, DR, 2020) |
| "Colorectal cancer is a major cause of mortality worldwide." | ( Alvarado, DM; Chen, B; Ciorba, MA; Iticovici, M; Kau, NS; Parikh, PJ; Park, H; Thotala, D, 2020) |
| "Colorectal cancer is one of the most common cancers all over the world and its incidence is increasing each day." | ( Asemi, Z; Hallajzadeh, J; Maleki Dana, P; Mansournia, MA; Mobini, M; Sharifi, M; Yousefi, B, 2020) |
| "Colorectal cancer is the third common cancer in this world, accounting for more than 1 million cases each year." | ( Li, B; Sheng, J; Sun, H; Yu, FB; Zhang, Y; Zhu, YT, 2020) |
| "Colorectal cancer is a digestive tract malignancy and the third leading cause of cancer‑related mortality worldwide." | ( Hu, C; Hua, Y; Yang, Y; Zhang, S; Zhong, Y, 2020) |
| "Colorectal cancer is the second most lethal cancer type across all ages and sexes, the many mechanisms of which are still currently being further elucidated." | ( Kim, HJ; Lee, HW; Oh, JH; Park, BM; Roh, JI, 2020) |
| "Colorectal cancer is the second most common cancer in women and the third most common cancer in men in the world." | ( Ashwin, KR; Deshpande, AY; Kumar, R; Reddy, GRK; Somashekhar, SP, 2021) |
| "Colorectal cancer is one of the most common cancers in the world." | ( Akkuş, E; Gürbüz, M; Utkan, G, 2021) |
| "Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease." | ( Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L, 2020) |
| "Colorectal cancer is the third most commonly occurring malignancy and is ranked second among the leading cause of cancer death globally." | ( Jayabalan, R; Johnson, EM; Lee, H; Suh, JW, 2020) |
| "Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide." | ( Artac, M; Ates, O; Beypinar, I; Demir, H; Eren, T; Ergun, Y; Korkmaz, M; Sakalar, T; Sakin, A; Taskoylu, BY; Turhal, S, 2021) |
| "Most colorectal cancers are microsatellite-stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies." | ( Nusrat, M, 2020) |
| "Colorectal cancer is a major health problem with a significant impact on the patients' quality of life." | ( Dai, J; Jia, X; Liu, C; Wang, N; Wu, Y; Yang, L; Zhang, R, 2021) |
| "Metastatic colorectal cancer is associated with poor overall survival and limited treatment options." | ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020) |
| "Colorectal cancer is the third most common cause of cancer-related death in the world because of its poor prognosis and many related complications." | ( Chen, M; Chen, Y; Lv, L; Tian, K; Wang, D, 2021) |
| "Colorectal cancer is one of the primary causes of cancer-related mortality worldwide." | ( Allam, RM; Salama, AAA, 2021) |
| "Colorectal cancer is of particular concern due to its high mortality rate count." | ( Boniewska-Bernacka, E; Dyrda, G; Janas, K; Słota, R, 2021) |
| "Colorectal cancer is relatively uncommon malignancy in India when compared with the Western world, disease affecting individuals above 40 years of age and is rare below 40 years of age." | ( Motepalli, PRK; Nukala, RL, 2020) |
| "Colorectal cancer is one of the commonest malignancies worldwide." | ( Amare, GG; Belayneh, YM; Meharie, BG, 2021) |
| "Colorectal cancer is the third most common cancer worldwide." | ( Chen, YM; Li, P; Liu, JF; Qiao, X; Wen, X; Yang, J; Zhang, BY; Zhang, L; Zhao, SL, 2021) |
| "Colorectal cancer is one of the malignant tumors with high morbidity and lethality." | ( An, J; Cheng, K; Hu, YG; Liu, B; Xuan, Y; Yang, XQ; Zhang, RY; Zhao, YD, 2021) |
| "Colorectal cancer is the second leading cause of cancer-related death worldwide." | ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| "Colorectal cancer is the second most common cause of cancer death worldwide." | ( Abdulhamid, AS; Alharbi, FA; Alomari, MS; Aziz, M; Ghaddaf, AA; Mullah, AN; Zaidi, SF, 2021) |
| "Colorectal cancer is the third most common cancer and second leading cause of cancer mortality in Australia, thus carrying a significant disease burden." | ( Burge, M; Dean, A; Gibbs, P; Jalali, A; Lee, B; Lee, M; Lim, SH; Min, ST; Nott, L; Roohullah, A; Shapiro, J; Steel, S; Tognela, A; Wong, HL; Wong, R; Yip, D; Zimet, A, 2022) |
| "The diagnosis of colorectal cancer is not difficult if the patient has typical symptoms; however, diagnosis may be difficult in cases with atypical symptoms and signs." | ( Harada, Y; Kawamura, R; Shimizu, T; Suzuki, Y, 2021) |
| "Colorectal cancer is one of the most common cancers throughout the world, and no definitive cure has ever been found." | ( Camci, IY; Nemati, M; Pouya, FD; Rasmi, Y; Tutar, Y, 2021) |
| "The pathogenesis of colorectal cancer is a multifactorial process." | ( Al-Otaibi, TM; Almarhoon, ZM; Alonazi, M; Barakat, A; Ben Bacha, A; El-Sayed, NNE; Masand, VH, 2021) |
| "Colorectal cancer is the second most common malignant tumor in China." | ( , 2021) |
| "Drug resistance in colorectal cancer is a great challenge in clinic." | ( Fang, Y; Liu, P; Shen, X; Wang, W; Wu, S; Zhang, H; Zhou, Y, 2021) |
| "The treatment of colorectal cancer is limited by high recurrence rate and multidrug resistance." | ( Cheng, Y; Han, X; Ma, X; Mo, F; Wang, H; Zeng, H; Zhao, Y; Zheng, Y, 2021) |
| "Colorectal cancer is one of the life-threatening ailments causing high mortality and morbidity worldwide." | ( Chae, HJ; Choi, H; Deshar, B; Kim, GJ; Kim, HJ; Kim, SH; Kwon, H; Nam, JW; Shin, MJ; Suh, SS; Youn, UJ, 2021) |
| "Colorectal cancer is a highly prevalent disease, requiring effective strategies for prevention and treatment." | ( Baranoski, A; Bittencourt Junior, FF; da Silva Fleming de Almeida, T; do Amaral, LA; Duenhas Monreal, AC; Freitas Dos Santos, E; Leite Kassuya, CA; Milan Brochado Antoniolli-Silva, AC; Murino Rafacho, BP; Oliveira de Souza, GH; Oliveira, RJ; Souza Maris, R, 2021) |
| "Colorectal cancer is the third most frequently diagnosed cancer malignancy and the second leading cause of cancer-related deaths worldwide." | ( Alijas, S; Alonso, MJ; Bouzo, BL; Conejos-Sánchez, I; de la Fuente, M; Jatal, R; Lores, S, 2021) |
| "Colorectal cancer is the third most common cancer and accounts for the second highest number of cancer-related deaths worldwide." | ( Guest, PC; Jamialahmadi, T; Majeed, M; Sahebkar, A; Tasbandi, A, 2022) |
| "Colorectal cancer is with high incidence worlwide." | ( Chen, R; Feng, D; Liu, Z; Qing, W; Xing, X, 2021) |
| "Colorectal cancer is one the most common cancers in the western world with increasing incidence." | ( Angelsen, JH; Bjørnbeth, BA; Fristrup, CW; Grønbech, JE; Hemmingsson, O; Isaksson, B; Juel, IS; Larsen, PN; Lindell, G; Mortensen, FV; Mortensen, KE; Rizell, M; Sandström, P; Sandvik, OM; Sparrelid, E; Taflin, H; Taskén, K; Yaqub, S, 2021) |
| "Colorectal cancer is the second leading cause of cancer deaths in Latinos in the U." | ( Carroll, JE; Cottrell, EC; Ezekiel-Herrera, DN; Gielbultowicz, SH; Heintzman, JD; Lucas, JA; Marino, M; Quiñones, AR, 2022) |
| "Colorectal cancer is the fourth most diagnosed malignancy worldwide and surgery is one of the cornerstones of the treatment strategy." | ( Burggraaf, J; Galema, HA; Hilling, DE; Hutteman, M; Keereweer, S; Lauwerends, LJ; Meijer, RPJ; Vahrmeijer, AL; Verhoef, C, 2022) |
| "Colorectal cancer is the third most commonly occurring cancer in men and the second in women." | ( Jäntti, MH; Nunn, RC; Talman, V; Tarvainen, I; Tuominen, RK, 2022) |
| "Colorectal cancer is one of the most frequent tumor entities, with an increasing incidence and mortality in younger adults in Europe and the United States." | ( Arnold, C; Boengler, K; Brunner, T; Christmann, M; Demuth, P; Fahrer, J; Huber, M; Linnebacher, M; Rasenberger, B; Seiwert, N; Wittmann, S, 2022) |
| "Colorectal cancer is the third most common cancer worldwide, with an obvious need for more accurate prognostics." | ( Beilmann-Lehtonen, I; Björkman, K; Böckelman, C; Haglund, C; Kaprio, T; Stenman, UH, 2022) |
| "Colorectal cancer is a common malignancy occurring in the digestive system and ranks second in cancer mortality worldwide." | ( Ding, K; Du, Z; He, J; Lu, W; Pan, X; Qi, Y; Yao, S; Zhou, M, 2021) |
| "Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC)." | ( Christy-Bittel, J; Ciardiello, F; Desai, J; Gollerkeri, A; Grothey, A; Kopetz, S; Maharry, K; Tabernero, J; Trevino, TL; Van Cutsem, E; Velez, L; Wasan, H; Yaeger, R; Yoshino, T, 2021) |
| "Colorectal cancer is the main leading cause of death from cancer worldwide." | ( Liu, Y; Rang, WQ; Wang, L; Xiong, WJ; Yu, C, 2021) |
| "Colorectal cancer is considered as a major cancer among all types of cancers, especially in developed countries." | ( An, L; Li, G; Li, P; Ma, J; Zhang, T, 2022) |
| "Colorectal cancer is globally one of the most common cancers in all age groups." | ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022) |
| "Colorectal cancer is one of the most deadliest malignancies worldwide." | ( Mehrgou, A; Teimourian, S, 2022) |
| "Colorectal cancer is a commonly diagnosed cancer worldwide." | ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| "Colorectal cancer is one of the most commonly diagnosed and deadly cancers worldwide." | ( Chang, H; Deng, Z; Fu, H; He, J; Li, C, 2023) |
| "Colorectal cancer is the third leading cause of cancer incidence and mortality in the United States." | ( Amarakoon, D; Lee, HS; Lee, SH; Song, HJ; Tamia, G; Wei, CI, 2022) |
| "Colorectal cancer is the third most frequently encountered cancer worldwide." | ( Assa, A; Holliday, N; Kowalski, M; Pai, SB; Patil, K; Terrell, C, 2022) |
| "The majority of colorectal cancer is diagnosed in patients following symptomatic presentation in the UK." | ( Abel, GA; de Wit, N; Funston, G; Moullet, M; Mounce, LT; Walter, FM; Zhou, Y, 2022) |
| "Colorectal cancer is one of the most commonly diagnosed malignancies globally and nearly half of these patients develop metastatic colorectal cancer (mCRC)." | ( Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW, 2022) |
| "Colorectal cancer is the third most common malignancy that leads to significant mortality around the world." | ( Chen, Y; He, Z; Ke, J; Le, Z; Liu, H; Liu, L; Liu, Z, 2022) |
| "Colorectal cancer is a major public health problem with significant number of cases and death in the population." | ( Abd Rahim, MA; Amir, PN; Avoi, R; Giloi, N; Hayati, F; Ibrahim, MY; Jeffree, MS; Oo Tha, N; Robinson, F; Syed Abdul Rahim, SS; Yusof, SN, 2022) |
| "Colorectal cancer is known as the third most common cancer in both women and men." | ( Cacan, E; Caldiran, FY, 2022) |
| "Colorectal cancer is the third most common cancer type worldwide." | ( Angelov, M; Atanasova, L; Hristova-Avakumova, N; Kamenova, K; Minchev, V; Nikolov, R; Surcheva, S; Todorov, L, 2021) |
| "Colorectal cancer is among the most frequently diagnosed cancers in patients today." | ( Alper, M; Ardıl, B, 2022) |
| "Colorectal cancer is among the most common cancers and accounts for nearly 9% of all cancers in the world." | ( Naqishbandi, AM, 2022) |
| "Colorectal cancer is related to ulcerative colitis." | ( Chen, Y; Diao, T; Li, D; Shang, G; Shi, L; Sun, L; Yin, X, 2022) |
| "Colorectal cancer is the most-incidence associated extremely high mortality rate worldwide." | ( Xu, C; Zhao, M; Zhu, H, 2022) |
| "Colorectal cancer is a significant cause of morbidity and represents a serious public health issue in many countries." | ( Aono, Y; Horinaka, M; Iizumi, Y; Imai, A; Ishikawa, H; Mutoh, M; Nishimoto, E; Ono, H; Sakai, T; Takakura, H; Taniguchi, K; Yasuda, S, 2022) |
| "Colorectal cancer is one of the most frequently diagnosed forms of cancer, and the therapeutic solutions are frequently aggressive requiring improvements." | ( Chioran, D; Coricovac, D; Dehelean, CA; Dinu, S; Dolghi, A; Grosu, C; Merghes, PE; Pinzaru, I; Sarau, CA, 2022) |
| "Colorectal cancer is one of the most common gastrointestinal malignancies globally." | ( Chen, H; Lai, S; Pang, Q; Wang, Y; Xiao, H, 2022) |
| "Colorectal cancer is a common cancer in both men and women." | ( Aderibigbe, BA; Alven, S; Buyana, B; Naki, T, 2022) |
| "Colorectal cancer is the fourth leading cause of cancer-related deaths that has significantly increased over the past three decades." | ( Habibian, A; Rezazadeh, A; Soleimanjahi, H; Soudi, S, 2022) |
| "Colorectal cancer is one of the most common gastrointestinal malignancies, with high incidence rates, a low rate of early diagnosis, and complex pathogenesis." | ( Bian, Y; Chai, R; Chen, Y; Li, J; Wang, X; Zhao, S, 2022) |
| "Colorectal cancer is one of the most common malignancies causing the majority of cancer-related deaths." | ( Huang, W; Jiapaer, Z; Li, C; Liu, H; Ma, W; Shao, S; Zhang, L, 2022) |
| "Colorectal cancer is a common malignancy of the gastrointestinal tract with an extremely high mortality rate." | ( Han, Z; Li, Y; Ma, Z; Qiao, M; Song, B; Wang, B; Xu, H; Yang, J; Yu, L, 2022) |
| "Colorectal cancer is a common malignancy of the gastrointestinal tract with an extremely high mortality rate." | ( Han, Z; Li, Y; Ma, Z; Qiao, M; Song, B; Wang, B; Xu, H; Yang, J; Yu, L, 2022) |
| "Colorectal cancer is the ninth leading cause of death in Spain." | ( de Castro, NM; García-Beloso, N; Gayoso-Rey, M; López-López, A; Piñeiro-Corrales, G; Robles-Torres, D; Romero-Ventosa, EY, 2022) |
| "Colorectal cancer is the ninth leading cause of death in Spain." | ( de Castro, NM; García-Beloso, N; Gayoso-Rey, M; López-López, A; Piñeiro-Corrales, G; Robles-Torres, D; Romero-Ventosa, EY, 2022) |
| "Colorectal cancer is the fourth most common cancer worldwide and the third most frequently diagnosed form of cancer associated with high mortality rates." | ( Car, H; Lazny, R; Markiewicz, KH; Milewska, S; Misztalewska-Turkowicz, I; Niemirowicz-Laskowska, K; Sawicka, D; Siemiaszko, G; Szymczuk, D; Wilczewska, AZ, 2023) |
| "Colorectal cancer is one of the most common types of cancer in the world and the study of the role of nutrients in preventing or inhibiting the growth of this cancer is of interest to scientists." | ( Ghavami, M; Haseli, R; Honarvar, M; Yavari, K, 2023) |
| "Colorectal cancer is one of the most common cancers worldwide with limited therapeutic options." | ( Azimpour, AI; Buchert, M; Burgess, AW; Cathcart-King, Y; Christie, M; Ernst, M; Faux, MC; Garnham, AL; Gogos, S; O'Keefe, R; Prato, E; Preaudet, A; Putoczki, TL; Weinstock, J, 2022) |
| "Colorectal cancer is the third leading cause of death in patients with cancers in America." | ( Deng, Y; He, TC; Qiao, M; Wang, J; Wei, Q; Yan, Z; Ye, J; Zhang, J; Zhou, Y, 2023) |
| "Colorectal cancer is a malignant disease with a high incidence and low survival rate, and the effectiveness of traditional treatments, such as surgery and radiotherapy, is very limited." | ( Guo, X; Huang, R; Jiang, C; Liu, Q; Liu, Y; Wang, M, 2023) |
| "Colorectal cancers are one of the most prevalent tumour types worldwide and, despite the emergence of targeted and biologic therapies, have among the highest mortality rates." | ( Brown, SD; Corbett, RD; Holt, RA; Jones, MR; Jones, SJM; Kalloger, S; Laskin, J; Lim, HJ; Marra, MA; Milne, K; Mungall, AJ; Mungall, K; Nelson, BH; Ng, T; Schaeffer, DF; Titmuss, E; Topham, JT; Williamson, LM; Wilson, D, 2023) |
| "Colorectal cancer is a disease of older patients, but few guidelines directly address age in their recommendations." | ( Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS, 2023) |
| "Colorectal carcinoma is the most common cancer of the gastrointestinal tract." | ( Eunus, MF; Hossain, MI; Karim, SN; Saleh, FM; Tanzim, MA, 2023) |
| "Colorectal cancer is among the frequently diagnosed cancers with high mortality rates around the world." | ( Fahimirad, S; Fattahi, F; Ghorbanpour, M; Hajmalek, N; Hassani, S; Kheradmand, F; Maghsoudi, H; Malekinejad, F; Sheikhnia, F, 2023) |
| "Colorectal cancer is one of the widespread and lethal types of malignancies." | ( Amin, M; Barzegari, E; Jamalan, M; Navidifar, T; Saeb, S, 2023) |
| "Colorectal cancer is among the most prevalent and lethal cancers globally." | ( De Stefano, L; Rea, I; Tramontano, C, 2023) |
| "Colorectal carcinoma is the second most common cause of cancer-related deaths in North America." | ( Alghamdi, S; Alloush, F; Bahmad, HF; Kilinc, E; Lusnia, C; Poppiti, RJ; Salami, A; Sawah, R; Sutherland, T, 2023) |
| "Colorectal cancer is the commonest cancer in multi-ethnic Singapore and requires surgery for curative treatment." | ( Au-Yong, A; Aw, D; Chin, SE; Chong, CXZ; Chong, Y; Foo, FJ; Gwee, R; Ho, LML; Khoo, N; Koh, D; Koh, FH; Ladlad, J; Lie, SA; Loh, L; Matthews, A; Ng, JL; Sivarajah, SS; Tan, WJ; Wan, FT; Zaw, MW, 2023) |
| "Colorectal cancer is the most prevalent gastrointestinal neoplasm." | ( Voutsadakis, IA, 2023) |
| "Colorectal cancer is a heterogenous group of neoplasms showing a variety of clinical and pathological features depending on their anatomical location." | ( Błachnio-Zabielska, AU; Markowska, AJ; Markowski, AR; Pogodzińska, K; Zabielski, P, 2023) |
| "Colorectal cancer is the third most common cancer, with nearly 2 million cases worldwide and just under 1 million deaths in 2020." | ( Di Re, A; Shah, D; Toh, JWT, 2023) |
| "Colorectal cancer is still a major global health concern, and early detection and accurate biomarker analyses are critical to its successful management." | ( Rouhi, J; Tao, C, 2023) |
| "Colorectal cancer is a malignant tumor that poses a serious threat to human health." | ( Deng, Y; Gong, W; Hou, X; Huang, L; Li, C; Liang, W; Mo, C; Ou, M; Sha, Y, 2023) |
| "Colorectal cancer is one of the most common malignancies." | ( Arıkan, S; Demircioglu, MK; Duzkoylu, Y; Kılavuz, H; Sarı, S, 2023) |
| "Colorectal cancer is a major public health concern, with increasing incidence and mortality rates worldwide." | ( Bonfiglio, R; Casciardi, S; Giacobbi, E; Mauriello, A; Melino, G; Palumbo, A; Palumbo, V; Scimeca, M; Scioli, MP; Servadei, F; Sisto, R; Trivigno, D, 2024) |
| "Colorectal cancer is still unmanageable despite advances in target therapy." | ( Aragão, CFS; da Matta Guedes, PM; de Araújo Júnior, RF; de Carvalho, TG; de Paiva Souza, SV; de Santana Oliveira, A; Garcia, VB; Jorquera-Cordero, C; Lara, P; Schomann, T; Soares, LAL, 2023) |
| "Colorectal cancer is a common malignant tumour." | ( Guo, P; Li, J; Liu, B; Liu, W; Yao, P; Zhao, G; Zheng, X, 2023) |
| "Colorectal cancer is one of the most common malignant tumors in the digestive system, and its high incidence and metastasis rate make it a terrible killer that threatens human health." | ( Li, Y; Peng, Q; Wang, L, 2023) |
| "Colorectal cancer is the third most common malignant tumor worldwide, causing serious harm to human health." | ( Ge, L; Lin, Y; Ma, Z; Shi, H; Wu, L, 2023) |
| Excerpt | Reference |
|---|
| "Thirty patients with advanced colorectal cancer were treated preoperatively by combined regional radiofrequency hyperthermia and 5-FU." | ( Wu, GR, 1992) |
| "148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2." | ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "The benefits from medical treatment in colorectal cancer are limited." | ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease." | ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Seventeen patients with colorectal cancer who failed local chemotherapy received 5-FU as a 4-hour infusion, preceded by a bolus of FA and IFN." | ( Boese-Landgraf, J; Boewer, C; Hilgenfeld, RU; Hoksch, B; Knauf, WU; Kreuser, ED; Matthias, M; Oldenkott, B; Schalhorn, A; Zeitz, M, 1992) |
| "Twenty-four patients with advanced colorectal cancer received two cycles of combination chemotherapy consisting of mitomycin 10 mg/m2 for 5 days continuous infusion and allopurinol 300 mg x 3/day p." | ( Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992) |
| "A cohort of 35 patients with advanced colorectal cancer, not previously exposed to chemotherapy, were included in a phase II study exploring the combination of interferon-alpha, 9 MU subcutaneously three times weekly, and 5-fluorouracil 750 mg/m2/day during 5 consecutive days in continuous intravenous infusion followed with weekly bolus injection of fluorouracil 750 mg/m2." | ( Antón, A; Aranda, E; Blanco, E; Camps, C; Díaz Rubio, E; González Larriba, JL; Jimeno, J; Lízón, J; Massuti, B, 1992) |
| "Thirty-three patients with advanced colorectal cancer were treated with this combination." | ( Bisagni, G; Boni, C; Ceci, G; Cocconi, G; Di Blasio, B; Passalacqua, R, 1991) |
| "Ninety-six patients with colorectal cancer (stage B2-C) were randomized to the control arm or to receive adjuvant chemotherapy with folinic acid, FU and MMC." | ( Astone, A; Barone, C; Cassano, A; Coco, C; Franchi, F; Netri, G; Pozzo, C; Ratto, C; Ricevuto, E; Sofo, L, 1991) |
| "Advanced colorectal cancer belongs to the most chemotherapy-resistant human malignancies." | ( Blijham, GH, 1991) |
| "Two groups of patients with colorectal cancer and remote metastases in the liver are presented: one received surgical treatment alone, the other combined therapy." | ( Dimitrov, V; Dudunkov, Z; Kurtev, P; Kurteva, G; Ralchev, K, 1991) |
| "17 patients with metastasizing colorectal cancer were treated in a phase II-study with systemic intravenous chemotherapy (Petrelli N, Proc ASCO 286, 1987) consisting of leucovorin 500 mg/m2 in a 2 hr infusion and 5-fluorouracil (5-FU) 600 mg/m2 bolus one hour after the commencement of the leucovorin infusion." | ( Baur, M; Dittrich, C; Havelec, L; Mader, R; Marosi, C; Scheithauer, W; Schlappack, O, 1991) |
| "Chemotherapy for colorectal cancer with liver metastases following surgical operation for primary tumor should be selected following surgical intervention." | ( Ishida, Y; Kojima, N; Kusumoto, S; Nakayoshi, A; Oka, H, 1991) |
| "With colorectal cancer, the therapeutic outcome for multiple hepatic metastasis extending to the bilateral lobe, even when various chemotherapies are administered, is extremely poor." | ( Gotohda, H; Katoh, M; Kinami, Y; Kumaki, T; Saitoh, H; Takashima, S; Takegawa, S; Tomita, F, 1991) |
| "Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole." | ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991) |
| "The substantial recurrence rate of colorectal cancer following potentially curative resection has fuelled the search for effective adjuvant therapy." | ( Green, M; Wirth, A; Zalcberg, JR, 1991) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| "After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy." | ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990) |
| "Fourteen colorectal cancer patients with metastatic liver metastases who received prophylactic intra-arterial infusion chemotherapy (IAIC) after curative resection for liver metastases at the National Cancer Center Hospital from May 1987 to December 1989 were reviewed." | ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| "To improve the detection of colorectal neoplasms by CT we prospectively studied the use of intrarectally administered water for CT scan in 16 patients with colorectal cancer proved by barium enema and endoscopy." | ( Deininger, HK; Gaa, J, 1990) |
| "In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP." | ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990) |
| "Forty-one patients with advanced colorectal cancer were entered into a randomized controlled trial of treatment with proglumide--a gastrin receptor antagonist." | ( Ballantyne, KC; Charnley, RM; Jones, J; Morris, DL, 1990) |
| "Of 24 evaluable patients with colorectal cancer, 1 complete and 9 partial responses were seen (42%); 4 of 10 patients who had been refractory to conventional FU treatment responded to the FU/LV regimen." | ( Anderson, I; Mortimer, JE, 1990) |
| "Fifty-nine colorectal cancer patients with metastatic liver cancer who underwent intra-arterial infusion chemotherapy (IAIC) at the National Cancer Center Hospital from May 1986 to February 1989 were reviewed." | ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Fifty-nine colorectal cancer patients with metastatic liver cancer who underwent intra-arterial infusion chemotherapy (IAIC) at the National Cancer Center Hospital from May 1986 to February 1989 were reviewed." | ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter." | ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989) |
| "Thirty-two patients with untreated advanced colorectal carcinoma received high-dose methotrexate pretreatment followed sequentially by 5-fluorouracil (5-FU)." | ( Ajani, JA; Bedikian, AY; Kanojia, MD, 1989) |
| "Seven patients with metastatic colorectal cancer have been treated with a regimen involving an 120-hour continuous infusion of rIL-2, 3 x 10(6) mu/m2." | ( Franks, CR; Hamblin, TJ; Inzani, V; Palmer, P; Sadullah, S; Stevenson, FK; van der Plas, J; Williamson, P, 1989) |
| "27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)." | ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989) |
| "Indications and contraindications for treatment of colorectal carcinomas with chemotherapeutic agents are described." | ( Herrmann, R, 1988) |
| "In progressive colorectal cancer these treatment results can be regarded as a significant change in the natural history of the disease." | ( Freund, M; Poliwoda, H; Preusser, P; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, H, 1988) |
| "Fifteen patients with 12 metastatic colorectal cancers, one carcinoid, one islet cell tumor, and one hepatoma were treated with three dose levels: 5,000 cGy (5,000 rad), ten patients; 7,500 cGy (7,500 rad), three patients; and 10,000 cGy (10,000 rad), two patients." | ( Atri, M; Boos, GJ; Bret, PM; Herba, MJ; Illescas, FF; Rosenthall, L; Thirlwell, MP, 1988) |
| "Twenty-two patients with advanced colorectal cancer (CRC) (12 without prior chemotherapy) and fourteen with pretreated breast cancer (BC) were given mitozolomide (MTZ), IV infusion, every six weeks." | ( Armand, JP; Delgado, FM; Hayat, M; Herait, P; May-Levin, F; Oliveira, J; Rougier, P, 1988) |
| "Twenty-four patients with metastatic colorectal cancer were treated with recombinant IL-2 (rIL-2) by continuous intravenous infusion for 5 days (18 x 10(6) U/m2 per 24 h), followed by three injections of 5-fluorouracil (600 mg/m2) and folinic acid (25 mg/m2) at weekly intervals." | ( Broom, J; Eremin, O; Heys, SD; Simpson, WG; Whiting, PH, 1995) |
| "Twenty-one patients with advanced colorectal cancer, all previously pretreated with a fluoropyrimidine-based regimen, received oral etoposide: 100 mg/die for 21 consecutive days, every three weeks." | ( Barni, S; Frontini, L; Labianca, R; Luporini, G; Marini, G; Pancera, G; Zaniboni, A, 1995) |
| "Four colorectal cancer patients with numerous metastases to both lobes of liver were given intraarterial administration of above anticancer drugs every 1-2 weeks after resection of primary lesions." | ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995) |
| "A total of 496 previously untreated colorectal cancer patients were randomized to receive either Roferon-A (9 MIU) subcutaneously three times per week, with 5-FU (750 mg/m2/d) by continuous intravenous (i." | ( , 1995) |
| "Stage-adjusted treatment of colorectal tumors requires precise knowledge of the extent of the underlying disease." | ( Binter, G; Lechner, P; Lind, P, 1995) |
| "Twenty patients with metastatic colorectal cancer who were not responsive or in progression within 6 months after completing fluoropyrimidine-based chemotherapy entered the study." | ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "Forty-three elderly metastatic colorectal cancer patients entered the study: their median ECOG performance status was 1 (0-2) and median age 74 years (69-83), the predominant site of metastasis was liver and all but one of the patients had received no previous chemotherapy." | ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "The risk of colorectal cancer among patients with ulcerative colitis can be reduced through pharmacological therapy." | ( Adami, HO; Baron, J; Ekbom, A; Pinczowski, D; Yuen, J, 1994) |
| "Two cases of hepatic metastasis of colorectal cancer were treated effectively by intrahepatic-arterial infusion immunotherapy using OK-432 (2 KE/week or 2 weeks), recombinant IL-2 (35 x 10(4) JRU or 40 x 10(4) JRU/week or 2 weeks), MMC (4 mg/week or 2 weeks) and 5-FU (250 mg/day during admission, 250 mg/week or 2 weeks during outpatient treatment)." | ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Kurosaka, Y; Matsushita, M; Takashima, S; Tomita, F, 1994) |
| "Better prognostic predictors in colorectal cancer than the Dukes stage are necessary for individualized therapy and follow-up." | ( Bergström, R; Gerdin, B; Glimelius, B; Lindmark, G; Påhlman, L, 1994) |
| "A total of 101 patients with advanced colorectal cancer in two consecutive Southern Italian Oncology Groups (GOIM) studies (8501 and 8801--arm A) were treated with a sequential combination of high dose methotrexate (HDMTX) and fluorouracil (FU)." | ( Colucci, G; Giotta, F; Giuliani, F; Leo, S; Maiello, E; Pedicini, A; Pezzella, G; Prete, F; Romito, S; Valori, V, 1994) |
| "Second-line therapy of patients with colorectal cancer metastatic to the liver is unsatisfactory." | ( Bakal, CW; Cynamon, J; Haynes, H; Kaleya, R; Martinelli, DJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1994) |
| "Twenty-four patients with unresectable colorectal cancer with bulky liver metastases who had failed prior systemic therapy were randomized to treatment with either embolization or chemoembolization." | ( Bakal, CW; Cynamon, J; Haynes, H; Kaleya, R; Martinelli, DJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1994) |
| "Patients with advanced colorectal cancer were treated with 5-FU (300 mg/m2/day) given as a protracted venous infusion via an indwelling central venous catheter and portable battery driven pump." | ( Carter, R; Cunningham, D; Evans, C; Findlay, M; Ford, H; Hill, A; Husband, J; Nicolson, M; Norman, A, 1994) |
| "Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination." | ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994) |
| "The current EORTC study for colorectal cancer investigates the role of the combination of short time regional and long term systemic chemotherapy." | ( Schmoll, HJ, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "Nineteen patients with advanced colorectal cancer were treated with continuous intravenous infusion of 5-FU (500 mg/day)." | ( Ando, J; Kotake, K; Koyama, Y; Nasu, J; Ogata, Y; Ozawa, I, 1994) |
| "Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment." | ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | ( Nordlinger, B; Rougier, P, 1993) |
| "Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper." | ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7-neocarzinostatin (A7-NCS)." | ( Honda, M; Kitamura, K; Noguchi, A; Otsuji, E; Takahashi, T; Yamaguchi, T, 1993) |
| "The treatment of advanced colorectal cancer has improved in recent years." | ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W." | ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995) |
| "Twenty-four patients previously treated for colorectal carcinoma who had suspected recurrence to the liver underwent an 18FDG PET scan of the entire body." | ( Campbell, MG; Chapman, WC; Delbeke, D; Pinson, CW; Powers, TA; Sandler, MP; Vitola, JV; Wright, JK, 1996) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)." | ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995) |
| "Consistent results from studies of colorectal cancer in Japan, the United States, and Europe, indicate that CPT-11 is active as a single agent in patients who have developed progressive disease following 5-fluorouracil (5-FU)-based treatment." | ( Rothenberg, ML, 1996) |
| "79 patients with measurable advanced colorectal cancer (CRC) and no prior chemotherapy were included." | ( Blanco, E; Colmenarejo, A; de la Gándara, I; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Juárez, F; Martínez-Martínez, B, 1995) |
| "Chemotherapy for advanced colorectal cancer is reviewed stressing the historical development of combination chemotherapy and the application of a new idea called biochemical modulation based upon a preclinical biochemical and molecular pharmacological rationale." | ( Aiba, K, 1996) |
| "24 evaluable patients at high risk for colorectal cancer were treated in a dose-finding study with oltipraz 125, 250, 500, or 1,000 mg/m2 as a single oral dose." | ( Balshem, AM; Brennan, J; Clapper, ML; Engstrom, PF; Frucht, H; Gallo, JM; Goosenberg, EB; Green, F; Halbherr, TC; Hamilton, TC; Litwin, S; O'Dwyer, PJ; Pfeiffer, GR; Szarka, CE; Yao, KS, 1996) |
| "Forty-six patients with colorectal cancer were studied for the effects of intraportal chemotherapy in terms of the administered dose of 5-FU." | ( Akaishi, O; Hanai, A; Kikuchi, K; Matsuzaki, H; Miyake, H; Oikawa, H; Ozasa, T; Seo, K; Tanaka, K; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 1996) |
| "Twenty patients resected for colorectal cancer were treated with 20 g/day of the fibre Plantago ovata seeds for 3 months, which increased the intake of fibre by 17." | ( Clausen, MR; Hove, H; Mortensen, PB; Nordgaard, I, 1996) |
| "Patients with far advanced colorectal cancers received chemotherapy consisting of low-dose cyclophosphamide (LDCY) 333 mg/m2 every four weeks intravenously and by oral administration of 5'-DFUR (a masked compound of 5-Fluorouracil)." | ( Fujiwara, T; Hizuta, A; Iwagaki, H; Orita, K; Perdomo, JA; Tanaka, N, 1996) |
| "Twenty-two patients with colorectal cancer and synchronous unresectable hepatic metastases were treated by resection the primary tumour with concurrent insertion of an Infusaid infusaport system for regional chemoperfusion (hepatic arterial 20, portal venous 2)." | ( Clingan, PR; Dasappa, V; King, DW; King, J; Morris, DL; Ross, WB, 1996) |
| "For first-line treatment of metastatic colorectal cancer, the best available regimens have been those which include 5-fluorouracil (5-FU) and folinic acid; a meta-analysis of nine randomised clinical studies of such regimens produced a mean response rate of 23%." | ( Cunningham, D, 1996) |
| "In patients with colorectal cancer, the administration of adjuvant intraportal chemotherapy (with mitomycin and fluorouracil) has been reported to improve long-term survival in comparison with patients who are not given this treatment." | ( Bonistalli, L; Costantini, M; Messori, A; Tendi, E; Trallori, G, 1996) |
| "Forty-four patients with metastatic colorectal cancer were treated, predominantly on an outpatient basis, with subcutaneous IFN alpha-2a and IL-2 three times per week followed by once a week bolus intravenous 5-FU injections." | ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996) |
| "In 37 patients with colorectal cancer, 5'-DFUR was administered orally/preoperatively (800 mg/day x more than 4 days before operation and 300 mg on the day of operation)." | ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol." | ( Hausamen, TU; Loeffler, TM, 1996) |
| "Fifty-two patients previously treated for colorectal carcinoma presented on 61 occasions with suspected recurrence and underwent 18FDG-PET of the entire body." | ( Arildsen, RC; Chapman, WC; Delbeke, D; Pinson, CW; Powers, TA; Sandler, MP; Vitola, JV; Wright, JK, 1997) |
| "In the chemotherapy of colorectal cancers the most frequently given drug is 5-fluorouracil, which in certain cases reduces or delays the appearance of the local recurrence or metastasis." | ( Fónyad, G; Jeney, A; Katona, C; Kralovánszky, J; Pandi, E; Rosta, A; Tóth, K, 1997) |
| "Forty-six disseminated colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based determination of TS mRNA pretreatment." | ( Baranda, J; Boswell, W; Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Tan, M, 1997) |
| "Advanced colorectal cancer is currently treated with 5-fluorouracil, generally in combination with other agents such as leucovorin." | ( Judson, IR, 1997) |
| "The standard regimen for treatment of colorectal cancer is combination 5-FU plus leucovorin (LV)." | ( Grem, JL, 1997) |
| "In patients with metastatic colorectal cancer (CRC), conventional chemotherapy with 5-fluorouracil (5-FU) plus leucovorin provides an overall response rate of approximately 25% but has had little effect on survival." | ( Clark, JW, 1997) |
| "Based on the observation that colorectal tumors have increased levels of topoisomerase I relative to normal tissue, investigations have focused on the camptothecin derivatives, particularly topotecan, as an effective treatment." | ( Creemers, GJ, 1997) |
| "Over the last 40 years the treatment of colorectal cancer has not achieved the same progress as treatment for other types of tumors." | ( Franchi, F; Satta, F, 1997) |
| "The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy." | ( Colditz, GA; Fuchs, C; Giovannucci, E; Grodstein, F; Kautzky, M; Martinez, ME; Platz, EA; Stampfer, MJ, 1998) |
| "The 24 patients with advanced colorectal cancer were divided into 2 groups randomly and both were treated with 5-FU 250 mg/day by continuous hepatic arterial infusion for three weeks." | ( Ishida, H; Ishikawa, K; Itoh, I; Iwase, H; Kameya, T; Makuuchi, H; Mukai, M; Ohtaki, M; Sadahiro, S; Suzuki, T; Tajima, T; Tokunaga, N; Yasuda, S, 1998) |
| "Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks." | ( Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G, 1998) |
| "In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worsening of disease-related symptoms and quality of life (QOL)." | ( Michael, M; Moore, MJ, 1998) |
| "Three patients with colorectal cancer and pulmonary metastasis who had previously undergone surgical treatment, were treated by combination chemotherapy with CDDP and 5-FU regimen, but the growth of the metastatic tumor could not be controlled finally." | ( Horie, H; Hosoya, Y; Ishizuka, T; Kanazawa, K; Kashiwagi, H; Kojima, M; Konishi, H; Shitou, K, 1998) |
| "The review focuses on the treatment of colorectal cancer and summarizes the Japanese experience and the phase I and II trials performed in the United States and Europe." | ( Benner, SE; Canetta, RM; Sulkes, A, 1998) |
| "The treatment of colorectal cancer severely affects both patients suffering from colorectal cancer and their families." | ( Berg, D, 1998) |
| "Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio." | ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "The treatment of advanced colorectal cancer has been evaluated in a series of randomized trials, including infusional and modulated 5-fluorouracil (5-FU), and three meta-analyses encompassing trials of 5-FU plus leucovorin, continuous-infusion 5-FU, and intra-arterial fluoropyrimidines." | ( Benson, AB, 1998) |
| "Patients with advanced measurable colorectal cancer who had failed previous therapy with intravenous bolus 5-fluorouracil (5-FU) were eligible." | ( Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999) |
| "Treatments of advanced colorectal cancer progressing after a 5FU based chemotherapy have not been extensively studied." | ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin, were enrolled onto this study." | ( Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Raderer, M; Scheithauer, W; Valencak, J; Weinländer, G, 1999) |
| "Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only." | ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999) |
| "A total of 39 colorectal cancer samples from patients were treated in vitro with 5-FU (10 microg/ml), 5-FU (10 microg/ml) + leucovorin (5 microg/ml), HCPT (0." | ( Li, N; Ou, Q; Shen, B; Wang, H; Yu, B; Zhang, H; Zheng, M, 1999) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)." | ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999) |
| "A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks." | ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999) |
| "16 patients with advanced colorectal cancer were treated with 650 mg/m2/d fluorouracil as 5 day continuous infusion and randomized to receive either 20 mg/m2 or 100 mg/m2 calcium folinate as short infusion twice daily." | ( Jaehde, U; Kreuser, ED; Schunack, W; Streit, M; Stremetzne, S, 1999) |
| "The surgical treatment of colorectal cancer (CRC) in elderly patients (age 70 years or older) has improved, but data on adjuvant and palliative chemotherapy tolerability and benefits in this growing population remain scarce." | ( Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ, 1999) |
| "Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy." | ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "In phase II trials in patients with colorectal cancer that was recurrent or refractory to 5-Ruorouracil (5-FU)based front-line therapy, response rates of 14% to 22% and median survival times of 8 to 10 months have been consistently reported by groups from Japan, Europe, and the United States using avariety of drug administration schedules Two recently reported phase III trials comparing CPT-II against infusional 5-FU or best supportive care demonstrated that CPT-II confers a survival advantage over either of the two other approaches." | ( Blanke, CD; Rothenberg, ML, 1999) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| "Examining drug-resistant proteins in colorectal cancers may be useful in selecting adjuvant chemotherapy and in predicting prognosis more accurately." | ( Hishikawa, Y; Kohno, H; Kubota, H; Nagasue, N; Nakashima, Y; Sutoh, I; Tabara, H; Tachibana, M, 2000) |
| "60 patients with metastatic colorectal cancer were included in a phase II trial in which 50% of patients had received prior chemotherapy of up to three regimens." | ( Focan, C; Focan-Henrard, D; Kreutz, F; Moeneclaey, N, 2000) |
| "To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III." | ( Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J, 2000) |
| "In patients with colorectal cancer, selective high 5-fluorouracil concentration in the cancer tissue could be achieved by a combination of 5'-deoxy-5-fluorouridine and local immunotherapy with a mixture of OK-432 and fibrinogen." | ( Amano, M; Haba, A; Monden, M; Monden, T; Ohue, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N, 2000) |
| "Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating from 0." | ( Beijnen, JH; Keizer, HJ; Kuppen, PJ; Marinelli, A; Mulder, GJ; Pijl, ME; Tollenaar, RA; Vahrmeijer, AL; van Bockel, JH; van de Velde, CJ; van Dierendonck, JH, 2000) |
| "Two patients with advanced colorectal cancer were consecutively administered two different chemotherapeutic regimens." | ( Endo, W; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T, 2000) |
| "In this study, we have focused on colorectal cancer, which is known to be highly resistant to genotoxic chemotherapy and gamma irradiation." | ( Baldwin, AS; Cusack, JC; Liu, R, 2000) |
| "A total of 35 patients with primary colorectal cancer who underwent surgical treatment were examined by chemosensitivity test with the viable tumor samples using Histoculture Drug Response Assay (HDRA)." | ( Imaseki, H; Isono, K; Iwasaki, K; Kondo, S; Kouno, T; Makino, H; Nakajima, K; Natsume, T; Ochiai, T; Okazumi, S; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 2000) |
| "Fifteen patients with colorectal cancer (nonresectable, 1; noncurative resection, 5; recurrent disease, 9) were treated with CPT-11 (40-50 mg/m2) plus CBDCA (70-100 mg/m2) once a week for 2-3 weeks followed by a one-week rest." | ( Fujioka, M; Hashimoto, D; Idezuki, Y; Inokuma, S; Ishida, H; Ishizuka, N; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Okita, H; Suzuki, T; Takahama, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2000) |
| "Treatment of advanced colorectal cancer has progressed substantially." | ( Burzykowski, T; Buyse, M; Carlson, RW; Molenberghs, G; Piedbois, P; Thirion, P, 2000) |
| "Treatment of human colorectal cancer cells HT29 with interleukin 1beta (IL-1beta) induces expression of the multidrug resistance protein (MRP1) gene encoding the ATP-dependent glutathione S-conjugate export (GS-X) pump and the gamma-glutamylcysteine synthetase (gamma-GCSh) gene encoding heavy (catalytic) subunit of gamma-glutamylcysteine synthetase, the rate-limiting enzyme for the biosynthesis of glutathione (GSH)." | ( Ikegami, Y; Ishikawa, T; Kuo, MT; Lin-Lee, YC; Tatebe, S; Xie, QW, 2000) |
| "A total of 10 patients with metastatic colorectal cancer, all of whom had developed progressive disease from advanced or metastatic colorectal cancer while receiving or within 6 months after discontinuing first-line chemotherapy with 5-FU and leucovorin, were entered in this study." | ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "In patients with metastatic colorectal cancer, intravenous oxaliplatin has been trialled as a monotherapy and in combination with other agents." | ( Clemett, D; Culy, CR; Wiseman, LR, 2000) |
| "Among colorectal cancer patients with recurrent or metastatic sites, survival was significantly prolonged for a group undergoing LV/5-FU therapy based on biochemical modulation compared with a group receiving no chemotherapy (best supportive care)." | ( Maeda, Y; Sasaki, T, 2000) |
| "Gastrin is a growth factor for colorectal cancer, and therefore, anti-gastrin hormone therapy has a potential role in treatment of this disease." | ( Justin, T; Michaeli, D; Smith, AM; Watson, SA, 2000) |
| "Gene therapy for colorectal cancer is still in the early stages of development, and fundamental research in the molecular and cellular biology will improve the therapy." | ( Kaibara, N; Nakamura, S, 2001) |
| "The mainstay of chemotherapy in colorectal cancer patients for the past 40 years has been fluorouracil (5-FU)." | ( Rothenberg, ML, 2000) |
| "Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d." | ( Govindarajan, R, 2000) |
| "Patients with advanced colorectal cancer who had received prior therapy were eligible for the trial." | ( Lange, LM; Shields, AF; Zalupski, MM, 2001) |
| "In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration." | ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of 5-fluorouracil with leucovorin or levamisole." | ( Kerr, DJ, 2001) |
| "Inhibition of NF-kappaB activation in colorectal cancer cells was performed by treatment of LOVO cells with PS-341 or infection with an adenovirus encoding IkappaB super-repressor, a selective NF-kappaB inhibitor." | ( Adams, J; Baldwin, AS; Cusack, JC; Elliott, P; Liu, R; Russo, SM; Tepper, JE, 2001) |
| "Peritoneal seeding from colorectal cancer has a very poor prognosis and is relatively resistant to systemic chemotherapy." | ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "Fluoropyrimidine therapy for elderly colorectal cancer patients remains controversial." | ( Fujioka, M; Hashimoto, D; Hoshino, T; Idezuki, Y; Inokuma, S; Ishida, H; Murata, N; Nakada, H; Ohsawa, T; Takeuchi, I, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "Treating elderly patients with colorectal cancer is a challenging task for which many aspects have to be taken into account." | ( Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U, 2001) |
| "Metastatic colorectal cancer patients with measurable disease who were chemotherapy-naive or pretreated only with a 5-FU-bolus-based chemotherapy were eligible for this study." | ( Allegrini, G; Bocci, G; Brunetti, I; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "Treatment for advanced colorectal cancer has nevertheless made progress in the last few years." | ( Beretta, GD; Labianca, R; Mosconi, S; Pessi, MA; Poletti, P, 2001) |
| "Of a cohort of 1,242 patients with colorectal cancer (documented in 213 centres), 616 had received complementary treatment with OE (182 OE only, 405 other complementary drugs, 29 protocol violators) and 626 had not received OE (368 control only, 229 other complementary drugs, 29 protocol violators)." | ( Bock, PR; Hanisch, J; Kulig, J; Popiela, T, 2001) |
| "Complementary treatment of colorectal cancer patients with OE improves their quality of life by reducing both the signs and symptoms of the disease and the adverse reactions associated with adjuvant antineoplastic therapies." | ( Bock, PR; Hanisch, J; Kulig, J; Popiela, T, 2001) |
| "For patients with incurable stage IV colorectal cancer, minimally symptomatic primary tumours were left in situ and 5-fluorouracil-based chemotherapy was administered systemically." | ( Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT, 2001) |
| "Subjects were advanced/recurrent colorectal cancer patients with lung metastasis, who underwent concomitant drug administration with 533 mg/m2/day of 5'-DFUR orally and 4 mg/m2/day of MMC every 2 weeks intravenously." | ( Fujita, H; Hiki, Y; Ike, H; Mitomi, T; Otani, Y; Oya, K; Sadahiro, S; Shimada, H; Yamaguchi, S, 2001) |
| "Chemotherapy for advanced colorectal cancer is based on i." | ( Cassidy, J; Hoff, PM; Schmoll, HJ, 2001) |
| "Metastatic colorectal cancer has traditionally been treated with i." | ( Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H, 2001) |
| "The repeated use of chemotherapy to treat patients with colorectal carcinoma may be limited by the fact it creates resistance cells." | ( Akiyama, S; Ando, H; Hibi, K; Hidemura, K; Ito, K; Kasai, Y; Nakao, A; Wong, L, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "(1) The reference treatment for colorectal cancer is surgery." | ( , 2001) |
| "There were 967 patients with colorectal cancers treated in Christchurch Hospital during the study period 1991-1995." | ( Coates, R; Frizelle, F; Israel, L; Lyall, P; McDonald, S, 2001) |
| "In patients with advanced or metastatic colorectal cancer, first-line therapy with intermittent capecitabine achieved significantly higher objective tumour response rates than therapy with fluorouracil plus leucovorin in pooled analysis." | ( Goa, KL; McGavin, JK, 2001) |
| "Thirty-one patients with advanced colorectal cancer were treated with a regimen of epirubicin, cisplatin and continuous-infusion (c." | ( Caporale, A; Franchi, F; Gargano, L; Konstantatoy, E; Marcellini, M; Masciangelo, R; Menichetti, ET; Seminara, P, 2001) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "Sixty-four patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin were enrolled onto this study." | ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "In this study, a total of 64 colorectal cancer patients who received curative operation were examined for the effects of cimetidine treatment on survival and recurrence." | ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "Patients with metastatic colorectal cancer are usually offered systemic chemotherapy as palliative treatment." | ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002) |
| "The treatment of advanced colorectal cancer has long been a dilemma for clinicians." | ( Dangelica, MI; Nissan, A; Shoup, MC, 2002) |
| "Treatment with norcantharidin of colorectal cancer cells not only inhibited cell proliferation, but also induced apoptosis." | ( Jiang, Y; Kan, B; Lei, S; Liu, JY; Lu, Y; Luo, F; Mao, YQ; Peng, F; Tian, L; Wang, GS; Wang, QR; Wei, YQ; Yang, L; Zhao, X; Zou, LQ, 2002) |
| "Patients were treated for colorectal cancer and received chemotherapy consisting of leucovorin 20 mg m(-2) plus 5-fluorouracil 425 mg m(-2)." | ( De Vries, EG; Groen, HJ; Haasjes, J; Maring, JG; Piersma, H; Uges, DR; Van Gennip, AH; van Kuilenburg, AB, 2002) |
| "Twenty-five patients with advanced colorectal cancer were treated with 250 mg/m(2) irinotecan administered by intravenous infusion for 60 minutes." | ( Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A; Falcone, A, 2002) |
| "The mainstay of chemotherapy for colorectal cancer is 5-fluorouracil (5-FU) modulated by leucovorin (LV), alone or in combination with oxaliplatin or irinotecan (CPT-11)." | ( de Gramont, A; Kindler, HL, 2002) |
| "Targeted treatment of colorectal cancer based on TS quantitation has thus been hypothesized similar to the use of hormone receptor in breast cancer." | ( Aschele, C; Lonardi, S; Monfardini, S, 2002) |
| "Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey." | ( Grothey, A; Kellermann, L; Schmoll, HJ, 2002) |
| "These findings suggest that colorectal cancer patients treated with raltitrexed may develop drug-related systemic inflammation, which may be difficult to discriminate from infection." | ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "Adjuvant therapy for colorectal cancer includes chemotherapy, radiotherapy and immunotherapy." | ( Kumar, D; Prabhudesai, AG, 2002) |
| "By treating colorectal cancer cells with 100 microM ZnCl2, MAPKs were activated in two different phases, the initial weak activation occurred within 5 min and this was followed by a stronger and more prolonged activation." | ( Ahn, Y; Choi, KY; Kim, JA; Park, KS; Seong, BL; Yun, MS, 2002) |
| "The identification of colorectal cancer-specific prognostic factors will undoubtedly influence treatment decisions." | ( Schmoll, HJ, 2002) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| "The standard treatment for advanced colorectal cancer (CRC) has been 5-fluorouracil (5-FU)-based chemotherapy." | ( Cvitkovic, E; Sutherland, W; Wasserman, E, 2001) |
| "Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)." | ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002) |
| "Forty-six patients with metastatic colorectal cancer received this first-line treatment in nine German outpatient clinics." | ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003) |
| "Forty patients with colorectal cancer were divided into the RA treating group (n=20) and control group (n=20) for prospective study." | ( Chen, GH; Wang, JF; Wei, HB, 2003) |
| "Recent advances in the treatment of colorectal cancer have lead to significant gains in response rates and survival." | ( Hidalgo, M; Laheru, D; Messersmith, W, 2003) |
| "PFL-therapy is effective for advanced colorectal cancer with large tumor burden and showed the same prognostic result as the American and European trials in spite of smaller number of treatment cycles and a history of previous chemotherapy." | ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Two human colorectal cancer cells, SW620 (mutant p53) and RKO (wild-type p53), were treated with camptothecin, alone or in combination with adenoviral vectors expressing beta-galactosidase (Ad-LacZ), or E2F-1 (Ad-E2F-1)." | ( Dong, YB; McMasters, KM; Yang, HL, 2003) |
| "Patients with metastatic colorectal cancer who progressed after IFL therapy were randomly assigned to bolus and infusional FU and leucovorin (LV5FU2), single-agent oxaliplatin, or the combination (FOLFOX4)." | ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS." | ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "Advanced colorectal cancer (CRC) has a poor prognosis with a 5-year survival of only 5% despite treatment with chemotherapeutic agents." | ( Cree, IA; Di Nicolantonio, F; Knight, LA; Mercer, SJ; Sharma, S; Whitehouse, PA, 2003) |
| "The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements." | ( Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E, 2003) |
| "In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control." | ( Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M, 2003) |
| "Paired biopsies were obtained from colorectal cancer patients before and after treatment." | ( Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D, 2003) |
| "Patients with measurable metastatic colorectal cancer; no previous therapy for advanced disease (adjuvant therapy allowed if >6 months since completion); and performance status 0, 1, or 2 were eligible and were treated with oxaliplatin 85 mg/m2 days 1 and 15 plus LV 20 mg/m2 over 10 to 20 minutes, followed by a 500 mg/m2 bolus dose of FU on days 1, 8, and 15 every 28 days." | ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "Up to day traditional colorectal cancer surgical treatments and adjuvant or neoadjuvant pharmacological therapy cannot be modified, nevertheless "new drugs generation" known as signal transduction inhibitor could, in the future, prove to be an effective cancer treatment." | ( Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A, 2003) |
| "Thirty-eight colorectal cancer patients were randomly assigned to treatment group, which took cimetidine in the perioperative period, and control group to which no drug was given." | ( Bai, D; Li, Y; Shao, H; Wang, K; Yang, G; Yuan, H, 1999) |
| "Patients with stage 4 colorectal cancer were treated with oxaliplatin 85 mg/m2 by a 2-hour intravenous infusion, followed by leucovorin 500 mg/m2 by a 2-hour intravenous infusion, followed by 5-FU 400 mg/m2 by bolus injection, followed by 5-FU 2." | ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "Twenty-three patients with advanced colorectal cancer have been treated on this schedule at a single institution." | ( Eisenberg, SG; Hwang, JJ; Marshall, JL, 2003) |
| "Systemic therapy for metastatic colorectal cancer is evolving rapidly after many years without significant change." | ( O'Neil, BH, 2003) |
| "Among 182 patients with stage II-III colorectal cancers, 89 patients (adjuvant chemotherapy group) received oral 5-FU based-adjuvant chemotherapy, and 93 patients (surgery alone group) did not receive 5-FU." | ( Hidaka, S; Nagayasu, T; Nakagoe, T; Sawai, T; Tagawa, Y; Takeshita, H; Tsuji, T; Yamaguchi, H; Yasutake, T, 2004) |
| "Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months." | ( André, T; Artru, P; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Molitor, JL; Perez, N; Tournigand, C, 2004) |
| "A total of 30 colorectal cancer patients treated with the fluoropyrimidine-based combination S-1, all of whom had stage IV disease, were studied." | ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kawakami, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yochim, JM, 2004) |
| "The treatment of colorectal cancer has evolved dramatically over the last 15 years." | ( Grann, VR; Matasar, MJ; Neugut, AI; Sundararajan, V, 2004) |
| "In addition, the treatment of colorectal cancer cells with PMA resulted in significant reduction in the level of endogenous CDX2 and a significant increase in the level of endogenous COX-2, in a dose-dependent manner." | ( Freund, JN; Ha, EM; Jang, BC; Jang, IH; Kim, SP; Kwon, TK; Lee, SH; Lee, WJ; Lim, JH; Mun, KC; Park, JW; Song, DK; Suh, SI, 2004) |
| "Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate." | ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004) |
| "Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I." | ( Chabner, BA; Charlat, O; Clark, JW; Kelly, P; Kreconus, E; Nesbitt, S; Puchalski, TA; Ryan, DP; Stanton, VP; Supko, JG; Zhu, AX, 2004) |
| "5-FU as the backbone of colorectal cancer therapy." | ( Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E, 2004) |
| "New targets in the treatment of colorectal cancer are the EGF and VEGF receptor." | ( Folprecht, G; Köhne, CH, 2004) |
| "Patients with advanced colorectal cancer were treated with 5-FU [bolus (400 mg/m(2)) followed by a 22-h infusion (600 mg/m(2))] and LV (200 mg/m(2)) and escalating doses of SAM486A, 1-3-h infusion daily for 3 days." | ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Twenty-seven patients with metastatic colorectal cancer and 1 with pseudomyxoma peritonei were treated." | ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Eligible patients with metastatic colorectal cancer had progressive disease during, or within 12 weeks after, palliative fluoropyrimidine-based chemotherapy or in whom intolerable 5-FU toxicity had developed." | ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | ( Cohen, SM; Neugut, AI, 2004) |
| "It has proven clinical activity against colorectal cancer when used as first-line therapy." | ( Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D, 2004) |
| "Cancer chemotherapy in the treatment of colorectal cancer has been evolving so extensively than ever." | ( Aiba, K, 2004) |
| "Based on this analysis, treatment of colorectal cancer with oral capecitabine is cost saving in the Netherlands compared with 5-fluorouracil plus leucovorin administered according to the Mayo regimen." | ( Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH, 2004) |
| "For advanced colorectal cancer (ACC), 5-fluorouracil (5-FU) based chemotherapy has been the standard for some decades." | ( Punt, CJ; van Laarhoven, HW, 2004) |
| "The medical treatment of colorectal cancer (CRC) has rapidly evolved in recent years with the introduction of novel cytotoxic drugs into clinical practice such as irinotecan, oxaliplatin, and capecitabine." | ( Goetz, MP; Grothey, A, 2004) |
| "The treatment of colorectal cancer has undergone enormous changes in the past decade." | ( Abbruzzese, JL; Ellis, LM; Hoff, PM, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "As a control group, 31 colorectal cancers without preoperative treatment were analyzed." | ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004) |
| "Seventy-five patients with advanced colorectal cancer and treated with CPT-11 and 5-fluorouracil, entered the study." | ( Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E, 2004) |
| "Odds ratios (OR) for risk of colorectal cancer were calculated using conditional logistic regression adjusted for body mass index, physical activity, smoking, family history, use of hormone replacement therapy, aspirin use, and dietary intakes." | ( Feskanich, D; Fuchs, CS; Giovannucci, EL; Hankinson, SE; Hollis, BW; Kirkner, GJ; Ma, J, 2004) |
| "Fifty-one metastatic colorectal cancer patients who showed progressive disease in 5-FU/LV-containing regimens (median: two regimes) were treated with capecitabine 1,250 mg/m(2) twice daily (days 1-14 repeated every 3 weeks)." | ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "Chemotherapy for advanced colorectal cancer is much improved in this decade." | ( Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M, 2005) |
| "Peritoneal carcinomatosis from colorectal cancer is resistant to standard treatments and median survival time for patients ranges between 6 and 8 months." | ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| "Treatment of metastatic colorectal cancer with new drugs (NDs) as oxaliplatin and irinotecan had improved response and survival." | ( Boucher, E; Boudjema, K; de Guibert, S; Egreteau, J; Jacquelinet, C; Meunier, B; Raoul, JL, 2005) |
| "Although colorectal cancer has the third highest cancer mortality rate, the treatment remains far from optimized with patients showing variable responses to standard treatment." | ( Kidd, EA; Li, X; McLeod, HL; Shannon, WD; Watson, MA; Yu, J, 2005) |
| "Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)." | ( Boot, H; van Ruth, S; van Slooten, G; Verwaal, VJ; Witkamp, A; Zoetmulder, FA, 2005) |
| "Patients with previously untreated colorectal cancer (CRC) received concurrent 5FU, other patients with CRC received 5-FU at investigator discretion and all other patients received SIR spheres alone." | ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| "In the present study, HT-29 human colorectal cancer cells were treated with EGCG to examine its effects on pro-MMP-7 induction and production using RT-PCR and western blot analyses." | ( Kawabata, K; Kim, M; Murakami, A; Ohigashi, H, 2005) |
| "Since colorectal cancer is the second most prevalent cancer worldwide, its treatment remains a major challenge for researchers, gastroenterologists and oncologists." | ( Galle, PR; Moehler, M; Teufel, A, 2005) |
| "Patients with advanced (stage IV) colorectal cancer were treated with S-1 twice daily based on the patient's body surface area (BSA; BSA < 1." | ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yang, D; Yochim, JM, 2005) |
| "Drug treatment of colorectal cancer has made impressive progress during the past 10 years." | ( Jäger, D; Knuth, A; Pestalozzi, BC, 2005) |
| "Seventeen colorectal cancer patients received as first (12 cases) or second line (5 cases) treatment a combined chronotherapy with CPT 11 (infused at day 1 from 2 to 8 am; peak at 5 am), given with 5 FU (700 mg/m2 per day ; days 2-5) and folinic acid (300 mg/m2 per day, days 2-5) both infused from 10 pm to 10 am with a peak at 4 am, and carboplatin (40 mg/m3/day - days 2-5 ; infused from 10 am to 10 pm - peak at 4 pm)." | ( David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2005) |
| "A total of 56 patients with advanced colorectal cancer receiving CPT-11 therapy (125 mg/m2 once weekly) were enrolled in this multicenter trial." | ( Abenhardt, W; Ballo, H; Behrens, R; Behringer, D; Boeck, HP; Braumann, D; Geer, T; Greinwald, R; Karthaus, M; Kindler, M; Kleeberg, U; Messmann, H; Schimke, J; Steinmetz, T, 2005) |
| "Thirty-eight patients with measurable colorectal cancer, progressive after previous irinotecan-containing chemotherapy for metastatic disease, were registered in this trial." | ( Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY, 2005) |
| "However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited." | ( Chan, AT; Curhan, GC; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES, 2005) |
| "We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy." | ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005) |
| "However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery." | ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005) |
| "p21 expression in colorectal cancer, especially in combination with p53 mutation, is a predictor of resistance to the combination chemotherapy with gefitinib." | ( Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP, 2005) |
| "Blood samples from colorectal cancer patients undergoing oxaliplatin treatment were analyzed for novel adducts of intact Hb-oxaliplatin, which were characterized with nanoelectrospray ionization quadrupole time-of-flight MS." | ( Li, XF; Mandal, R; Peng, J; Sawyer, M, 2005) |
| "Forty-five colorectal cancer patients were treated with a CPT11-including regimen (FOLFIRI)." | ( Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G, 2005) |
| "In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity." | ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| "After subcapsular liver implantation of colorectal cancer cells in 30 WAG rats (on day 0), the animals were randomly assigned to three interventional treatment groups." | ( Bechstein, WO; Khan, MF; Maataoui, A; Mack, MG; Oppermann, E; Qian, J; Roozru, M; Schmidt, S; Vogl, TJ, 2005) |
| "For the treatment of metastatic colorectal cancer, improved response rates and prolonged survival have been reported when irinotecan or oxaliplatin was added to 5-FU/FA; a further increase in efficacy was shown when bevacizumab, an antibody to vascular endothelial growth factor, was added to chemotherapy." | ( Folprecht, G; Köhne, CH, 2005) |
| "We divided gastric cancer and the colorectal cancer patients, who performed chemotherapy, into two groups of cimetidine administrated group and a non-administration group, and reviewed whether cimetidine inhibited an expression of E-selectin on vascular endothelial cells by measuring E-selectin in plasma." | ( Imaeda, Y; Kawase, J; Kobayashi, K; Matsumoto, S; Umemoto, S, 2005) |
| "Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i." | ( Gollins, S; Grieve, R; Samuel, L; Twelves, C, 2006) |
| "We injected colon 26, a colorectal cancer cell line, in CDF1 mouse spleen and, from the following day, two kinds of COX-2 inhibitor (etodolac and nimesulide) were administered orally." | ( Aoki, T; Hisada, M; Ishizaki, T; Katsumata, K; Kawakita, H; Mori, Y; Tsuchida, A; Wada, T, 2006) |
| "(1) In patients with metastatic colorectal cancer initially treated with irinotecan combination therapy, second-line therapy with a combination of fluorouracil, folinic acid and oxaliplatin resulted in a median survival time of 21 months after the start of first-line chemotherapy, in one clinical trial." | ( , 2005) |
| "Human colorectal cancer cell line SL-174T was cultured and treated separately with four different dosages of L-NAME for 72 h." | ( Dong, XS; Sun, WZ; Yang, Y; Yu, LB; Zhao, DL, 2005) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | ( Kemeny, NE; Leonard, GD, 2006) |
| "Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-gamma during the treatment with cetuximab (initial dose of 400 mg/m(2), followed by weekly infusions of 250 mg/m(2)) plus weekly irinotecan (90 mg/m(2))." | ( Battistoni, F; Di Cuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B, 2006) |
| "In all, 38 patients with metastatic colorectal cancer were treated with erlotinib at a continuous daily oral dose of 150 mg." | ( Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M, 2006) |
| "One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included." | ( Capellá, G; Cuatrecases, M; de Oca, J; Dotor, E; Figueras, A; Germà, JR; Guinó, E; Martínez-Iniesta, M; Molleví, DG; Moreno, V; Navarro, M; Pareja, L; Peinado, MA; Serrano, T; Vilardell, F; Villanueva, A, 2006) |
| "The modern treatment of colorectal cancer." | ( András, C; Farczádi, E; Szántó, J, 2006) |
| "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined." | ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006) |
| "To identify genes silenced in human colorectal cancers, we performed a microarray analysis for genes whose expression was induced by treatment of HCT116 human colon cancer cells with a demethylating agent, 5-aza-2'-deoxycitidine (5-aza-dC)." | ( Ichimura, S; Mori, A; Nakazawa, K; Okochi-Takada, E; Ushijima, T; Wakabayashi, M; Yasugi, T, 2006) |
| "This study examines patterns of colorectal cancer screening and follow-up within the nation's largest integrated health care system: the Veterans Health Administration." | ( Asch, SM; Brook, RH; Etzioni, DA; Ko, CY; Lee, ML; Parkerton, PH; Rubenstein, LV; Yano, EM, 2006) |
| "In recent years, chemotherapy for colorectal cancer has advanced rapidly." | ( Akazai, Y; Kimura, H; Nitta, Y, 2006) |
| "Thirty patients with colorectal cancer undergoing chemotherapy were randomised to receive either creatine (n=16) or placebo (n=15) for 8 weeks." | ( Baier, P; Holm, E; Lochs, H; Norman, K; Ocran, K; Pirlich, M; Schütz, T; Stübler, D, 2006) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| "In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment." | ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006) |
| "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV." | ( Shimamura, T; Tada, M; Yamaguchi, K, 2006) |
| "Novel methods of colorectal cancer prevention and therapy are therefore of considerable importance." | ( Chell, S; Kadi, A; Kaidi, A; Paraskeva, C; Williams, AC, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | ( Eguchi, T; Shirao, K, 2006) |
| "The charts of 114 patients with colorectal cancer treated with cetuximab were reviewed." | ( Fakih, MG; Lombardo, J; Wilding, G, 2006) |
| "We randomised 60 patients with colorectal cancer (53 patients received adjuvant therapy and seven patients received palliative therapy) to start therapy with either oral capecitabine or Nordic bolus FL." | ( Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K, 2006) |
| "In patients with colorectal cancer an accurate diagnostic work-up is mandatory in order to perform the most specific treatment." | ( Deandreis, D; Pelosi, E, 2007) |
| "When human colorectal cancer cells were treated with 0." | ( Aung, HH; He, TC; Luo, X; Ni, M; Song, WX; Tong, R; Wang, A; Wang, CZ; Xie, JT; Yuan, CS; Zhang, B, 2006) |
| "Patients with advanced colorectal cancer continue to have poor outcomes because of therapy-refractory disease." | ( Taghizadeh, F; Tai, IT; Tang, MJ, 2007) |
| "The treatment of colorectal cancer is rapidly becoming a significant financial burden to health-care systems within economically developed nations." | ( Cunningham, D; Starling, N; Tilden, D; White, J, 2007) |
| "Thirty colorectal cancer patients received adjuvant chemotherapy of leucovorin plus 5-FU after operations." | ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| "In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments." | ( Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M, 2007) |
| "We showed in colorectal cancer cell lines that the expression of MV-H/F, but also of RSV-F, as well as VSV-G can synergistically enhance p53-independent clinically relevant chemotherapy (FOLFOX) over most of the cytotoxic dose range." | ( Grunwald, T; Hoffmann, D; Kuate, S; Wildner, O, 2007) |
| "The standard treatment of metastatic colorectal cancer (mCRC) is combination of 5- fluorouracil/folinic acid with irinotecan or oxaliplatin-based chemotherapy." | ( Gordon, M; Lenz, HJ; Zhang, W, 2006) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "Fifty five patients with advanced colorectal cancer were treated by FOLFIRI or FOLFOX regimen from April 2005 to June 2006." | ( Chiba, H; Honda, K; Kondo, H; Makino, K; Mizushima, T; Ohura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2006) |
| "Chemotherapy for colorectal cancer has changed greatly." | ( Takahashi, K, 2006) |
| "Multimodal treatment of recurrent colorectal cancer confined to the liver should begin with consideration of repeated hepatectomy." | ( Ahmad, A; Bilchik, AJ; Chen, SL, 2007) |
| "Twenty-five colorectal cancer patients were included in our study; these had undergone surgical resection of the primary tumor, received post-operatively 5-FU-based adjuvant chemotherapy and then suffered from recurrences." | ( Delladetsima, J; Gouveris, P; Kyriakou, V; Lazaris, AC; Nonni, A; Papathomas, TG; Patsouris, ES; Tsavaris, N, 2007) |
| "Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication." | ( Beauvillain, L; Bihannic, R; Bousquet, A; Burnat, P; Ceppa, F; Cremades, S; Fontan, E, 2007) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "We studied patients with advanced colorectal cancer, starting treatment with non-curative intent." | ( Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C, 2007) |
| "Patients with metastatic colorectal cancer that had received no prior chemotherapy for advanced disease were treated with oral gefitinib (250 mg daily) plus oral capecitabine (1000 mg/m2 twice a day on Days 1-14) and intravenous oxaliplatin (120 mg/m2 on Day 1 of each 3-week cycle)." | ( Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M, 2007) |
| "Thirty-eight patients with advanced colorectal cancer were treated at Sylvester Comprehensive Cancer Center, University of Miami, from 2000 to 2004, and received weekly intravenous infusion of irinotecan at 110 mg/m with a combination of 120 mg/kg floxuridine and 500 mg/m leucovorin administered as a 24-h continuous intravenous infusion." | ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "Furthermore, we show that colorectal cancer patients treated with cetuximab, an antagonist of the EGFR, develop hypomagnesemia, emphasizing the significance of EGF in maintaining Mg(2+) balance." | ( Bindels, RJ; Groenestege, WM; Hoenderop, JG; Janssen, R; Knoers, NV; Tejpar, S; Thébault, S; van Cutsem, E; van den Berg, D; van den Heuvel, LP; van der Wijst, J, 2007) |
| "Patients with metastatic colorectal cancer received folate (> 350 microg) daily and vitamin B(12) (1000 microg) every 9 weeks starting 7 days before chemotherapy." | ( Alberts, SR; Ames, M; Goetz, MP; Goldberg, RM; Gornet, MK; Kim, GP; Mahoney, MR; Nicol, SJ; Rubin, J; Weinshilboum, RM, 2007) |
| "Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial." | ( Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N, 2007) |
| "In human colorectal cancer model CXF280, antitumor activity of the combination at two-thirds of the maximum tolerated dose (MTD) was superior to that of each monotherapy at MTD." | ( Kondoh, K; Mori, K; Sawada, N, 2007) |
| "The treatment of metastastic colorectal cancer has dramatically evolved." | ( Abbas, F; André, T; de Gramont, A; Louvet, C; Tournigand, C, 2007) |
| "Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy." | ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007) |
| "Most patients with colorectal cancer undergo treatment with curative intent and subsequently enter a surveillance programme." | ( Burkill, G; Miles, K, 2007) |
| "In patients with Dukes'C colorectal cancer who underwent curative surgical resection of the primary tumour, followed by 5-FU-based adjuvant chemotherapy, p53 mutation status as assessed by gene sequencing is a significant predictor of overall and metastasis-free survival." | ( Ahmed, IA; Anderson, JJ; Angus, B; Challen, C; Kelly, SB; Lunec, J, 2008) |
| "Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited." | ( Chan, AT; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES; Wu, K, 2008) |
| "Patients with metastatic colorectal cancer who had previously received systemic chemotherapies were treated with single agent Val-boroPro 200 microg p." | ( Cheng, JD; Christiansen, VJ; Cohen, SJ; Egleston, B; Lee, HO; Magalong, K; McKee, PA; Meropol, NJ; Mullins, SR; Narra, K; Strzemkowski-Brun, B; Weiner, LM, 2007) |
| "At our hospital, 232 patients with colorectal cancer underwent outpatient home chemotherapy by placing a CV-port and using a portable disposable pump for continuous infusion of 5-FU between 1998 and 2005." | ( Inaba, Y; Muro, K; Najima, M; Nishiofuku, H; Sato, Y; Shimamoto, H; Ura, T; Yamaura, H, 2007) |
| "Serum NO levels in the patients with colorectal cancer were markedly higher than those in the patients with CRA, and L-arginine treatment was responsible for this increase (P < 0." | ( Gao, X; Ma, Q; Ma, Z; Song, Z; Wang, Y, 2007) |
| "To test this, MMR-deficient colorectal cancer cells (Dks-8) were xenografted into immune-deficient mice and treated with the antiangiogenic regimen of low-dose/metronomic cyclophosphamide for 2 weeks followed by a 2-week recovery period without therapy." | ( Coomber, BL; Rak, JW; Sasazuki, T; Shahrzad, S; Shirasawa, S, 2008) |
| "The human colorectal cancer SW 480 cells treated with the protein-extract of B." | ( Chang, TT; Chen, CH; Hung, RP; Lin, ML; Lu, FJ; Ong, PL; Weng, BC, 2008) |
| "Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy." | ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008) |
| "Patients with metastatic colorectal cancer included in this study were aged at least 70 years, with a performance status of 0/1, without geriatric syndrome and without previous palliative chemotherapy." | ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "Forty-four colorectal cancer patients and 20 gastric cancer patients treated with S-1 were enrolled as control groups." | ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008) |
| "The treatment of metastatic colorectal cancer with modern cytotoxic agents in combination with monoclonal antibodies against vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) has improved median overall survival from 6 months to almost 2 years." | ( Cunningham, D; Jackson, C, 2008) |
| "DNA samples from 107 European, advanced colorectal cancer patients treated with irinotecan-based regimens were genotyped for htSNPs as well as three coding region SNPs." | ( Altes, A; Baiget, M; Culverhouse, R; Hoskins, JM; Marcuello, E; Marsh, S; Maxwell, T; McLeod, HL; Paré, L; Van Booven, DJ, 2008) |
| "Neoadjuvant chemotherapy for metastatic colorectal cancer may render some unresectable patients resectable, affording these patients the possibility of prolonged survival." | ( Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F, 2008) |
| "364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group)." | ( Bechstein, WO; Bethe, U; Collette, L; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Praet, M; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Van Cutsem, E; Walpole, ET, 2008) |
| "Three colorectal cancer cell lines, RKO, HCTll6 and SW480, were treated hy 5-aza-2'-deoxycytidine and trichostatin A for demethylation." | ( Luo, J; Qi, J; Tao, WH; Zhang, JM; Zhu, YQ, 2007) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "We report two cases of recurrent colorectal cancer in two patients who were treated successfully with a combined oral chemotherapeutic agent folinate/tegafur/uracil (UFT/LV) dosage." | ( Hosotaki, K; Shimamoto, M; Tabira, Y; Tamori, Y, 2008) |
| "Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs." | ( Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM, 2008) |
| "Human colorectal cancer cell line SW480 was treated with AMD3100 at different final concentrations." | ( Li, JK; Shen, Y; Wang, YC; Yu, L; Zhang, JH; Zhou, LS, 2008) |
| "Advances in systemic therapy for colorectal cancer have dramatically improved prognosis." | ( Benson, AB; Mulcahy, MF; Shankaran, V; Wisinski, KB, 2008) |
| "When chemotherapy is conducted to treat colorectal carcinoma, especially when 5-FU is included in the regimen, anti-APRIL therapy might be an important assistant treatment to counter the impact of APRIL caused by antitumor drugs." | ( Feng, ZY; Guo, YW; Li, YW; Wen, ZF; Zheng, FP, 2008) |
| "Three human colorectal cancer cell lines SW480, HCT116 and HT29 were treated with RPM 10 nmol/L, PD98059 (10 micromol/L, 20 micromol/L, 40 micromol/L, 50 micromol/L), or RPM plus PD98059, respectively, and the sensitivity was analyzed by MTT assay." | ( Fang, JY; Shen, GF; Sun, DF; Zhang, YJ; Zhao, SL; Zheng, Q; Zhu, HY, 2007) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies." | ( Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H, 2008) |
| "In 32 pathologically confirmed colorectal cancer patients with CHD, the concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and lipoprotein (a) (Lp(a)) were detected at the baseline, before and after the operation, and at 6 months of postoperative atorvastatin treatment." | ( Gao, CY; Li, MW; Liang, ZT; Liao, YH; Wang, XP; Zeng, QT, 2008) |
| "During the follow-up of patients treated for colorectal carcinoma, ultrasonography is the most important imaging modality." | ( Bipat, S; IJzermans, JN; Oyen, WJ; Planting, AS; Stoker, J; van Leeuwen, MS, 2008) |
| "Changes in colorectal cancer risk in response to folic acid supplementation are likely a complex function of treatment start, duration, and effect on cell proliferation and mutations rates." | ( Boynton, A; Liu, AY; Luebeck, EG; Moolgavkar, SH; Ulrich, CM, 2008) |
| "A major obstacle in the treatment of colorectal cancer is relative insensitivity to the chemotherapeutic agent 5-Fluorouracil (5-FU)." | ( Augenlicht, LH; Gandhi, SJ; Pestell, RG; Pezo, RC; Shirley, LA; Singer, RH, 2008) |
| "Patients with metastatic colorectal cancer were treated with fluorouracil, leucovorin, and irinotecan and were also given ALVAC-CEA/B7." | ( Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M, 2008) |
| "Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3)." | ( Aeberhard, P; Harder, F; Herrmann, R; Laffer, U; Lorenz, M; Maibach, R; Metzger, U; Zuber, M, 2008) |
| "Twenty-four patients with metastatic colorectal cancer were treated." | ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| "In a cohort of colorectal cancer patients, those with MMR-deficient tumours seem not to benefit from 5-FU-based chemotherapy." | ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009) |
| "Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine." | ( Abaza, MS; Al-Attiyah, RJ; Bahman, AM, 2008) |
| "Patients with advanced colorectal cancer, unpretreated for metastatic disease, were enroled in the study." | ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009) |
| "Among 52 colorectal cancers, 31 tumors were both topoisomerase I and thymidylate synthase diploid, which may have a worse outcome for tumor chemotherapy; and there were five tumors with favorable genomics (topoisomerase I amplification and thymidylate synthase deletion)." | ( Holtschlag, V; McLeod, HL; Miller, R; Sharma, M; Watson, MA; Yu, J; Zhang, W, 2008) |
| "For advanced or metastatic colorectal cancer, FOLFOX4/mFOLFOX6 followed by FOLFIRI may be effective and comparatively safe treatments." | ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "Twelve subjects with metastatic colorectal cancer within the liver failing first-line chemotherapy were treated in four cohorts with a single dose (3 x 10(6) to 1 x 10(8) particles) of NV1020, a multimutated, replication-competent HSV." | ( Bhargava, A; Brody, L; Brown, K; Covey, A; Fong, Y; Getrajdman, G; Jarnagin, W; Karrasch, M; Kemeny, N; Kim, T; Mescheder, A; Schwartz, L, 2009) |
| "5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle." | ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009) |
| "Among colorectal cancer patients receiving first-line chemotherapy, increasing levels of IGFBP-3, an endogenous antagonist to IGF-I, are associated with an improved objective treatment response and a prolonged time to cancer progression." | ( Fuchs, CS; Goldberg, RM; Green, EM; Meyerhardt, JA; Pitot, HC; Pollak, M; Sargent, DJ; Wolpin, BM, 2008) |
| "Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study." | ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years." | ( Davies, JM; Goldberg, RM, 2008) |
| "HCT-116 (colorectal cancer), PC-3 (prostate cancer) and MCF-7 (breast adenocarcinoma) cell lines were treated with insulin, IGF-I or insulin analogues, and proliferation and protection from apoptosis were measured by cell counting and fluorescent-activated cell sorter (FACS) analysis, respectively." | ( Laron, Z; Simon, M; Weinstein, D; Werner, H; Yehezkel, E, 2009) |
| "Metastatic colorectal cancer patients included in the OPTIMOX1 phase III study received first-line oxaliplatin-based chemotherapy (FOLFOX)." | ( André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009) |
| "Chemosensitivity in advanced colorectal cancer specimens was examined using an ATP-based chemotherapy response assay." | ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009) |
| "A 64-year-old man with metastatic colorectal cancer who was on hemodialysis was treated with irinotecan 50 mg/m(2) weekly for 3 weeks, followed by 1 week with no treatment." | ( Boesler, B; Czock, D; Keller, F; Rasche, FM; Shipkova, M, 2009) |
| "In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury." | ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D, 2009) |
| "Patients with metastatic colorectal cancer (mCRC) who progress despite treatment with fluoropyrimidine and irinotecan or oxaliplatin have diminished survival, but they may derive clinically meaningful benefit from second-line or later chemotherapy." | ( Bachet, JB; Lièvre, A; Mitry, E; Rougier, P, 2009) |
| "Following the treatment of colorectal cancer cell lines with 5-aza-2-deoxycytidine, DNA methyltransferase 1 small interfering RNA, or trichostatin A, the induction of OSMR mRNA and the enrichment in the level of histone acetylation were observed." | ( Choi, E; Deng, G; Kakar, S; Kim, YS; Okudiara, K; Sleisenger, MH, 2009) |
| "In patients with colorectal cancers and treated with the FOLFOX-FOLFIRI regimen, taste disorders are frequent occurrences." | ( Adachi, M; Iida, A; Mori, K; Sakakibara, T; Sugawara, S; Sugiura, M; Takimoto, N; Yamamura, K, 2009) |
| "Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified." | ( Angitapalli, R; Fakih, MG; Kumar, PR; Litwin, AM; Lombardo, J; Mashtare, T; Nasser, E; Wilding, GE, 2009) |
| "All the patients with metastatic colorectal cancer treated with at least one line of chemotherapy for metastatic disease and progressed after I line chemotherapy were considered eligible and enrolled into the trial." | ( Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D, 2009) |
| "Chemotherapy is widely used in colorectal cancer that has relapsed or failed to respond to first-line treatment." | ( Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I, 2009) |
| "In our study, human colorectal cancer cells (DLD-1, CaCo-2 and SW620) were treated with rimonabant and analyzed for markers of cell proliferation, cell viability and cell cycle progression." | ( Bifulco, M; Borrelli, F; Gazzerro, P; Grimaldi, C; Izzo, AA; Laezza, C; Malfitano, AM; Pisanti, S; Proto, MC; Santoro, A, 2009) |
| "A total of 145 colorectal tumors were treated by ESD and another 228 were treated by EMR." | ( Fu, KI; Fujii, T; Fukunaga, S; Fukuzawa, M; Ikehara, H; Itoi, T; Matsuda, T; Nakajima, T; Saito, Y; Sakamoto, T; Uraoka, T, 2010) |
| "Management of palliative treatment of colorectal cancer therefore is becoming of a great importance." | ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009) |
| "Forty-four patients with gastric or colorectal cancer developing WHO side-effect grading system of grade 2 or higher were randomized to either control group (n = 22) or Gln group (n = 22) during next cycle of chemotherapy." | ( Li, J; Li, Y; Liu, F; Ni, X; Ping, X; Yu, B, 2009) |
| "Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled." | ( Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC, 2009) |
| "In a second study, superficial hepatic colorectal cancer (CRC) metastases were treated at 45 W/4 cm for 9 minutes without inflow occlusion in 11 patients." | ( Gnerlich, JL; Hawkins, WG; Linehan, DC; Ritter, JH; Strasberg, SM, 2009) |
| "Rapamycin suppressed advanced stage colorectal cancer, even with oral administration." | ( Candinas, D; Egger, B; Hunt, KK; Laemmle, A; Roh, V; Strehlen, M; Stroka, D; Trochsler, M; Vorburger, SA; Wagner, M, 2009) |
| "The records of patients with metastatic colorectal cancer who were heavily pretreated with irinotecan and oxaliplatin and subsequently received cetuximab plus irinotecan-based therapy were reviewed." | ( Chang, HJ; Han, HS; Hong, YS; Jung, KH; Kim, SY; Lee, KS, 2009) |
| "Totally 38 patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin were enrolled." | ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009) |
| "Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy." | ( Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ, 2009) |
| "Ninety-nine patients with colorectal cancer who had moderate to severe OM (WHO grade >or= 2) in the first cycle of chemotherapy were randomly assigned to receive either placebo, rhITF 10 mg/mL (ie, low dose), or rhITF 80 mg/mL (ie, high dose) by oral spray (300 microL, eight times each day) for 14 consecutive days in the second chemotherapy cycle." | ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "A retrospective, pilot study of 79 colorectal cancer patients treated with chemotherapy were divided into 3 groups: bevacizumab (n = 28), ESA (n = 21), and bevacizumab plus ESA (n = 28)." | ( Desai, SJ; Guo, JJ; Partridge, SM; Pruemer, JM; Rockey, ML; Roddy, JV; Safa, MM, 2010) |
| "HT-29 human colorectal cancer xenograft model was used and tumour growth, microvessel density and VEGF quantification were performed in tumours after the administration of metronomic CPT-11, L-OHP, 5-FU and their simultaneous combination." | ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009) |
| "Patients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan-cetuximab after failure of irinotecan-based chemotherapy were eligible." | ( Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Labianca, R; Loupakis, F; Mandolesi, A; Masi, G; Negri, F; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F, 2009) |
| "Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years." | ( Landherr, L; Nagykálnai, T, 2009) |
| "Patients suffering from advanced colorectal cancer can experience unintended weight loss and/or treatment-induced gastrointestinal toxicity." | ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010) |
| "Eighty-two patients with advanced colorectal cancer receiving a palliative chemotherapy were prospectively randomized to either oral enteral nutrition supplement (PN-) or oral enteral nutrition supplement plus supplemental PN (PN+)." | ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010) |
| "The aim of this study is to identify colorectal cancer specific gene methylation determining chemosensitivity to S-1/CPT-11 therapy." | ( Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K, 2010) |
| "Treatment of patients with metastatic colorectal cancer (MCRC) previously exposed to oxaliplatin-based regimen is challenging." | ( Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2010) |
| "Treatment options for metastatic colorectal cancer (mCRC) patients have rapidly increased in the past years, but 50 - 70% of mCRC patients are still unlikely to undergo radical resection of metastases and are candidates for palliative therapy only." | ( Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Vasile, E, 2010) |
| "Twenty-seven patients with advanced colorectal cancer were enrolled in this study, and the UGT1A1*28 polymorphism was genotyped before chemotherapy." | ( Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S, 2010) |
| "NAC by FOLFOX for liver metastasis of colorectal cancer showed a high reduction rate, and there was a little influence to hepatectomy indicating that FOLFOX could be an effective therapy." | ( Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M, 2009) |
| "We report 5 cases of metastatic colorectal cancer with intermittent hepatic arterial infusion (HAI) and systemic chemotherapy (CPT-11, biweekly) in 2006-2008." | ( Ide, Y; Mikami, K; Murata, K, 2009) |
| "Patients with metastatic colorectal cancer that had progressed after chemotherapy with irinotecan, oxaliplatin, and fluoropyrimidine were included." | ( Inaba, Y; Kawai, H; Muro, K; Najima, M; Sato, Y; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Utsunomiya, S; Yamaura, H; Yatabe, Y; Yokota, T, 2011) |
| "From April, 2007 to February, 2009, 23 colorectal cancer patients were treated with Bevacizumab." | ( Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y, 2010) |
| "Seventy to 40% of K-RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies." | ( Bearzi, I; Berardi, R; Biagetti, S; Bisonni, R; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Mandolesi, A; Menzo, S; Pierantoni, C; Scartozzi, M; Silva, RR; Zaniboni, A, 2010) |
| "Treatment for colorectal cancer (CRC) has seen major advances, resulting in longer survival times for many patients." | ( Viale, PH, 2010) |
| "Imaging of colorectal cancer using a 2-step, pretargeting system produced the best imaging results 24 hours after peptide administration using a 4-day interval between injection of the bsAb and the peptide." | ( Aarts, F; Bleichrodt, RP; Boerman, OC; Chang, CH; Goldenberg, DM; Hendriks, T; McBride, WJ; Oyen, WJ; Sharkey, RM, 2010) |
| "Hepatic toxicity of chemotherapy for colorectal cancer and its complications after hepatic metastasis surgery are unclear." | ( André, T; Baumgaertner, I; Hannoun, L; Poynard, T; Ratziu, V; Vaillant, JC, 2010) |
| "Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression." | ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D, 2010) |
| "HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups." | ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| "Clinical efficacy of chemotherapy in colorectal cancer is subjected to broad inter-individual variations leading to the inability to predict outcome and toxicity." | ( Bonnans, C; Breuker, C; Brouillet, JP; Evrard, A; Hollande, F; Joubert, D; Kantar, J; Lallemant, B; Leguelinel, G; Lumbroso, S; Pascussi, JM; Poujol, S; Raynal, C, 2010) |
| "The use of sulindac sulfone (SFN) for colorectal cancer (CRC) therapy is limited due to its toxicity." | ( Arber, N; Aroch, I; Giladi, N; Kazanov, D; Kraus, S; Shpitz, B, 2010) |
| "In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy." | ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010) |
| "Treatment of colorectal cancer (CRC) has developed considerably over the past decade, especially in the areas of targeted therapeutics and biomarker development." | ( Lenz, HJ; Winder, T, 2010) |
| "Twenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m(2), single dose on the first day), and oral administration of capecitabine (1." | ( Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy, 2010) |
| "The specific advantage of colorectal cancer screening include the earlier detection of such cancers, the detection of benign conditions such as polyps that can predispose to cancer and the potential for earlier and curative therapy in these patients." | ( Ryan, JJ; Waldby, G, 2010) |
| "Representative colorectal cancer and non-cancerous cell lines were treated with dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase." | ( Hughes, TA; Jayne, DG; Madhok, BM; Perry, SL; Yeluri, S, 2010) |
| "Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy." | ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011) |
| "Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%." | ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010) |
| "Chemotherapy for colorectal cancer (CRC) was representative of the cancer unable to expect achieving response in previous times." | ( Muro, K, 2010) |
| "Approximately 25% of patients with colorectal cancer develop metastases to the liver, and surgery is currently the best treatment available." | ( Alcala, MA; Bartlett, DL; Lee, BC; Lee, DH; Lee, YJ; Park, BH; Park, K; Yoo, J, 2010) |
| "As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer." | ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010) |
| "Human colorectal cancers with NTR1 were treated with various HDACi, and NTR1 expression and function were assessed." | ( Evers, BM; Jackson, LN; Johnson, SM; Wang, Q; Wang, X, 2010) |
| "A patient treated for colorectal cancer with single agent irinotecan received methimazole co-medication for Graves' disease." | ( de Jong, FA; Loos, WJ; Mathijssen, RH; Planting, AS; Schellens, JH; van Aken, MO; van der Bol, JM; Verweij, J; Visser, TJ; Wiemer, EA, 2011) |
| "The prognosis of metastatic colorectal cancer remains poor despite advances made in recent years, particularly with new treatments directed towards molecular targets." | ( Díaz-Rubio, E; García-Foncillas, J, 2010) |
| "Fifty-one metastatic colorectal cancer patients who failed to respond to first-line chemotherapy were enrolled in the study from April to July 2005." | ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011) |
| "5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development." | ( Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011) |
| "A total of 32 subjects with colorectal cancer undergoing 5FU treatment, 15 of whom had liver metastases, were examined in a 1." | ( Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011) |
| "For patients with advanced colorectal cancer, FOLFOX chemotherapy can decrease the proportion of regulatory T lymphocytes and results in Th1/Th2 cytokine drift to Th1 type." | ( Duan, GL; Huang, CX; Jiang, YQ; Li, ZY; Wang, QQ, 2010) |
| "Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were divided into two groups: those with UGT1A1*1/*1 genotype and those with UGT1A1*1/*6 or *1/*28 genotype." | ( Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2011) |
| "Between June 2004 and July 2008, 10 colorectal cancer patients, who exhibited a replacement of over three quarters of their normal liver by metastatic tumors and were of Child-Pugh class B or C in liver function with progressive disease after undergoing chemotherapy, underwent whole-liver RT." | ( Hong, YS; Jung, KH; Kim, DY; Kim, SY; Kim, TH; Yeo, SG, 2010) |
| "In advanced colorectal cancer, chemotherapy is usually administered without pauses and until progression but patients can experience cumulative toxicity and cannot tolerate a heavy therapeutic charge." | ( Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A, 2011) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "The study prospectively accrued colorectal cancer patients (n=106) completely resected and adjuvantly treated with FU and oxaliplatin according to the FOLFOX4 regimen (infusional FU, folinic acid, and oxaliplatin)." | ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after administration of irinotecan as a second-line chemotherapy." | ( Furuse, J; Hosokawa, Y; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H, 2010) |
| "Accurate staging of colorectal cancer (CRC) with clinicopathological parameters is important for predicting prognosis and guiding treatment but provides no information about organ site of metastases." | ( Braaf, LM; Bruin, SC; Joosse, SA; Klijn, C; Liefers, GJ; Morreau, H; Tollenaar, RA; van Beers, EH; van Velthuysen, ML; Van't Veer, LJ; Verwaal, VJ; Wessels, LF, 2010) |
| "Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital." | ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010) |
| "Patients with wild-type KRAS metastatic colorectal cancer that had progressed after chemotherapy with irinotecan, oxaliplatin, and fluoropyrimidine were included." | ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR." | ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011) |
| "Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy." | ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Boland, CR; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Goel, A; Jover, R; Llor, X; Morillas, JD; Nguyen, TP; Nicolás-Pérez, D; Payá, A; Pérez-Carbonell, L; Reñé, JM; Rojas, E; Xicola, RM; Zapater, P, 2011) |
| "Plasma samples were obtained from 12 colorectal cancer patients who underwent chemotherapy with capecitabine alone (1000 mg/m(2)) or combined with oxaliplatin (130 mg/m(2))." | ( Czejka, M; Ettlinger, D; Farkouh, A; Georgopoulos, A; Scheithauer, W; Schueller, J, 2010) |
| "KRAS mutations are frequent in colorectal cancer (CRC) and are associated with clinical resistance to treatment with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies." | ( Fischer, M; Gurney, A; Hoey, T; Kapoun, AM; Lewicki, J; O'Young, G; Wang, M; Yen, WC, 2011) |
| "Fifty patients with unresectable colorectal cancer treated with mFOLFOX6 therapy were enrolled in this study." | ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Itoyama, S; Kumamoto, K; Kuwabara, K; Miura, I; Mori, T; Ohsawa, T; Okada, N; Tamaru, J; Yamada, H; Yokoyama, M, 2010) |
| "Recent advances in chemotherapy for colorectal cancer prolonged survival." | ( Inoue, T; Ishikawa, H; Ko, S; Kunishige, T; Mukogawa, T; Nakamoto, T; Nishiwada, T; Watanabe, A, 2010) |
| "A cohort of patients with stage IV colorectal cancer treated from 1989 through 1995 served as a historical control for comparison with prospective cohorts treated from 1996 through 2002 or from 2003 through 2009." | ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011) |
| "Cancer stem-like cells (CSCs) in colorectal cancers (CRC) may account for the failure of treatments because they are resistant to many current anticancer therapies." | ( Dong, TT; Feng, B; Lv, B; Wang, LL; Zheng, MH; Zhou, HM, 2011) |
| "Metastatic colorectal cancer is frequently treated with irinotecan, a topoisomerase-I inhibitor." | ( Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K, 2011) |
| "The study included 329 colorectal cancer patients from the Israeli population-based Molecular Epidemiology of Colorectal Cancer study who were treated with a chemotherapy regimen that included irinotecan." | ( Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K, 2011) |
| "We reviewed 104 colorectal cancer patients treated with standard chemotherapy with bevacizumab and examined the incidence of interstitial lung disease and its clinical features." | ( Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K, 2011) |
| "Most drugs used for colorectal cancer therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER) pathway." | ( Aneja, R; Banerjee, S; Jaiswal, AS; Narayan, S; Ostrov, DA; Sarkar, FH, 2011) |
| "Metastatic colorectal cancer (CRC) patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are resistant to treatment with cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor." | ( Han, B; Jang, J; Kang, WK; Lee, I; Lee, J; Park, C; Park, JO, 2011) |
| "The growth rate of the colorectal cancer colostomy implantation model was significantly lower than control cells when treated with oridonin (P<0." | ( Ding, Y; Jin, H; Liu, X; Tan, X, 2011) |
| "Forty-five patients with colorectal cancer were randomly assigned to two groups, the 22 in the control group treated with CM alone and the 23 in the treated group treated with CM plus SJZD." | ( Xiao, H; Yang, J, 2011) |
| "In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression." | ( Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gallardo, E; Lamas, MJ; Lopez, R; Touris, M; Vidal, Y, 2011) |
| "In this study, human colorectal cancer cells treated with HDACi exhibited reduced EGFR expression, thereby disturbed EGF-induced ERK and Akt phosphorylation." | ( Chen, CC; Chou, CW; Huang, WC; Wu, MS, 2011) |
| "We report two cases of advanced colorectal cancer which showed splenomegaly after administration of oxaliplatin-based chemotherapy." | ( Furuse, J; Hanai, C; Hosokawa, Y; Kawase, T; Kitagawa, N; Konno, T; Motoori, S; Nishimura, H; Saisho, H, 2011) |
| "Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study." | ( Crucitti, P; Falcone, A; Frezza, AM; Galluzzo, S; Graziano, F; Loupakis, F; Muda, AO; Perrone, G; Rabitti, C; Rizzo, S; Russo, A; Ruzzo, AM; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B; Zoccoli, A, 2012) |
| "Patients with metastatic colorectal cancer who had progressed on therapy with 5-FU, oxaliplatin and irinotecan in the first and second line setting and on the combination of irinotecan and cetuximab in third line setting independent of their KRAS mutation status, were treated with irinotecan and cetuximab combined with bevacizumab in a dosage of 5 mg/kg." | ( Bjerregaard, JK; Fromm, AL; Hoegdall, E; Jensen, BV; Jørgensen, TL; Larsen, FO; Nielsen, D; Pfeiffer, P; Qvortrup, C; Skougaard, K; Vistisen, K, 2011) |
| "Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimidine, oxaliplatin and irinotecan; novel agents need to be explored in this setting." | ( Kindler, HL; Knost, JA; Modi, S; Polite, BN; Sharma, MR; Sleckman, BG; Stadler, WM; Taber, D; Vokes, EE; Wallace, JA; Wroblewski, K, 2012) |
| "Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality in the United States, and new treatment options are needed." | ( Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K, 2011) |
| "In this review, the role of PET in colorectal cancer (CRC) is discussed, including its well established role in the assessment of recurrent disease and emerging applications such as initial staging, monitoring therapy efficacy, and radiotherapy planning." | ( Lin, M, 2011) |
| "Since colorectal cancer initially develops in the mucous membrane of the large intestine, a nonabsorbable colonoscopic imaging agent capable of being administered intracolonically was designed." | ( Hiwatari, K; Hoffman, RM; Pham, W; Sakuma, S; Yamashita, S, 2011) |
| "The prognosis of patients with advanced colorectal cancer with icterus is dismally poor, and adequate chemotherapy for these patients has not been established yet." | ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "For patients with metastatic colorectal cancer (mCRC), no standard therapy exists after progression on 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab." | ( Altomare, I; Bendell, JC; Blobe, GC; Bullock, KE; Honeycutt, W; Hsu, SD; Hurwitz, HI; Morse, MA; Pang, H; Sutton, L; Uronis, HE; Zafar, SY, 2011) |
| "Tissues of 82 patients treated for colorectal cancer (CRC) were analyzed using antibodies against AIF, p53, DR4, DR5, cleaved caspase-3 and the TUNEL method to detect apoptosis; whereas staining of Ki-67 was used as a proliferation marker." | ( Akil, H; Jauberteau, MO; Labrousse, F; Mathonnet, M; Nouaille, M; Perraud, A; Petit, D, 2011) |
| "Because CYP2W1 is highly expressed in colorectal tumors, GW-610 represents a promising agent for CRC therapy." | ( Bradshaw, TD; Choo, HL; Leong, CO; Muruhadas, A; Randhawa, N; Stevens, MF; Tan, BS; Tiong, KH, 2011) |
| "We retrospectively studied 104 colorectal tumors treated with EMR from 1995 to 2004, and 85 colorectal tumors treated with ESD from 2005 to 2009." | ( Bhatia, V; Haba, S; Hara, K; Hijioka, S; Imaoka, H; Kondo, S; Mizuno, N; Niwa, Y; Ogura, T; Tajika, M; Tanaka, T; Yamao, K, 2011) |
| "We have previously reported that colorectal cancer tumor xenograft growth was arrested following treatment with liposomal preparation of siDCAMKL-1." | ( Anant, S; Houchen, CW; May, R; Mondalek, FG; Pantazis, P; Ponnurangam, S; Qu, D; Ramanujam, RP; Sureban, SM, 2011) |
| "Patients with metastatic colorectal cancer, who had been exposed to 5-FU, oxaliplatin, and irinotecan in the first- and second line setting and mainly with irinotecan and cetuximab as third line treatment, were treated with capecitabine and bevacizumab." | ( Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO, 2012) |
| "A series of 20 patients with colorectal cancer or head and neck cancer were pre-treated with phytomenadione cream (0." | ( Gharibyar, M; Kohoutek, M; Pospíšková, M; Serclová, M; Sternberský, J; Tomková, H; Zábojníková, M, 2013) |
| "Key to the clinical management of colorectal cancer is identifying tools which aid in assessing patient prognosis and determining more effective and personalised treatment strategies." | ( Concannon, CG; Dicker, P; Hector, S; Huber, HJ; Kay, EW; Kehoe, J; McCawley, N; McNamara, D; Murray, F; Prehn, JH; Rehm, M; Schmid, J, 2012) |
| "A total of 3359 patients with colorectal cancer treated with the FOLFOX4 regimen were included in the analyses: 1515 from 2 Asian studies (Japanese Post Marketing Surveillance and Multicenter Asia Study in Adjuvant Treatment of Colon Cancer with Oxaliplatin/5-FU/LV), and 1844 from 4 Western studies (EFC2962, N9741, EFC4584, and Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer)." | ( André, T; Brienza, S; de Gramont, A; Goldberg, RM; Gomi, K; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012) |
| "Resistance of colorectal cancer (CRC) to the available chemotherapy reveals the demand for identification of new anticancer agents." | ( Abdul-Razzak, KK; Aldaher, AN; Alkofahi, AS; Alsarhan, AM; Mhaidat, NM; Thorne, RF, 2012) |
| "A large proportion of colorectal cancer patients does not benefit from the use of anti-epidermal growth factor receptor (EGFR) treatment although in the absence of a mutation of the K-RAS gene." | ( Bearzi, I; Biagetti, S; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Maccaroni, E; Mandolesi, A; Scartozzi, M; Silva, R; Zaniboni, A, 2012) |
| "What are the colorectal cancer prognostic factors which would guide the chemotherapy? TNM classification, number of examined lymph nodes, MSI status, and presence or not of a perforation or a perinervous, lymphatic or venous invasion is recognized prognostic factors." | ( Brezault, C; Chaussade, S; Coriat, R; Esch, A; Perkins, G, 2012) |
| "Treatment of colorectal cancer with 5-ASA inhibited mTOR signalling in vitro and in vivo." | ( Baan, B; Bos, CL; Dihal, AA; Hardwick, JC; Heijmans, J; Hoff, E; Hommes, DW; Koelink, PJ; Muncan, V; Peppelenbosch, MP; Richel, DJ; van den Brink, GR; Verspaget, HW; Voorneveld, PW; Wildenberg, ME, 2012) |
| "The subject was 28 patients of colorectal cancer with synchronous unresectable liver metastasis who received mFOLFOX6 as a first-line treatment from 2005 to 2010." | ( Amano, K; Chikatani, K; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Iwama, T; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y, 2011) |
| "Plasma samples were collected from 27 colorectal cancer patients on cytostatic treatment, 27 with cytostatic drugs plus monoclonal antibodies (cytostatic-Mabs) and 15 non-treated patients." | ( Cavia-Saiz, M; Coma-Del Corral, MJ; De Santiago, R; Garcia-Giron, C; Herreros-Villanueva, M; Lopez, AS; Muñiz, P, 2012) |
| "Improved survival of colorectal cancer has been made over the last 3 decades; reasons may be attributed to early detection through screening, and better treatment options." | ( Chu, F; Chua, TC; Liauw, W; Morris, DL, 2012) |
| "Patients with advanced colorectal cancer (CRC) who have received oxaliplatin, 5-fluoropyrimidine, and irinotecan chemotherapy (with or without bevacizumab) and antiepidermal growth factor receptor therapy (if KRAS is wild type) have no further standard treatment options." | ( Beeke, C; Bishnoi, S; Broadbridge, V; Jain, K; Karapetis, CS; Luke, C; Padbury, R; Price, TJ; Townsend, AR, 2013) |
| "We randomly assigned 287 Stage III colorectal cancer patients after curative resection between 2002 and 2008 to receive 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (combined therapy) or 6 cycles of systemic chemotherapy alone (monotherapy)." | ( Bao, Y; Feng, WM; Huang, SX; Tang, CW; Tao, YL; Wang, Y; Zheng, YY, 2012) |
| "A considerable number of metastatic colorectal cancer (mCRC) patients who progress on standard treatment with 5-fluorouracil (5FU), oxaliplatin, irinotecan and monoclonal antibodies, still have adequate performance status and desire further treatment." | ( Costa, FP; Ferrarotto, R; Hoff, PM; Kopetz, S; Machado, K; Mak, MP; Overman, MJ; Shah, N; Takahashi, TK, 2012) |
| "Murine C26 and MC38 colorectal cancer cells were grown under hypoxia and normal oxygenation in vitro, and treated with different concentrations of tirapazamine." | ( Borel Rinkes, IH; Emmink, BL; Govaert, KM; Kranenburg, O; Minchinton, AI; Nijkamp, MW; Steller, EJ, 2012) |
| "Thirty-six patients with advanced colorectal cancer were retrospectively assigned to one of two treatment groups: FOLFOX4 (control) or FOLFOX4 plus Endostar (Endostar) according to patient accreditation." | ( Huang, XE; Li, CG; Li, Y; Qian, ZY; Xu, HX; Xu, X, 2011) |
| "Patients with colorectal cancer treated with oxaliplatin based chemotherapy (FOLFOX or XELOX) were retrospectively divided into two groups according to the use of GM1." | ( Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ, 2012) |
| "Fifty evaluable colorectal cancer patients were treated with vitamin D(3) at 2000 IU/day for 6 months." | ( Andrews, C; Fakih, MG; McMahon, J; Muindi, JR, 2012) |
| "Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy." | ( Berger, S; Dechant, M; Derer, S; Kellner, C; Klausz, K; Lammerts van Bueren, JJ; Lohse, S; Nagelmeier, I; Overdijk, MB; Parren, PW; Peipp, M; Scheel, AH; Schlaeth, M; Schneider-Merck, T; Valerius, T; van de Winkel, JG, 2012) |
| "Human colorectal cancer cell lines Caco-2 and HCT-8 were treated with 1 μM nicotine alone or in combination with 1 μM α-BTX in complete or in serum free medium." | ( Bizzarri, M; Coluccia, P; Cucina, A; D'Anselmi, F; Dinicola, S; Pasqualato, A; Proietti, S, 2012) |
| "Human colorectal cancer LOVO cells were treated by hyperthermia at 44°C for 2 hr or/and TF siRNA." | ( Ji, SQ; Li, H; Liu, YC; Tang, JQ; Tian, ML; Wan, YL; Wang, X; Yu, G; Zhang, J; Zhu, J, 2012) |
| "Predictors of the response of colorectal cancer to chemotherapy remain poorly understood." | ( Goto, T; Hibi, K; Kigawa, G; Kitamura, Y; Nemoto, H; Saito, M; Sakuraba, K; Sanada, Y; Shinmura, K; Shirahata, A; Yokomizo, K, 2012) |
| "Treatment decisions in colorectal cancer subsequent to surgery are based mainly on the TNM system." | ( Klar, E; Krentz, H; Linnebacher, M; Pahnke, J; Prall, F; Schiffmann, L; Schwarz, F; Vollmar, B, 2012) |
| "Rapidly increasing colorectal cancer (CRC) incidence in Malaysia and the introduction of cutting edge new treatments, which prolong survival, mean that treatment outcome measures meed to be evaluated, including consideration of patient's quality of life (QoL) assessment." | ( Ezat, S; Natrah, MS; Rizal, AM; Saperi, S; Syed, MA, 2012) |
| "The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer." | ( Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M, 2012) |
| "Four human colorectal cancer cell lines (HCT116, DLD-1, SW480, and KM12C) were treated with compound C." | ( Liou, D; Marambaud, P; Perillo, W; Wang, P; Yang, WL, 2012) |
| "The human colorectal cancer (CRC) cell lines HT29 and SW480 were treated with nigericin or oxaliplatin under the conditions specified." | ( Dong, TT; Fan, XK; Feng, B; Wang, LL; Zhao, HC; Zheng, MH; Zhou, HM, 2012) |
| "A total of 18 colorectal cancer patients who received bevacizumab combined with chemotherapy were included." | ( Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z, 2012) |
| "SW480 human colorectal cancer cells were treated with empty PEG-liposomes, free oxaliplatin or PEG-liposomal oxaliplatin." | ( Fu, ZX; Liu, HZ; Yang, C, 2012) |
| "The study included 28 metastatic colorectal cancer (mCRC) patients who underwent 2 FDG PET/CT scans (baseline and at day 14 of the first course of polychemotherapy)." | ( Buvat, I; Emonts, P; Flamen, P; Garcia, C; Hendlisz, A; Necib, H; Vanderlinden, B; Wagner, A, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "The treatment of metastatic colorectal cancer (CRC) has evolved rapidly over the last decade, with combination chemotherapy and targeted biologic agents leading to significant improvements in survival." | ( Blazer, DG; Hsu, D; Papalezova, K; Stinnett, S; Tyler, D; Zani, S, 2013) |
| "Human colorectal cancer cell lines HCT116 and DLD-1 were treated with a panel of small interfering RNAs directed against the PI3K/AKT/mTOR and Ras pathways; proliferation, apoptosis, and protein expression were assessed." | ( Elliott, VA; Evers, BM; Gao, T; Mustain, WC; Rychahou, PG; Valentino, JD; Wang, C; Zaytseva, YY, 2012) |
| "The failure of colorectal cancer treatments is partly due to overexpression of CXCR4 by tumor cells, which plays a critical role in cell metastasis." | ( Abedini, F; Chong, PP; Domb, AJ; Farber, IY; Hong, PD; Hosseinkhani, H; Ismail, M; Omar, AR; Yu, DS, 2012) |
| "Using the human colorectal cancer cell lines HT-29, SW620 and LS174T, we demonstrated that treatment of these cancer cells with PT induces apoptosis using MTT, Annexin V assay and Hoechst 33258 staining." | ( Kim, DG; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Lee, SO; Lee, ST; Trang, KT, 2012) |
| "Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody." | ( Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA, 2012) |
| "The maximum concentration of colorectal cancer patient administered oxaliplatin was 1650ng/mL." | ( Fujikawa, A; Furugen, A; Iseki, K; Ito, H; Kobayashi, M; Mano, N; Miyamori, K; Ogura, J; Takahashi, N; Tanaka, N; Yamada, T; Yamaguchi, H, 2012) |
| "Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection." | ( Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F, 2013) |
| "We investigated CIMP and MSI status in colorectal cancer patients treated with adjuvant FOLFOX." | ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013) |
| "Patients undergoing liver resection for colorectal cancer liver metastasis (CRCLM) are often treated with chemotherapy before surgery." | ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013) |
| "Growth inhibition of the human colorectal cancer cell line HCT116 treated with cisplatin, oxaliplatin, Lipoplatin™ and Lipoxal™ plus gamma-radiation was determined by a colony formation assay." | ( Kotb, R; Paquette, B; Sanche, L; Tippayamontri, T, 2012) |
| "Metastatic colorectal cancer with KRAS codon 12 or 13 mutations is not currently treated with anti-epidermal growth factor antibodies." | ( Bando, H; Fujii, S; Kadowaki, S; Kajiura, S; Nishina, T; Ohtsu, A; Shinozaki, E; Tsuchihara, K; Yamanaka, T; Yamazaki, K; Yoshino, T; Yuki, S, 2012) |
| "Half of patients with KRAS wild-type colorectal cancer do not benefit from adding anti-epithelial growth factor receptor (EGFR) to standard chemotherapy regimens." | ( Adotevi, O; Borg, C; Degano, SV; Demarchi, M; Dobi, E; Godet, Y; Ivanaj, A; Jary, M; Kantelip, B; Kim, S; Monnien, F; N'Guyen, T; Pivot, X; Thierry-Vuillemin, A, 2013) |
| "Resected colorectal cancer patients (n=143) were analyzed for colonic methanogenesis and pH before and during the 24 weeks of 5-fluorouracil chemotherapy and for gastrointestinal symptoms during chemotherapy." | ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based." | ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| "Sixty-seven of 72 colorectal cancer patients treated at our hospital fulfilled the inclusion criteria of the study which was conducted from December 2010 to February 2012." | ( Cai, HK; Deng, YC; He, HF; Hu, Y; Tian, W; Zhou, MQ, 2012) |
| "Patients with documented metastatic colorectal cancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle." | ( Adenis, A; Barone, C; Bouché, O; Cihon, F; Cupit, L; Falcone, A; Goldberg, RM; Grothey, A; Humblet, Y; Laurent, D; Lenz, HJ; Mineur, L; Sargent, DJ; Siena, S; Sobrero, A; Tabernero, J; Van Cutsem, E; Wagner, A; Ychou, M; Yoshino, T, 2013) |
| "Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy." | ( Bertarelli, G; Biondani, P; Cortinovis, D; de Braud, F; Di Bartolomeo, M; Fanetti, G; Mariani, L; Melotti, F; Milione, M; Perrone, F; Pietrantonio, F, 2013) |
| "One hundred and twenty patients with colorectal cancer at Ruijin Hospital, Shanghai Jiaotong University School of Medicine were randomly assigned to the pure chemotherapy group (as the control group) and the QM + chemotherapy group (as the treatment group), 60 in each group." | ( Chen, JX; Shen, XH, 2012) |
| "Metastatic colorectal cancer (mCRC) is frequently characterized by the presence of mutations of the KRAS oncogene, which are generally associated with a poor response to treatment with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies." | ( Ballestrero, A; Cerruti, G; Chiara, S; Dono, M; Ferrarini, M; Massucco, C; Mora, M; Sonaglio, C; Truini, A; Truini, M; Zoppoli, G; Zupo, S, 2013) |
| "Patients with metastatic colorectal cancer receive chemotherapy prior liver resection more and more frequently." | ( Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A, 2013) |
| "Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan." | ( Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013) |
| "We compared the results of stage IV colorectal cancer patients treated within a large Dutch phase III trial (CAIRO), in which standard chemotherapy and standard safety eligibility criteria were used, to patients treated outside the trial during the trial accrual period in a representative selection of 29 Dutch hospitals." | ( Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW, 2013) |
| "A retrospective analysis of 106 colorectal cancer patients receiving an oxaliplatin-based treatment and 56 receiving an irinotecan-based treatment was performed." | ( Cortejoso, L; Escolar, F; García, MI; García-Alfonso, P; González-Haba, E; López-Fernández, LA; Sanjurjo, M, 2013) |
| "The risk of colorectal cancer is reduced among users of oral contraceptives or menopausal hormone therapy, but associations with reproductive characteristics that are markers of a woman's endogenous hormone milieu have not been consistently observed." | ( Brenner, H; Chang-Claude, J; Herpel, E; Hoffmeister, M; Roth, W; Rudolph, A; Schirmacher, P; Toth, C, 2013) |
| "Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy." | ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013) |
| "Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles." | ( Baek, JY; Hong, YS; Ji, JH; Kang, HJ; Kim, KP; Kim, SY; Kim, TW; Lee, J; Park, SH; Park, YS; Shim, BY; Shin, SJ, 2013) |
| "Patients with metastatic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(2) plus either brivanib 800 mg orally daily (arm A) or placebo (arm B)." | ( Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR, 2013) |
| "Compared to SW480 and HCT116 colorectal cancer cells, P6C cells were highly resistant to Camptothecin and 5-fluorouracil, the commonly used chemotherapeutic agents to treat colorectal cancers." | ( Chen, Q; Du, L; Hao, JJ; Jin, HJ; Li, BW; Liu, HM; Rao, GH; Wang, J; Wang, MR; Wang, XH; Yang, YL, 2013) |
| "Liver resection is essential part of colorectal cancer liver metastases (CLM) treatment." | ( Kryj, M; Maciejewski, A; Półtorak, S; Zeman, M, 2013) |
| "The rapidly increasing of incidence colorectal cancer (CRC) in Malaysia and the introduction of new treatments that prolong survival advocating treatment outcome measures such as patients' quality of life (QOL) are evaluated in this study." | ( Abdul Manaf, MR; Aljunid, SM; Ismail, F; Muhammad Annuar, MA; Saad, NM; Sagap, I; Sulong, S; Wan Puteh, SE, 2013) |
| "Thyroid function in colorectal cancer patients receiving fluoropyrimidine-based chemotherapy with or without bevacizumab was evaluated at baseline and monthly." | ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H, 2013) |
| "Postoperative chemotherapy for Colorectal cancer (CRC) patients is not all effective and the main reason might lie in cancer stem cells (CSCs)." | ( Chen, S; Guo, X; He, S; Kuang, Y; Li, P; Xue, X; Zhao, H; Zhi, Q; Zhou, J, 2013) |
| "Treatment of colorectal cancer (Caco2) cells with curcumin resulted in concentration-dependent cell death with an EC50 of 22." | ( Aguilar, BJ; Amissah, F; Duverna, R; Lamango, NS; Poku, RA, 2013) |
| "As oxaliplatin is a standard agent in colorectal cancer therapy today, all clinicians and pathologists should be aware of such non-neoplastic lesions as one of the rare differential diagnoses of metastatic liver tumor, to prevent overtreatment." | ( Endo, Y; Fujisawa, M; Kai, K; Matsukawa, A; Matsumoto, Y; Nobuhisa, T; Notohara, K; Sato, S; Uchino, K; Watanabe, T, 2013) |
| "In the intention to treat analysis, 57 colorectal cancer events were identified among orlistat initiators and 246 among non-initiators, with median follow-up times of 2." | ( Hong, JL; Jick, SS; Meier, CR; Sandler, RS; Stürmer, T, 2013) |
| "A total of 250 White metastatic colorectal cancer patients homogenously treated with a first-line FOLFIRI regimen were genotyped for a panel of variants in five transporter genes." | ( Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V, 2013) |
| "Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy." | ( Barugel, M; Bodoky, G; Burkes, R; Błasińska-Morawiec, M; Canon, JL; Cunningham, D; Douillard, JY; Humblet, Y; Jassem, J; Kocákova, I; Oliner, KS; Patterson, SD; Rivera, F; Rong, A; Rother, M; Ruff, P; Sidhu, R; Siena, S; Šmakal, M; Tabernero, J; Wiezorek, J; Williams, R, 2013) |
| "In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy." | ( Barugel, M; Bodoky, G; Burkes, R; Błasińska-Morawiec, M; Canon, JL; Cunningham, D; Douillard, JY; Humblet, Y; Jassem, J; Kocákova, I; Oliner, KS; Patterson, SD; Rivera, F; Rong, A; Rother, M; Ruff, P; Sidhu, R; Siena, S; Šmakal, M; Tabernero, J; Wiezorek, J; Williams, R, 2013) |
| "From 1999 to 2010, 114 patients with colorectal cancer and PM were treated with CCRS + HIPEC." | ( Boige, V; Borget, I; Caramella, C; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Farron, M; Goéré, D; Honoré, C; Malka, D; Pottier, E, 2013) |
| "Thirteen patients with metastatic colorectal cancer who suffered from oxaliplatin-induced sensory neuropathy were evaluated to determine the neuropathy Grade before and after the administration of pregabalin." | ( Hasegawa, T; Hirakawa, K; Hirakawa, T; Inoue, T; Maeda, K; Nagahara, H; Noda, E; Shibutani, M, 2013) |
| "Peritoneal involvement in colorectal cancer (CRC) is an adverse prognostic feature, which may prompt consideration of adjuvant chemotherapy in stage II disease." | ( Cook, M; El-Zimaity, H; Grin, A; Hafezi, S; Kirsch, R; Messenger, DE; O'Connor, BI, 2013) |
| "In this double blind crossover study, colorectal cancer patients undergoing oxaliplatin-based chemotherapy were randomised to receive Ca/Mg (1g Ca Gluconate plus 1g MgSO4) on cycle 1 and placebo (vehicle alone) on cycle 2, or to receive the same treatments in the opposite sequence." | ( Han, CH; Hill, A; Khwaounjoo, P; Kilfoyle, DH; McKeage, MJ, 2013) |
| "Thus, we cotreated human colorectal cancer cells (Caco-2) with the small-molecule inhibitors and hydrogen peroxide or the approved drug temozolomide." | ( Brockmann, A; Brunner, T; Hantusch, A; Marx, A; Pott, M; Strittmatter, T, 2014) |
| "Treatment-naïve metastatic colorectal cancer patients received CPT-FUFA (January 2000-December 2003; control group) and bevacizumab_CPT-FUFA (January 2007-December 2010; study group)." | ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014) |
| "In the randomized, controlled COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy (CORRECT) trial, regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle plus best supportive care (BSC) was associated with a significantly longer median overall survival than placebo plus BSC in patients with previously treated, progressive mCRC." | ( Carter, NJ, 2014) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "Treatment of primary colorectal cancer xenografts with a small-molecule BMI-1 inhibitor resulted in colorectal CIC loss with long-term and irreversible impairment of tumor growth." | ( Arrowsmith, CH; Baiazitov, R; Cao, L; Davis, T; Dick, JE; Du, W; Frelin, C; Gallinger, S; Gibson, L; Iscove, NN; Kreso, A; Leung, C; Lima-Fernandes, E; Moon, YC; O'Brien, CA; Pedley, NM; Sydorenko, N; Szentgyorgyi, E; van Galen, P; Wang, Y, 2014) |
| "Advances in colorectal cancer (CRC) diagnosis will be enhanced by development of more sensitive and reliable methods for early detection of the disease when treatment is more effective." | ( Baker, MS; Fanayan, S; Hancock, WS; Packer, NH; Sethi, MK; Smith, JT; Thaysen-Andersen, M, 2014) |
| "In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy compared with low expression." | ( Bjarnason, G; Harbison, C; Jonker, DJ; Karapetis, CS; Khambata-Ford, S; Langer, C; Malone, DP; Moore, MJ; O'Callaghan, CJ; Price, TJ; Shapiro, J; Simes, RJ; Siu, LL; Tebbutt, N; Tu, D; Wong, RP; Zalcberg, JR, 2014) |
| "Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy." | ( Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P, 2014) |
| "Ninety-two metastatic colorectal cancer patients treated with first-line 5-fluoropyrimidine (5-FU), leucovorin, and oxaliplatin (FOLFOX), capecitabine, and oxaliplatin (XELOX) and sixty-two patients receiving 5-FU, leucovorin, and irinotecan (FOLFIRI) were reviewed." | ( Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D, 2014) |
| "The failure of EGFR inhibitors in colorectal tumors with KRAS mutations requires the development of alternative treatment strategies for this patient subgroup." | ( Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H, 2014) |
| "Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70)." | ( Ang, B; Cao, X; Fang, H; Huang, X; Li, N; Sun, Y; Wan, T; Wang, W; Wu, Y; Xu, X, 2014) |
| "A mouse model for colorectal cancer was utilized whereby colonic apoptosis and cell proliferation was measured 6 h after azoxymethane treatment by hematoxylin and immunohistochemical staining." | ( Abbott, CA; Benkendorff, K; Esmaeelian, B; Le Leu, RK, 2013) |
| "In patients with incurable colorectal cancer, capecitabine maintenance therapy following combined chemotherapy can achieve a prolonged PFS with a good safety and tolerance and retains the possibility of further intense therapy in the event of disease progression." | ( Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D, 2013) |
| "For metastatic colorectal cancer the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is now commonly included in first-line therapy regimens and has led to modest but significant improvements in patient outcomes compared with chemotherapy." | ( Arentz, G; Bruhn, MA; Cunningham, D; Hardingham, JE; Hocking, C; Khoon Lee, C; Price, TJ; Shivasami, A; Tebbutt, NC; Townsend, AR; Wrin, J, 2014) |
| "The expression of miR-497 in colorectal cancer cells with prior treatment with bufalin was determined using real-time quantitative PCR." | ( Feng, W; Hu, Q; Hu, SJ; Liang, B; Peng, W; Qiu, YY; Tang, QF; Yin, PH, 2014) |
| "We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer." | ( Hida, J; Inoue, K; Kogita, A; Okuno, K; Sugiura, F; Sukegawa, Y; Yoshioka, Y, 2013) |
| "When treating colorectal cancer with chemotherapy, it is important to elucidate how the prognosis can be improved while maintaining the quality of life( QOL)." | ( Hagino, S; Iwata, K; Kiriyama, M; Kurata, T; Makita, N; Tsuneda, A, 2013) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "A total of 54 patients with advanced colorectal cancer who were treated between May 2005 and May 2013 with FOLFOX4 as first-line chemotherapy and with FOLFIRI as second-line chemotherapy at Kosin University Gospel Hospital (Busan, Korea) were reviewed retrospectively." | ( Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE, 2014) |
| "Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II." | ( Artells, R; Cordeiro, A; Diaz, T; Ferrer, G; Hernandez, R; Monzo, M; Moreno, I; Navarro, A; Tapia, G; Tejero, R, 2014) |
| "Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy." | ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014) |
| "Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm)." | ( Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B, 2014) |
| "A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated." | ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "Synchronous colorectal cancer liver metastasis (SCLM) remains a clinical challenge, largely because of the limited availability of tools that use reliable prognostic indicators to guide treatment." | ( Hong, YS; Kim, HO; Kim, JC; Kim, JS; Kim, TW; Lee, HS; Yu, CS, 2014) |
| "Bilateral implants of HT29 colorectal cancer in the femoral regions of Balb/c (nu/nu) mice were treated with a single 30-min shot of modulated, 13." | ( Andocs, G; Balla, P; Balogh, L; Jeney, A; Kiszner, G; Krenacs, T; Meggyeshazi, N; Teleki, I, 2014) |
| "Oxaliplatin is an integral component of colorectal cancer treatment, but its use is limited by neurotoxicity." | ( Alberts, S; Ansari, R; Childs, BH; Chowhan, N; Grothey, A; Hainsworth, JD; Hart, L; Hochster, HS; Keaton, M; Ramanathan, RK; Rowland, K, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| "Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies." | ( Abalı, H; Beşen, AA; Dişel, U; Köse, F; Özyılkan, Ö; Sezer, A; Sezgin, N; Sümbül, AT; Sümbül, Z, 2014) |
| "To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping." | ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014) |
| "Patients with metastatic colorectal cancer (mCRC) frequently experience treatment-related adverse events (AEs), which may lead to nonadherence or discontinuation from their treatment regimen." | ( Brent, L; Khoukaz, T; McNeal, D; Mitchell, J, 2014) |
| "Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments." | ( Adams, R; Butler, R; Fisher, D; Kaplan, R; Lowdell, C; Madi, A; Maughan, T; Meade, AM; Middleton, G; Pugh, C; Sizer, B; Sydes, B; Wasan, H; Wilson, R, 2014) |
| "We enrolled patients with advanced colorectal cancer who had received no previous chemotherapy for metastases." | ( Adams, R; Butler, R; Fisher, D; Kaplan, R; Lowdell, C; Madi, A; Maughan, T; Meade, AM; Middleton, G; Pugh, C; Sizer, B; Sydes, B; Wasan, H; Wilson, R, 2014) |
| "Mutation in p53 is the key event in colorectal cancer (CRC) and an important target for the treatment of CRC through gene therapy." | ( Baradia, D; Bhatt, P; Khatri, N; Kumar, M; Misra, A, 2015) |
| "Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab." | ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014) |
| "Oxaliplatin is a first-line therapy for colorectal cancer, but cancer cell resistance to the drug compromises its efficacy." | ( Chian, S; Li, YY; Tang, XW; Wang, XJ, 2014) |
| "The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years." | ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "The treatment of colorectal cancer (CRC) might be improved by the identification of a signalling pathway that could be targeted with novel therapeutics." | ( Matsumura, Y; Yasunaga, M, 2014) |
| "Unlike for fit elderly metastatic colorectal cancer (mCRC) patients, general approaches to initial treatment for the frail older mCRC patients are not clear." | ( Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I, 2014) |
| "Among the advanced colorectal cancer patients receiving fluorouracil-based chemotherapy, those with plasma concentration of 5-FU above 26." | ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014) |
| "The p53-wild type colorectal cancer cells were exhibited greater cytotoxicity, apoptosis and survivin reduction than the p53-null cancer cells after treatment with honokiol." | ( Chao, JI; Lai, YJ; Lin, CI; Wang, CL, 2014) |
| "The securin-null colorectal cancer cells were more sensitive on the reduction of cell viability than the securin-wild type cancer cells following butein treatment." | ( Chao, JI; Chien, PH; Huang, YT; Lin, CI; Lin, J; Tang, TT, 2014) |
| "Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated." | ( Chang, SC; Chang, YY; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "We enrolled 36 patients with colorectal cancer, treated with adjuvant mFOLFOX6 or XELOX chemotherapy, and 22 healthy volunteers." | ( Basdanis, G; Dermitzakis, EV; Eleftheraki, A; Fountzilas, G; Georgiadis, G; Kimiskidis, VK; Konstantis, A; Lazaridis, G; Tsiptsios, I, 2014) |
| "However, the role of LSD1 in colorectal cancer (CRC) carcinogenesis, prognosis and treatment remains uncharacterized." | ( Chen, HC; Chen, SJ; Hsu, HC; Hung, HY; Liu, YS; Tseng, KC; Yang, TS; Yeh, CY; You, JF, 2015) |
| "Stathmin-1 is a potential candidate in colorectal cancer therapy that targets simultaneously the twin problems of metastatic spread and chemoresistance." | ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Finally, we established a colorectal cancer xenograft model and found that selenite treatment markedly inhibits tumour growth through the MAPK/PKD1/CREB/Bcl-2 pathway in vivo." | ( An, J; Ci, Y; Duan, J; Hui, K; Luo, H; Shi, K; Shi, L; Wu, P; Xu, C; Yang, Y, 2014) |
| "Protein profiles of human colorectal cancer SW480 cells treated with or without CAPE were analysed using a two-dimensional (2D) electrophoresis gel-based proteomics approach." | ( Dong, H; He, YJ; Li, WL; Liu, BH; Mou, ZR; Wu, YZ, 2014) |
| "These differentiated proteins in colorectal cancer cells following CAPE treatment, may be potential molecular targets of CAPE and involved in the anti-cancer effect of CAPE." | ( Dong, H; He, YJ; Li, WL; Liu, BH; Mou, ZR; Wu, YZ, 2014) |
| "Mechanistic studies in a colorectal cancer mouse model revealed that FOLFIRI-like therapy including the drugs CPT11 and 5-fluorouracil (5FU) damaged host immunocompetence in a manner that limits treatment outcomes." | ( Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M, 2014) |
| "Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy." | ( Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A, 2014) |
| "The treatment of localized colorectal cancer (CRC) depends on resection of the primary tumor with adequate margins and sufficient lymph node sampling." | ( Albrecht, DM; Clipson, L; Deming, DA; Grudzinski, JP; Halberg, RB; Hall, LT; Leystra, AA; Lubner, SJ; Maher, ME; Matkowskyj, KA; Washington, MK; Weichert, JP, 2014) |
| "Only articles in which gastric and colorectal cancer was reported after tamoxifen therapy for breast cancer were included." | ( Chen, S; Li, J; Liu, H; Yang, G, 2015) |
| "Patients with K-RAS mutated colorectal cancer, progressing on first-line oxaliplatin-based chemotherapy with bevacizumab, were eligible for this multicenter open-label phase I/II trial." | ( Cohen, D; Cohen, S; Denlinger, C; Gold, PJ; Hochster, HS; Leichman, CG; Leichman, L; Lenz, HJ; Messersmith, W; ONeil, BH; Uboha, N, 2015) |
| "Unfortunately, advanced colorectal cancer is often resistance to such chemotherapy and poor outcome." | ( Chang, SW; Chen, TH; Huang, CC; Lee, H; Wu, DW, 2015) |
| "In practice, patients with metastatic colorectal cancer in treatment failure or relapse after first-line therapy should not expect too much from the addition of aflibercept or bevacizumab to a second-line protocol." | ( , 2014) |
| "Management of advanced colorectal cancer is challenging due to the lack of efficient therapy." | ( Bettaieb, A; Jeannin, JF; Martin, A; Paul, C; Racoeur, C; Rollet, CE; Scagliarini, A; Seignez, C, 2014) |
| "We present a patient with recurrent colorectal cancer and four hepatic metastases who was treated with RFA combined with aflibercept, another VEGF inhibitor and systemic chemotherapy." | ( Agarwal, A; Butler-Bowen, H; Daly, KP; Saif, MW, 2014) |
| "Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumour biology." | ( Bosch, LJ; Haan, JC; Israeli, D; Kabbarah, O; Koopman, M; Labots, M; Meijer, GA; Mekenkamp, LJ; Nagtegaal, ID; Punt, CJ; Qu, X; Rausch, C; Tol, J; van de Wiel, MA; van Essen, HF; van Grieken, NC; Verheul, HM; Voorham, QJ; Ylstra, B, 2014) |
| "Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate." | ( Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL, 2015) |
| "Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy." | ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014) |
| "Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled." | ( Bortlíček, Z; Kubáčková, K; Linke, Z; Pikus, T; Pokorná, P; Prausová, J; Vyzula, R, 2015) |
| "The subjects were 14 patients with colorectal cancer who received ≥3 courses of SOX+BV therapy in our department." | ( Higashi, Y; Ishikawa, S; Maruo, H; Murakami, T; Nishiyama, R; Shoji, T; Suzuki, K; Taniguchi, M; Yamazaki, M, 2014) |
| "In metastatic colorectal cancer (mCRC) with wild-type K-ras, cetuximab-based regimen is an option for third-line therapy." | ( Liu, FY; Wang, JY; Yang, TS; Yen, TC, 2015) |
| "Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities." | ( Choi, YH; Kim, RB; Lenehan, J; Parfitt, J; Teft, WA; Welch, S; Winquist, E, 2015) |
| "Patients with recurrent colorectal cancer and prior treatment with fluoropyrimidines, oxaliplatin, and irinotecan or unable to receive standard chemotherapy because of toxicity concerns were included." | ( Barucca, V; D'Antonio, C; Di Rocco, R; Durante, V; Falcone, R; Marchetti, P; Milano, A; Onesti, CE; Righini, R; Roberto, M; Romiti, A; Tomao, S, 2015) |
| "Human colorectal cancer cell line, HCT116, and its isogenic cells were treated with FIbersol-2." | ( Cuesta-Sancho, S; Olson, SL; Ouchi, M; Ouchi, T; Reif, D; Shimomura, K; So, EY, 2015) |
| "Self-renewing colorectal cancer stem/progenitor cells (CSC) contribute to tumor maintenance and resistance to therapy." | ( Allen, JE; Dicker, DT; El-Deiry, WS; Prabhu, VV, 2015) |
| "To explore the cost of treating colorectal cancer in the modern era, data were entered onto a prospective database at four hospitals." | ( Ananda, S; Chapman, M; Field, K; Gibbs, P; Guerrieri, M; Jones, I; Kosmider, S; Skinner, I; Tran, B, 2016) |
| "The combined treatment of human colorectal cancer cells with silibinin and metformin may induce apoptosis at a dose that does not affect HCoEpiC." | ( Chen, LJ; Cheng, JT; Chuang, TW; Chung, KM; Lin, KC; Niu, HS; Tsai, CC, 2015) |
| "Efficacy of doxorubicin (DOX) in colorectal cancer treatment is limited by undesirable side-effects, which are partially due to nonspecific delivery DOX to the tumor target site." | ( Cheewatanakornkool, K; Dass, CR; Manchun, S; Sriamornsak, P, 2015) |
| "K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates to second/third-line cetuximab with chemotherapy were prospectively allocated into 2 groups on the basis of their profile: favourable (BRAF and PIK3CA exon 20 wild type, EGFR GCN ≥ 2." | ( Abouelkhair, KM; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Ibrahim, EM; Loretelli, C; Mandolesi, A; Maristella, B; Scarpelli, M; Scartozzi, M, 2015) |
| "A total of 87 patients with metastatic colorectal cancer were treated with cetuximab for 2-16 months, in combination with chemotherapy between August 2008 and July 2012, and tissue samples were used to detect K-ras mutations." | ( Cheng, LW; Cheng, Y; Chi, ZC; Li, Z; Liu, XW; Sun, BS, 2015) |
| "Forty-two patients with gastric or colorectal cancer underwent chemotherapy, including FAM or FOLFOX4 regimens." | ( Kong, W; Li, Y; Liu, F; Ni, X; Ping, X; Shen, J; Wang, J; Yu, B, 2015) |
| "Supernatants of re-cultivated murine colorectal cancer cell Colon26 and human colorectal cancer cell RKO after pre-treatment with or without artesunate were enrolled, and their effects on five immune parameters were assessed, including killing activity of natural killer (NK) and lymphocyte proliferation, as measured by MTT, and expressions of interleukin 2 receptor (IL-2R)α, CD3ε(+)ζ(+) and CD3ε(-)ζ(+) on lymphocytes, as analyzed by flow cytometry." | ( Cui, C; Feng, H; Feng, Z; Fu, J; Fu, Z; Han, Z; Liu, J; Shi, X; Tong, H; Wang, Y, 2015) |
| "Ninety-three patients with colorectal cancer who developed moderate-to-severe COM (WHO grade ≧1) during any cycle of chemotherapy using FOLFOX, FOLFIRI, and/or XELOX treatment were randomly assigned to receive either TJ-14 (n = 46) or placebo (n = 47)." | ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015) |
| "Our study underscores the complexity of colorectal cancer aggravated by mobility of Alu elements and stresses the importance of personalized strategies, using a systematic and dynamic view, for effective cancer therapy." | ( Andersen, CL; Belling, K; Bolund, L; Brünner, N; Jensen, NF; Li, J; Lin, X; Rasmussen, MH; Stenvang, J; Tarpgaard, LS; Yang, G; Zhu, S, 2015) |
| "To determine whether female colorectal cancer patients experienced a higher incidence of dose-limiting toxicity than men when treated with adjuvant capecitabine." | ( Chambers, CR; Danilak, M; Ghosh, S; Ilich, AI; Kim, CA; Mulder, KE; Sawyer, MB; Spratlin, JL, 2016) |
| "Metastatic colorectal cancer (CRC) is complex clinical challenge for which there are limited treatment options." | ( Acuna, SA; Angarita, FA; McCart, JA; Ottolino-Perry, K; Sellers, C; Tang, N; Zerhouni, S, 2015) |
| "SW48, LIM 1215, and GEO colorectal cancer cell lines were engrafted into nude mice and treated for 3 weeks with irinotecan and/or cetuximab." | ( Bianco, R; Cardone, C; Ciardiello, D; Ciardiello, F; Fenizia, F; Formisano, L; Lambiase, M; Martinelli, E; Martini, G; Morgillo, F; Napolitano, S; Normanno, N; Troiani, T; Vitagliano, D, 2015) |
| "The down-regulation of miR-197 in colorectal cancer cells after exposure to 5-fluorouracil might be related to the mechanism of resistance to fluoropyrimidine-based chemotherapy." | ( Bai, C; Chen, Y; Han, Q; Sun, Z; Zhao, L; Zhao, RC; Zhou, J; Zhou, N, 2015) |
| "Metastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study." | ( Abbruzzese, JL; Eng, C; Fogelman, D; Gallick, G; Jacobs, C; Jimenez, CA; Kopetz, S; Malik, Z; Morris, J; Overman, MJ; Parikh, N; Qiao, W; Reddy, SM; Shureiqi, I; Wolff, RA, 2015) |
| "Clinical therapy for metastatic colorectal cancer (CRC) remains limited, especially when the tumor harbors a KRAS mutation." | ( Chiu, TK; Chiu, VK; Fara, M; le Rolle, AF; Paty, PB; Shia, J; Weiser, MR; Zeng, Z, 2015) |
| "A 60s-year-old woman with metastatic colorectal cancer was treated using mFOLFOX6 plus bevacizumab." | ( Hayashi, T; Kato, J; Kobune, M; Miyanishi, K; Okagawa, Y; Onuma, H; Osuga, T; Sato, T; Sato, Y; Takimoto, R, 2015) |
| "The patient, diagnosed with metastatic colorectal cancer, had diarrhea and neutropenia grade 4 and mucositis and neurological toxicity grade 3 under 5-FU-based therapy and exceeded by more than 50% the average survival after metastasectomy." | ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Patients with colorectal cancer and peritoneal carcinomatosis (CRC/PC) may benefit from cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC)." | ( Beaty, KA; Dineen, SP; Fournier, KF; Mansfield, PF; Rafeeq, S; Robinson, KA; Roland, CL; Royal, RE, 2016) |
| "The profiles of 167 metastatic colorectal cancer Canadian patients treated with FOLFIRI-based regimens were examined and the findings were replicated in an independent cohort of 250 Italian patients." | ( Cecchin, E; Chen, S; Couture, F; Guillemette, C; Innocenti, F; Jonker, D; Laverdière, I; Lévesque, E; Toffoli, G; Villeneuve, L, 2015) |
| "Metastatic colorectal cancer carries a poor prognosis and cannot be cured by currently available therapy." | ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "Despite the increased understanding of colorectal cancer and the introduction of targeted drug therapy, the metastatic phase of the disease remains refractory to treatment." | ( Dahan-Farkas, N; Harmse, L; Panayides, JL; Penny, C; van Otterlo, W, 2015) |
| "The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance." | ( Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K, 2016) |
| "Twenty patient-derived colorectal cancer xenografts were then treated with TAK-733 in vivo." | ( Arcaroli, JJ; Bagby, SM; Britt, BC; Eckhardt, SG; Henthorn, PK; Klauck, PJ; Lieu, CH; Messersmith, WA; Pitts, TM; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ, 2015) |
| "The subjects had liver metastatic colorectal cancers that were unresponsive to systemic chemotherapy (FOLFOX/FOLFIRI) or to additional molecular-target therapies for progressive disease." | ( Fujimoto, D; Goi, T; Kimura, Y; Koneri, K; Morikawa, M; Naruse, T; Yamaguchi, A, 2015) |
| "Optimal preoperative treatment before colorectal cancer metastases (CRCM) resection remains unclear." | ( Canon, JL; Carrasco, J; Chapaux, X; Danse, E; Gigot, JF; Gizzi, M; Hubert, C; Humblet, Y; Jouret-Mourin, A; Lannoy, V; Lefesvre, P; Navez, B; Pairet, G; Sempoux, C; Tinton, N; Van den Eynde, M, 2015) |
| "The growth of colorectal cancer cells in mice can be inhibited by BER treatment, and this anti-cancer effect of BER can be further enhanced by EGFR gene knockout in macrophages." | ( Cao, H; Lu, L; Lu, N; Tong, Z; Zhang, M, 2015) |
| "In Korean colorectal cancer patients treated with adjuvant FOLFOX chemotherapy, body weight gain during the treatment period has a negative prognostic influence in overweight and obese patients." | ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, DW; Lee, KH; Oh, DY; Park, JW; Park, KJ; Ryoo, SB, 2015) |
| "The diagnosis and treatment of colorectal cancer is one of the main diseases of gastrointestinal surgeons." | ( Chen, P; Gu, J, 2015) |
| "A total of 103 colorectal cancer patients undergoing surgical operations in our department between October 2013 and October 2014 were prospectively enrolled in this study and were randomly divided into peritoneal chemotherapy group(55 cases) and control group(48 cases) according to the random table." | ( Feng, L; Liu, Q; Liu, Y; Wu, X; Xia, D; Xu, L, 2015) |
| "In stage II colorectal cancer, the in vitro ATP-CRA may be useful in identifying patients likely to benefit from fluorouracil-based adjuvant chemotherapy." | ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| "A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance." | ( Bardelli, A; Bartolini, A; Bianchi, AS; Cam, N; Corti, G; Crisafulli, G; Di Nicolantonio, F; Lazzari, L; Li, G; Misale, S; Mussolin, B; Novara, L; Patel, R; Rospo, G; Russo, M; Shoemaker, R; Siena, S; Siravegna, G; Wei, G; Wild, R; Yan, S, 2016) |
| "We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens." | ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015) |
| "Patients with colorectal cancer treated with oxaliplatin are at risk of hypersensitivity reactions, with the incidence estimated to be 12%-20%." | ( Aisu, N; Fujita, H; Hirata, K; Hoshino, S; Iwamoto, S; Kiyomi, F; Kosaka, T; Kotaka, M; Maeda, K; Matsuoka, H; Yamashita, Y; Yoshida, Y, 2015) |
| "Three types of colorectal cancer cells at various stages of differentiation and invasive ability (SW480, HCT116 and LoVo) were treated with CA at final concentrations of 20, 40 and 80 µg/ml for 24 h." | ( Chen, Y; Li, J; Liu, S; Teng, Y; Wang, R; Wang, Z; Xi, S; Xu, S; Zhang, Y; Zou, X, 2016) |
| "We used colorectal cancer cells, HCT116, co-treated with transforming growth factor β1 (TGF-β1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay." | ( Bui, NT; Cho, M; Han, S; Ho, MT; Kim, YM; Shin, DB, 2016) |
| "We investigated mechanisms of colorectal cancer (CRC) chemoresistance to first-line chemotherapy (capecitabine plus oxaliplatin (XELOX)) and identified two putative chemoresistant microRNAs, miR-1914* and -1915, that are downregulated in plasma samples from patients with chemoresistant CRC." | ( Cai, G; Cai, S; Hu, J; Xu, Y, 2016) |
| "Patients with advanced colorectal cancer who had received chemotherapy in a practical healthcare setting from July 2004 through October 2010 were extracted from the ordering system database of Showa University Hospital." | ( Ikeda, S; Ikegami, N; Murayama, JI; Sakamaki, H; Shimizu, H; Yajima, S, 2016) |
| "The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore." | ( , 2015) |
| "Recommendations on systemic therapy in colorectal cancer were produced." | ( , 2015) |
| "Human colorectal cancer cell lines (HCT-116 and HT-29) were treated with sodium butyrate at concentrations ranging from 0." | ( Chen, J; Chen, S; Chu, X; Deng, H; Gong, M; Li, C; Li, Z; Mao, L; Sun, S; Yi, M; Zha, L; Zhang, J; Zhang, Z, 2016) |
| "Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed." | ( Berlin, J; Boman, B; Cason, RC; Chan, E; Cohen, D; Cohen, SJ; Fielding, A; Gold, P; Groshen, S; Hamilton, SR; Hochster, HS; Leichman, CG; Leichman, L; Lenz, HJ; Locker, G; Messersmith, W; O'Neil, BH, 2016) |
| "Notably, colorectal cancer cells are very sensitive to mono-treatments of another autophagy inhibitor, Bafilomycin A1." | ( Goulielmaki, M; Koustas, E; Moysidou, E; Oikonomou, E; Pintzas, A; Sasazuki, T; Shirasawa, S; Vlassi, M; Zografos, G, 2016) |
| "44 metastatic colorectal cancer patients received irinotecan-based chemotherapy." | ( Atasilp, C; Chamnanphon, M; Chansriwong, P; Puangpetch, A; Reungwetwattana, T; Sirachainan, E; Sukasem, C; Wongwaisayawan, S, 2016) |
| "Bag-1 is highly expressed in colorectal cancer, which plays a critical role in promoting metastasis, poor prognosis, especially in anti-apoptotic function, and is perhaps a valuable gene target for colorectal cancer therapy." | ( Huang, W; Ling, J; Liu, Z; Sun, N; Tian, A; Zhou, G, 2016) |
| "Adjuvant chemotherapy for colorectal cancer is mainly based on the combination of 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4)." | ( Balayssac, D; Buc, E; Déchelotte, P; Le Roy, B; Pereira, B; Pétorin, C; Pezet, D; Sauvanet, P; Tixier, L, 2016) |
| "Patients with colorectal cancer receiving capecitabine as part of their first-line treatment were recorded until detection of disease progression or up to a maximum of 12 cycles on standardized evaluation forms." | ( Arnold, D; Engelen, A; Göhler, T; Hinke, A; Höffkes, HG; Quidde, J; Schirrmacher-Memmel, S; Schröder, JK; Stein, A; Tschechne, B; Valdix, AR; Wohlfarth, T, 2016) |
| "The development of an efficient colorectal cancer therapy is currently a public health priority." | ( Chen, KC; Lee, SY; Peng, CL; Shieh, MJ; Wei, MF; Yang, CY; Yao, CJ, 2016) |
| "Patients with liver-only metastatic colorectal cancer (mCRC) who are not candidates for potentially curative resection may become resectable with more aggressive chemotherapy regimens." | ( Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A, 2016) |
| "Treatment of 20 colorectal cancer cell lines with the BETi JQ1 identified a subset of highly sensitive lines." | ( Arango, D; Chueh, AC; Dawson, MA; Dhillon, AS; Diez-Dacal, B; Filippakopoulos, P; Gahman, TC; Jayachandran, A; Mariadason, JM; Nightingale, R; Phesse, T; Shiau, AK; Sieber, OM; Tögel, L; Tran, H; Wu, R, 2016) |
| "A patient suffering from metastatic colorectal cancer, treatment-related toxicity and resistance to standard chemotherapy and radiation was assessed as part of a personalized oncogenomics initiative to derive potential alternative therapeutic strategies." | ( Ch'ng, C; Dar, N; Jones, MR; Jones, SJ; Laskin, J; Lim, HJ; Ma, Y; Marra, MA; Moore, R; Mungall, AJ; Ng, T; Pleasance, E; Renouf, DJ; Schein, JE; Schrader, KA; Sheffield, BS; Shen, Y; Yip, S; Zhao, Y, 2016) |
| "We categorized: 176 cases treated for colorectal cancer and we recorded the following data: type of surgery, body max index (BMI), haemoglobin value (Hb); preoperative prothrombin time (PT) and blood transfusions pre and postoperative and during surgery." | ( Arcuri, MF; Bertocchi, E; Del Rio, P; Dell'Abate, P; Perrone, G; Sianesi, M; Sozzi, F, 2016) |
| "Thirty-one consecutive patients with colorectal cancer who received oxaliplatin therapy were followed up for more than 3 years." | ( Dimopoulos, MA; Karandreas, N; Kokotis, P; Kostouros, E; Schmelz, M, 2016) |
| "In the setting of liver metastases from colorectal cancer (CRC), radioembolization with yttrium-90 has been used to treat chemotherapy refractory disease with a growing interest to establish its efficacy in prospective trials combined with first- and second-line chemotherapy." | ( Hickey, R; Lewandowski, RJ; Nimeiri, H; Salem, R; Sangha, BS, 2016) |
| "Although the risk of colorectal cancer was lower in statin users versus nonusers, no difference was observed among those who continued versus discontinued statin therapy, suggesting the potential for indication bias." | ( Ahmad, T; Boursi, B; Datta, J; Goldberg, DS; Lewis, JD; Mamtani, R; Scott, FI; Yang, YX, 2016) |
| "In a cohort of 109 metastatic colorectal cancer patients treated with irinotecan (180 mg/m(2)) in combination with other drugs, associations were assessed between 21 selected single nucleotide polymorphisms of NR1I2 or NR1I3 and pharmacokinetic parameters or toxicity of irinotecan and its metabolites." | ( Boyer, JC; Del Rio, M; Evrard, A; Gassiot, M; Mbatchi, LC; Robert, J; Thomas, F; Tubiana, N; Ychou, M, 2016) |
| "When SW480 colorectal cancer cells were treated with DADS, NF-κB nuclear localization and activity were diminished." | ( Colburn, NH; Gray, Z; Kim, YS; Li, W; Matter, MS; Saud, SM; Young, MR, 2016) |
| "For patients with colorectal cancer, lymph node metastasis is a very important factor for prognostic and treatment determinations." | ( Ehara, S; Ishida, K; Kato, K; Kawashima, K; Matsuo, M; Nakamura, R; Otsuka, K; Tomabechi, M, 2016) |
| "A new colorectal cancer targeting peptide, cyclo(1, 9)-CTPSPFSHC, has strong targeting ability and also shows great potential in the identification and treatment of colon cancer." | ( Deng, L; Ding, S; Fu, M; Gao, LQ; Liu, F; Liu, L; Wang, J; Yang, L, 2016) |
| "Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy." | ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016) |
| "The heterogeneous nature of colorectal cancer (CRC) complicates prognosis and is suggested to be a determining factor in the efficacy of adjuvant therapy for individual patients." | ( Clevers, H; De Sousa E Melo, F; Dekker, E; Drost, J; Fessler, E; Franitza, M; IJspeert, JE; Jansen, M; Linnekamp, JF; Medema, JP; Nürnberg, P; Prasetyanti, PR; van Hooff, SR; van Noesel, CJ; Vermeulen, L; Wang, X, 2016) |
| "A total of 75 patients with metastatic colorectal cancer from 8 German medical centers received ≤ 6 administrations of infusional 5-FU according to the AIO (folinate, 5-FU; n = 16), FOLFOX6 (leucovorin calcium [folinic acid], 5-FU, and oxaliplatin; n = 26), or FUFOX (oxaliplatin plus 5-FU/folinic acid; n = 33) regimen." | ( Bertsch, T; Birkmann, J; Braess, J; Holdenrieder, S; Jaehde, U; Kraff, S; Kunzmann, V; Link, K; Miller, MC; Moritz, B; Mueller, L; Roessler, M; Salamone, SJ; Stoetzer, OJ; Suttmann, I; Wilhelm, M, 2016) |
| "A total of 30 treatment-naïve colorectal cancer patients with metastatic disease were included." | ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016) |
| "All patients receiving chemotherapy for colorectal cancer in the outpatient clinic of the University of Mainz since 2006 were retrospectively analyzed for last line sorafenib exposure." | ( Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC, 2016) |
| "To achieve favorable therapy for colorectal cancer, PEG-PCL-based nanoparticles, which possess good biological compatibility, were fabricated as nanocarriers for the topoisomerase inhibitor, SN-38." | ( Lee, PC; Lee, SY; Lin, CY; Lin, SY; Luo, TY; Ning, ST; Peng, CL; Shieh, MJ; Shih, YH; Tsai, MH; Wei, MF, 2016) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date." | ( Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN, 2016) |
| "In 125 metastatic colorectal cancer (mCRC) patients, we investigated how clinical outcome of chemotherapy was related to CIMP status as detected by methylation-specific PCR (MSP) and to genetic status in five EGFR-related genes (KRAS, BRAF, PIK3CA, NRAS, and AKT1) as detected by direct sequencing." | ( Inoue, M; Ishioka, C; Komine, K; Ouchi, K; Shimodaira, H; Soeda, H; Takahashi, H; Takahashi, M; Takahashi, S; Zhang, X, 2016) |
| "Human colorectal cancer cell lines DLD1, HCT116, HT-29, LS513, and RKO were treated with indole-3-carbinol or vehicle." | ( Carney, PR; Geiger, P; Kennedy, GD; Megna, BW; Nukaya, M, 2016) |
| "Multiple colorectal cancer cell types express increased CYP1A1 mRNA levels (a specific marker of AHR-driven activity) after treatment with I3C, characterizing I3C treatment as agonistic of this pathway." | ( Carney, PR; Geiger, P; Kennedy, GD; Megna, BW; Nukaya, M, 2016) |
| "Unresectable liver metastases of colorectal cancer can be treated with systemic chemotherapy, aiming to limit the disease, extend survival or turn unresectable metastases into resectable ones." | ( Burgmans, MC; de Leede, EM; Kapiteijn, E; Martini, CH; Tijl, FG; Vahrmeijer, AL; van de Velde, CJ; van Erkel, AR; Verhoef, C; Vuyk, J, 2016) |
| "The overall survival rate for colorectal cancer patients in Malaysia is similar to those in other Asian countries, with staging at diagnosis, primary tumor size, involvement of lymph node and treatment modalities having significant effects." | ( Ahmad, F; Hassan, MR; Ismail, I; Mohammed, NS; Soelar, SA; Suan, MA, 2016) |
| "In patients with metastatic colorectal cancer failing all available options, regorafenib and TAS 102 represent the only chance of treatment." | ( Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L, 2017) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge." | ( Bhamre, R; Bhandare, M; Engineer, R; Ostwal, V; Pai, V; Patil, P; Saklani, A, 2017) |
| "5-FU is the first line therapy for colorectal cancer, however, treatment effect is often hampered by the development of drug resistance or toxicity at high doses." | ( Fu, Z; Gao, J; Gu, Y; Guo, W; Li, L; Liu, W; Shu, Y; Sun, Y; Wang, W; Xu, Q, 2016) |
| "A population of colorectal cancer cells was selected by the treatment of activin A." | ( Kang, SO; Liu, R; Sun, B; Wang, JH; Xu, C, 2016) |
| "PSB-603 alters cellular metabolism in colorectal cancer cells and increases their sensitivity to chemotherapy." | ( Coates, JL; Failla, LM; Heath, JK; Hollande, F; Mølck, C; Pascussi, JM; Ryall, J; Stewart, G, 2016) |
| "The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset." | ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016) |
| "Compare long-term outcomes in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC) treated with peritonectomy/HIPEC using oxaliplatin versus MMC." | ( Huo, YR; Leung, V; Liauw, W; Morris, DL, 2017) |
| "Anesthetics are unavoidable to colorectal cancer (CRC) patients who underwent surgical treatment." | ( Chen, Y; Deng, F; Ouyang, M; Sun, X; Tang, J; Tao, T; Wang, X; Xu, L; Yao, X; Zhao, L, 2016) |
| "Subsequently, the human colorectal cancer cell lines were implanted subcutaneously into nude mice to allow the evaluation of the in vivo tumor growth inhibitory effects of TFTD and nintedanib combination therapy." | ( Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T, 2016) |
| "Treatment of colorectal cancer cells with PRIMA-1Met inhibited p53-independent phosphorylation of MEK, which in turn impaired anchorage-independent cell growth in vitro." | ( Duan, Q; Lu, T; Potter, JA; Qiu, H; Taylor, GL; Wang, Y; Xiong, H; Xu, G; Yang, Q; Ye, D; Yu, S; Yuan, X; Zhang, P; Zhu, F; Zou, Y, 2016) |
| "All patients with metastatic colorectal cancer (mCRC) treated with regorafenib after failure of all standard systemic options were included." | ( Chiu, J; Choy, TS; Lam, KO; Lee, KC; Lee, VH; Leung, R; Yau, T, 2017) |
| "In metastatic colorectal cancer (mCRC), fluorouracil-based combination therapy with oxaliplatin or irinotecan is the mainstay of first-line treatment." | ( Bardelli, A; Santini, D; Sartore-Bianchi, A; Siena, S; Tonini, G, 2016) |
| "Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed." | ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017) |
| "Hypoxia is prognostically important in colorectal cancer (CRC) therapy." | ( Hu, Y; Huang, W; Liu, X; Liu, Y; Song, J; Song, S; Xi, N; Xie, Y; Zhang, L, 2016) |
| "Treatment patterns for metastatic colorectal cancer (mCRC) patients have changed considerably over the last decade with the introduction of new chemotherapies and targeted biologics." | ( Du, XL; Lairson, DR; Parikh, RC; Robert, MO, 2017) |
| "In stage III colorectal cancer, poorly differentiated cluster G1/G2 predicts a significant benefit from 5-fluorouracil-based adjuvant chemotherapy, whereas poorly differentiated cluster G3 predicts a poor response to it." | ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017) |
| "In SW480 colorectal cancer cells treated with the tankyrase inhibitor (TNKSi) G007-LK we found that AXIN1 was not required for degradasome formation." | ( Pedersen, NM; Stenmark, H; Thorvaldsen, TE; Wenzel, EM, 2017) |
| "A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group." | ( Barone, C; Basso, M; Berenato, R; Bossi, I; Capoluongo, E; Caporale, M; Danesi, R; de Braud, F; Del Re, M; Di Salvatore, M; Guarino, D; Martinetti, A; Mennitto, A; Mennitto, R; Orlandi, A; Pietrantonio, F; Rossi, E; Santonocito, C; Schinzari, G, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Consistent with this, in HCT116 colorectal cancer cells lacking DNA methyltransferases DNMT1 or DNMT3B, LCT13 expression decreases, while cells lacking both DNMTs or treated with the DNMT inhibitor 5-azacytidine (5-aza) show no change in LCT13 expression." | ( Cruickshanks, HA; Lund, JN; McMillan, LE; Meehan, RR; Parr, C; Peacock, O; Saddington, S; Sanner, J; Tufarelli, C; Vafadar-Isfahani, N; Yeo, Z, 2017) |
| "Metastatic colorectal cancer (mCRC) patients with available best objective response (ORR) and time to tumor progression (TTP) data were included from a randomized clinical trial investigating maintenance therapy after first line chemotherapy plus bevacizumab." | ( Belting, M; Bendahl, PO; Hagman, H; Johnsson, A; Melander, O; Sundberg, J, 2017) |
| "Treatment of colorectal cancer cells with luteolin induced mesenchymal-to-epithelial transition, reduced the expressions of mesenchymal markers and inhibited cell mobility in vitro." | ( Beuerman, RW; Chen, F; Jin, B; Lang, T; Liu, Y; Zhang, Y; Zhang, Z; Zhou, L, 2017) |
| "Patients with documented metastatic colorectal cancer and progression of disease during or within 3 months after the last standard therapy, with no evidence and history of previous thyroid disease were enrolled." | ( Madeddu, C; Mariotti, S; Massa, E; Massidda, M; Pani, F; Pusceddu, V; Puzzoni, M; Scartozzi, M, 2017) |
| "Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance." | ( Fan, W; Hu, YY; Lin, XP; Lu, WQ, 2017) |
| "All patients treated for colorectal cancer and beginning a protocol with at least one parenteral drug have been included." | ( Bastide, S; Cousin, C; Favier, M; Leguelinel-Blache, G; Loriot, V; Obled, S; Phouttasang, V; Thibault, V; Wolf, P, 2017) |
| "Treatment of colorectal cancer remains a challenge to clinicians as well as drug developers." | ( Ahmad, T; Ahmed, M; Czejka, M; Fan, Y; Khan, RA; Mansoor, N; Sharib, S; Yang, DH, 2017) |
| "After the induction of colorectal cancer, adult male Wistar rats were treated with saline (n = 7), DOX (1." | ( Cerar, A; Finderle, Ž; Injac, R; Perše, M; Potočnik, N, 2017) |
| "Screening of colorectal cancer is crucial for early stage diagnosis and treatment." | ( Bhattacharyya, D; Kumar, P; Misra, M; Mohanty, SK; Smith, YR, 2017) |
| "Forty patients with metastatic colorectal cancer receiving FOLFOX4 chemotherapy with or without bevacizumab and 40 healthy volunteers were included in the study." | ( Aleknavicius, E; Baltruskeviciene, E; Didziapetriene, J; Kazbariene, B; Krikstaponiene, A; Stratilatovas, E; Suziedelis, K; Venceviciene, L, 2018) |
| "We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy." | ( Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V, 2017) |
| "From January 2011 to January 2016, 696 colorectal cancer patients were enrolled in this study: 341 patients were randomly assigned to the intraoperative chemotherapy, which consist of portal vein chemotherapy, intraluminal chemotherapy and intraperitoneal chemotherapy, plus surgery group, whereas 344 patients were randomized to the control group to undergo surgery alone." | ( Chen, G; Ding, PR; Fan, WH; Huang, JQ; Jiang, W; Ke, CF; Kong, LH; Lei, J; Li, C; Li, LR; Lin, JZ; Liu, Q; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhang, RX; Zhou, WH, 2017) |
| "In preoperative blood management of colorectal cancer patients, intravenous iron therapy is increasingly used to treat anaemia and prevent red blood cell transfusions." | ( Dekker, JWT; Harlaar, JJ; Jeekel, J; Schipperus, M; Wilson, MJ; Zwaginga, JJ, 2017) |
| "Four colorectal cancer cell lines (SW480, DLD1, SW837, and HRT18) were used to test the effects of simvastatin alone, radiation alone, and combination therapy." | ( DeVecchio, J; Ferrandon, S; Kalady, MF; Karagkounis, G, 2018) |
| "While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population." | ( Grothey, A; Hubbard, J; Mahoney, MR; McCleary, NJ; Meyerhardt, JA; Sargent, D; Venook, A, 2018) |
| "The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate." | ( Alabiso, I; Alabiso, O; Baratelli, C; Brizzi, MP; Di Maio, M; Forti, L; Ottone, A; Scagliotti, GV; Sonetto, C; Tampellini, M, 2018) |
| "Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance." | ( Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J, 2017) |
| "Metastatic colorectal cancer is a common disease encountered in oncology practice and treatment options beyond fluoropyrimidines, irinotecan, oxaliplatin and monoclonal antibodies against epidermal growth factor receptor and vascular endothelium growth factor (VEGF) are limited." | ( Mercier, J; Voutsadakis, IA, 2017) |
| "Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited." | ( Kjeldgaard Vistisen, K; Larsen, FO; Nielsen, DL; Polk, A; Røed Skårderud, M, 2018) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment." | ( Ba, Y; Bai, YX; Bi, JW; Ding, KF; Feng, JP; Lei, J; Li, J; Lin, LZ; Liu, YP; Ma, LW; Shen, L; Shi, CM; Wang, D; Wang, JW; Wang, KM; Wu, CP; Wu, G; Xiong, JP; Xu, RH; Yang, Q; Yu, H, 2017) |
| "We found that PF treatment in colorectal cancer cells resulted in down-regulation of FoxM1." | ( Kang, Z; Li, C; Li, S; Yan, G; Yue, M, 2018) |
| "Early diagnosis of colorectal cancer (CRC) simplifies treatment and improves treatment outcomes." | ( Bathe, OF; Buie, WD; Farshidfar, F; Hilsden, R; Kopciuk, KA; MacLean, A; Mazurak, VC; McGregor, SE; Vogel, HJ, 2018) |
| "Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)." | ( Ferrarotto, R; George, B; Hobbs, B; Hoff, PM; Kopetz, S; Loyer, EM; Machado, KK; Mazard, T; Overman, MJ; Qiao, W; Raghav, K; Saltz, LB; Vauthey, JN, 2018) |
| "We describe 4 cases of locally advanced colorectal cancer resected successfully after neoadjuvant chemotherapy(NAC) conducted between April 2015 and August 2016." | ( Doi, Y; Kameda, Y; Masuda, M; Matsuura, H; Rino, Y; Sugano, N; Suzuki, Y; Takata, K; Yamaoku, K; Yoneyama, K, 2017) |
| "We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease." | ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018) |
| "For patients with advanced/recurrent colorectal cancer, the trifluridine/tipiracil combination tablet (TAS 102) and regorafenib are last-line treatments." | ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2018) |
| "Three-hundred and eight metastatic colorectal cancer patients treated with an irinotecan-containing chemotherapy were studied." | ( Barnadas, A; Gallano, P; Páez, D; Riera, P; Salazar, J; Sebio, A; Tobeña, M; Virgili, AC, 2018) |
| "Successful treatment of colorectal cancer (CRC) is greatly impeded by metastasis and chemoresistance, particularly to 5-fluoruracil (5-Fu), one of the staples of clinical intervention in advanced CRC." | ( Feng, C; Li, X; Liu, L; Lou, Y; Sun, Y; Wang, Y; Zhan, L; Zhang, L; Zhang, Y, 2018) |
| "In patients with metastatic colorectal cancer, combination treatment with several anti-cancer drugs is employed and improves overall survival in some patients." | ( Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H, 2018) |
| "For treatment of metastatic colorectal cancer, the dynamics of tumor growth is an important factor for treatment decision." | ( Chen, Y; Ding, J; Du, Y; Li, YT; Liu, JY; Luo, WX; Tang, J; Wu, Q, 2019) |
| "Furthermore, JIB-04-treated colorectal cancer cells showed reduced tumorigenic activity in vivo." | ( Ahn, YH; Cho, HI; Jang, YK; Jin, YH; Kim, MS; Park, EJ; Yoon, HJ, 2018) |
| "Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy." | ( Bacon, O; Barat, A; Betge, J; Biesma, HD; Byrne, AT; Cordes, M; Das, S; Ebert, MPA; Eijk, PP; Fender, B; Gaiser, T; Gallagher, WM; Hennessey, BT; Kay, EW; Klinger, R; Koopman, M; Lambrechts, D; Loupakis, F; McNamara, DA; Meijer, GA; Murphy, V; Neerincx, M; O'Connor, DP; Prehn, JHM; Punt, CJA; Smeets, D; van Dijk, E; van Grieken, NCT; Verheul, HMW; Ylstra, B, 2018) |
| "HCT116 colorectal cancer cells were treated with cobimetinib, and MTT assay, colony formation assay, and flow cytometry were used to evaluate cell viability, cell cycle, and apoptosis, respectively." | ( Gong, S; Peng, R; Xu, D; Zhu, J; Zou, F, 2018) |
| "In patients with advanced colorectal cancer (CRC), surgery is complemented with systemic therapy - chemotherapy and radiochemotherapy." | ( Kralova, V; Krbal, L; Matouskova, P; Rudolf, E; Skarkova, V; Soukup, J, 2018) |
| "Mortality for colorectal cancer is mainly due to liver metastases, surgical resection remains the curative treatment and use of neoadjuvant therapy improves resectability of metastases." | ( Bacha, D; Bayar, R; Ben Slama, S; Bouraoui, S; Khadhar, A; Lahmar, A; Sassi, A, 2017) |
| "Thrity-eight patients resected for colorectal cancer liver metastases after neoadjuvant chemotherapy were enrolled in this study." | ( Bacha, D; Bayar, R; Ben Slama, S; Bouraoui, S; Khadhar, A; Lahmar, A; Sassi, A, 2017) |
| "A large proportion of patients with colorectal cancer liver metastases (CRCLM) not amenable to curative liver resection will progress on systemic therapy." | ( Acuna, SA; Garfinkle, R; Levy, J; Pelletier, JS; Touchette, J; Vanounou, T; Zuckerman, J, 2018) |
| "Administration of dexmedetomidine in colorectal cancer surgery can provide effective cardiocerebral protection and it is worth popularizing in clinical practice." | ( Chu, CQ; Li, YX; Liu, SL; Wang, JT; Yi, XL; Yin, JH, 2018) |
| "Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options." | ( Bai, Y; Cao, P; Chen, D; Chen, H; Chen, ZD; Cheng, Y; Deng, Y; Fan, S; Guo, W; Hua, Y; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shen, L; Shu, Y; Su, W; Sun, S; Wang, H; Wang, J; Wang, S; Wu, C; Xu, J; Xu, N; Xu, RH; Yang, L; Yu, Z; Yuan, Y; Zhong, H; Zhou, J, 2018) |
| "Patients with colorectal cancer treated with capecitabine as an adjuvant chemotherapy will be randomised into either the cystine/theanine group (n=50) or placebo group (n=50)." | ( Ariyoshi, K; Hamaguchi, R; Iwase, S; Miyata, G; Oyamada, S; Sato, T; Takahashi, K; Tsuchiya, T, 2018) |
| "Chemotherapy for colorectal cancer remains an unsatisfactory method of treatment and requires the development of more advanced drug delivery systems (DDSs)." | ( Jin, K; Li, J; Li, W; Liu, X; Shang, W; Shi, G; Yan, X; Zhang, R; Zhao, J, 2019) |
| "While early stage colorectal cancer can be removed by surgery, patients with advanced disease are treated by chemotherapy, with 5-Fluorouracil (5-FU) as a main ingredient." | ( Gu, D; Liu, B; Song, R; Xie, J; Yu, B; Zhang, L; Zhang, X, 2018) |
| "RAS- or BRAF-mutated metastatic colorectal cancers (mCRCs) progressing after first-line treatment have a poor prognosis." | ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| "Patients with metastatic colorectal cancer (mCRC) who fail treatment with standard therapies, including chemotherapy and monoclonal antibodies targeting vascular endothelial growth factor or epidermal growth factor receptor, have few treatment options." | ( André, T; Arriaga, YE; Banzi, M; Barone, C; Brenner, B; Cascinu, S; Falcone, A; Garcia-Carbonero, R; Grothey, A; Hofheinz, RD; Kalmus, J; Kappeler, C; Maiello, E; Martinelli, E; Miriyala, A; Peeters, M; Seitz, JF; Sobrero, A; Spallanzani, A; Van Cutsem, E; Verma, U; Ychou, M; Zaniboni, A, 2019) |
| "Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy." | ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018) |
| "SW620, HCT 116, and HT-29 human colorectal cancer cell lines were treated with FTD and regorafenib simultaneously and sequentially." | ( Matsuo, K; Matsuoka, K; Nakagawa, F; Okabe, H; Takechi, T; Tanaka, N, 2018) |
| "Patients with metastatic colorectal cancer (mCRC) often suffer from progressive disease despite previous therapy." | ( Liu, RH; Liu, W; Men, SY; Xue, WS, 2018) |
| "A total of 75 colorectal cancer outpatients treated with an anti-EGFR antibody combined with FOLFOX, FOLFIRI, or 5-FU/leucovorin as the first- to third-line treatment were included." | ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018) |
| "In in vivo models of colorectal cancer, combination treatment significantly suppressed tumor growth." | ( Assiotis, I; Box, G; Chauhan, R; Cunningham, D; De Haven Brandon, A; Eason, K; Isacke, CM; Jenkins, L; Khan, K; Kirkin, V; Mancusi, C; Manodoro, F; Matthews, N; Robinson, P; Rust, AG; Sadanandam, A; Self, A; Starling, N; Valenti, M; Valeri, N; Vlachogiannis, G; Wagner, S; Whittaker, SR, 2019) |
| "First-line chemotherapy for metastatic colorectal cancer (mCRC) is effective and feasible in selected older patients." | ( Dehlendorff, C; Johansen, JS; Lund, CM; Nielsen, DL; Rønholt, F; Vistisen, KK, 2018) |
| "HER2-positve patients with stage II colorectal cancer can benefit from 5-fluorouracial based adjuvant chemotherapy, especially for patients with pMMR status." | ( Cai, S; Feng, Y; Huang, D; Li, Y; Peng, J, 2019) |
| "The subjects were 61 patients with colorectal cancer for whom combination chemotherapy with CPT-11 was indicated between May 2008 and December 2014." | ( Kato, K; Kurematsu, N; Sasaki, N; Tagawa, C; Tanaka, Y; Yoshino, M, 2018) |
| "In late-stage metastatic colorectal cancer, difficult treatment decisions should incorporate a thorough evaluation of the patient's general condition and subject for shared decision making." | ( Demuth, C; Hoegdall, E; Johansen, JS; Nielsen, D; Pallisgaard, N; Pfeiffer, P; Sorensen, BS; Spindler, KG; Vittrup Jensen, B, 2018) |
| "CT26 murine colorectal cancer cells were treated with physiologic levels of the potent inducer of immunogenic cell death mitoxantrone (MTX)." | ( Kunda, NM; Maker, AV; Prabhakar, BS; Qiao, G; Qin, J; Tulla, K, 2019) |
| "Because irinotecan is a key drug in colorectal cancer treatment, it was used for comparison in this study." | ( Goto, K; Hiramoto, K; Kondo, K; Ooi, K; Sano, R, 2018) |
| "First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI)." | ( Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H, 2019) |
| "All patients treated for colorectal cancer in a tertiary care centre, between January 2009 and December 2013, who had routine UGT1A1 genotyping for irinotecan dose-adjustment were included." | ( Anon, B; Barin-le Guellec, C; Caulet, M; Godart, B; Guyetant, S; Lecomte, T; Orain, I; Ouaissi, M; Pages, JC; Perray, C; Regnault, D; Tallet, A, 2019) |
| "Treatment with NOS inhibitors inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes/proteins involved in the angiogenesis pathway." | ( Gao, Y; Huo, X; Qian, SY; Sheng, S; Xu, Y; Zhou, S, 2019) |
| "In second-line treatment for metastatic colorectal cancer, mFOLFOX6 or FOLFIRI with erlotinib in a sequence-dependent fashion is not feasible despite potential promising activity." | ( Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM, 2019) |
| "Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies." | ( Bernard, MA; Coutureau, J; Droz, C; Duc, S; Forrier-Réglat, A; Gérard, S; Gouverneur, A; Grelaud, A; Jové, J; Lassalle, R; Noize, P; Ravaud, A; Rouyer, M; Smith, D, 2019) |
| "Treating colorectal cancer (CRC) continues to be a clinical challenge." | ( Dai, G; Gong, T; Ju, W; Meng, Q; Pan, Z; Sun, B, 2019) |
| "Ginsenoside Rb2 could inhibit EMT of colorectal cancer cells through the TGF-β1/Smad signaling, and might be a potential candidate for the treatment of colorectal cancer." | ( Dai, G; Gong, T; Ju, W; Meng, Q; Pan, Z; Sun, B, 2019) |
| "Female subjects with metastatic colorectal cancer receiving first-line chemotherapy demonstrated higher rates of a number of toxicities (essentially hematologic and gastrointestinal in nature)." | ( Abdel-Rahman, O, 2019) |
| "TAS-102 therapy for advanced/recurrent colorectal cancer is considered to be highly tolerable in patients 75 years and older." | ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "New drugs for metastatic colorectal cancer (mCRC) have been recently developed for use in later-line chemotherapy and have contributed to further prolongation of the survival of patients." | ( Fukuoka, T; Hirakawa, K; Iseki, Y; Maeda, K; Matsutani, S; Nagahara, H; Ohira, M; Shibutani, M; Wang, EN, 2019) |
| "Treatment of colorectal cancer mostly relies on traditional therapeutic approaches, such as surgery and chemotherapy." | ( Cheng, N; Li, L; Shen, J; Sun, G; Yang, T, 2019) |
| "Post-surgical colorectal cancer (CRC) patients with metastatic disease, treated with four different schedules of FOLFOX were included in this study." | ( Bano, N; Ikram, R, 2019) |
| "Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway." | ( Gao, Y; Huo, X; Li, HJ; Pang, L; Qian, SY; Yang, J; Zhou, S, 2019) |
| "In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival." | ( Ananda, S; Cooray, P; Delahunty, R; Desai, J; Gibbs, P; Johns, J; Kosmider, S; Lee, B; Lee, M; Mckendrick, J; Tie, J; Tran, B; Wong, HL; Wong, R, 2020) |
| "Treatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab." | ( Bashir, U; Cook, GJ; Goda, JS; Goh, V; Siddique, M; Weeks, A, 2019) |
| "By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines." | ( Burke, R; Clarke, PA; Hobbs, SM; McAndrew, C; Roe, T; Swabey, K; Tomlin, K; van Montfort, R; Westwood, I; Workman, P, 2019) |
| "We experienced a case of colorectal cancer wherein biweekly XELIRI plus Bmab therapy contributed to disease control as second-line treatment." | ( Fukunaga, M; Honda, S; Kobayashi, K; Konishi, K; Matsuno, Y; Nakai, S; Okada, K; Ota, H; Saito, A; Takeoka, T; Takiguchi, N; Yokoyama, S; Yukimoto, R, 2019) |
| "Korean female patients with colorectal cancer who received 5-FU chemotherapy experienced more frequent adverse drug reactions including alopecia and leukopenia than male patients." | ( Jung, J; Kim, KS; Kim, SY; Lee, E; Lee, S; Lim, H; Moon, A; Oh, S, 2019) |
| "Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy." | ( Argilés, G; Bendell, J; Chang, I; Ciardiello, F; Di Bartolomeo, M; Eng, C; Fakih, M; Falcone, A; Kim, TW; Kozloff, M; Roberts, L; Segal, NH; Sobrero, A; Tebbutt, NC; Uyei, A; Yan, Y, 2019) |
| "Only 10%-20% of colorectal cancer (CRC) patients observe effective responses to 5-fluorouracil (5-FU) based chemo-treatment." | ( Fang, X; Fang, Z; Hu, W; Jin, Y; Liu, T; Miao, QR; Wang, X, 2019) |
| "Metastatic colorectal cancer is a stumbling block in colorectal cancer management due to limited treatment approaches and unfavorable prognosis." | ( Hu, Y; Lin, Y; Wang, B; Yang, D; Zhou, P, 2019) |
| "Patients with advanced colorectal cancer often are treated with systemic cytotoxic therapy using fluorouracil (5-FU), oxaliplatin, irinotecan, and FOLFOX or FOLFIRI combination protocols." | ( Elmasry, M; Horst, D; Kirchner, T; Schmidt, EM; Schulz, GB; Spartalis, C, 2019) |
| "Frail patients without prior advanced colorectal cancer treatment were included in the study." | ( Aranda, E; Benavides, M; Calvo, A; Cano, T; Carrato, A; Dotor, E; Durán-Ogalla, G; Falcó, E; Ferreiro-Monteagudo, R; Gallego, J; García Alfonso, P; Grande, E; Layos, L; Massutí, B; Polo, E; Reboredo, M; Rodriguez-Garrote, M; Salud, A; Viéitez, JM, 2019) |
| "To compare outcomes for patients with colorectal cancer liver metastases (CRCLM) treated by drug-eluting bead chemoembolization (DEB-TACE) or radioembolization (TARE)." | ( Akinwande, O; Malone, C; Mokkarala, M; Noda, C; Ramaswamy, R, 2019) |
| "Resection margins in colorectal cancer carry clinical significance with regard to disease recurrence risk and selection for multimodal adjuvant therapy, especially with circumferential resection margins in rectal cancer." | ( D'Souza, B; Kaneko, Y; Lam, D; Norris, R; Scarlett, A; Woods, R, 2019) |
| "After exposure of colorectal cancer cells with (i) miR-145 and (ii) curcumin-loaded Pr NCs, a strong increase in the intracellular levels of miR-145, which translated into a decreased cell proliferation rate and migration capacity of the treated cells, was observed." | ( Alonso, MJ; Csaba, N; de la Fuente, M; González-Aramundiz, JV; López-López, R; Reimondez-Troitiño, S; Ruiz-Bañobre, J, 2019) |
| "Late-stage colorectal cancer is resistant to current treatments." | ( Kibi, M; Kobayashi, T; Kodama, Y; Nishiumi, S; Yoshida, M, 2019) |
| "Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy." | ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019) |
| "Patients with colorectal cancer undergo frequent diagnostic imaging to stage the extent of metastatic disease and assess response to treatment." | ( Miles, K; Yeoh, E, 2019) |
| "Intense efforts have been made in colorectal cancer (CRC) treatment in recent decades." | ( Hong, F; Li, J; Liu, N; Liu, T; Shi, J; Yang, W; Zhang, K; Zhou, Y, 2019) |
| "Metastatic colorectal cancer patients ≥ 70 years of age who are treated with 5FU-based combination chemotherapy are more likely to have serious adverse events, fatal adverse events as well as worse overall survival compared to younger patients." | ( Abdel-Rahman, O; Karachiwala, H, 2019) |
| "Patients with stage II or III colorectal cancer (CRC) exhibit various clinical outcomes after radical treatments." | ( Bi, HC; Chen, G; Chen, Y; Feng, JX; Gao, S; Hu, JJ; Jia, WH; Jiang, YM; Jin, Y; Ju, HQ; Kopetz, S; Li, YQ; Liu, J; Liu, KY; Liu, ZX; Lu, YX; Ogasawara, M; Pan, ZZ; Sheng, H; Tian, F; Wang, F; Wang, YN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL; Zhang, C; Zhao, Q, 2020) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "Though colorectal cancer is a complex process and chemotherapy is the first step toward the treatment of colorectal cancer, recently several studies suggested that dietary phytochemicals may also aid significantly in reducing colorectal cancer risk in human." | ( Gupta, MK; Sarojamma, V; Vadde, R, 2019) |
| "Metastatic colorectal cancer patients treated with aflibercept beyond second-line therapy were included." | ( Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D, 2020) |
| "Microsatellite-stable colorectal cancer (CRC) is known to be resistant to immunotherapy." | ( Huang, L; Li, X; Liu, Y; Shen, L; Song, W; Zhang, J, 2019) |
| "Human colorectal cancer SW1116 cells were treated with different concentration of ginsenoside PPD, Rh2, Rh3, and Rg3 in vitro." | ( Cong, D; Cong, Z; Lei, X; Yang, B; Zhang, X; Zhao, Q; Zhou, Y, 2020) |
| "Over 50% of colorectal cancer patients develop resistance after a transient response to therapy." | ( Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J, 2020) |
| "Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress." | ( Aquilani, R; Boschi, F; Brugnatelli, S; Buonocore, D; Condino, AM; Delfanti, S; Dossena, M; Maestri, R; Simeti, E; Verri, M, 2019) |
| "Treatment of colorectal cancer (CRC) remains a challenge because of the lack of effective early treatment strategies and high incidence of relapse." | ( Cheng, X; Huang, Z; Jin, W; Long, D, 2020) |
| "Outcomes for patients with metastatic colorectal cancer (mcrc) are improving with the introduction of new treatments." | ( Afzal, AR; Brezden-Masley, C; Cheung, WY; Dolley, A; Samawi, HH, 2019) |
| "Chemotherapy is currently used to treat colorectal cancer (CRC), the most common cancer worldwide." | ( Chang, CY; Pan, TM, 2019) |
| "However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy." | ( Fukuda, H; Hamaguchi, T; Kanemitsu, Y; Katayama, H; Miyamoto, K; Mizusawa, J; Nakamura, K; Sato, Y; Shibata, T; Shida, D; Shimada, Y; Takashima, A, 2019) |
| "To improve colorectal cancer treatment, in this study, we prepared a paclitaxel (PTX)-loaded PLGA nanoparticle (PLGA-PTX) and evaluated its tumor-targeting and antitumor activity by co-administration with iRGD." | ( Feng, Y; Hu, L; Huang, Q; Li, L; Li, S; Liu, S; Shi, Q; Su, T; Tan, H; Tao, Z; Yang, H; Zhong, Y, 2019) |
| "A total of 100 colorectal cancer patients treated with capecitabine as an adjuvant chemotherapy after surgery were randomly allocated into the cystine/theanine group (n = 52) or the placebo group (n = 48)." | ( Ariyoshi, K; Hamaguchi, R; Iwase, S; Miura, K; Miyata, G; Ohori, H; Oshio, H; Oyamada, S; Sato, T; Takahashi, K; Tsuchiya, T, 2020) |
| "Patients with liver metastases from colorectal cancer (CRC) were randomised in the FOXFIRE (FFr; ISRCTN83867919), SIRFLOX (SF; NCT00724503) and FOXFIRE-Global (FFrG; NCT01721954) trials of first-line oxaliplatin-fluorouracil (FOLFOX) chemotherapy combined with SIRT versus FOLFOX alone." | ( Fusco, F; Gibbs, P; Gray, AM; Love, S; Moschandreas, J; Sharma, RA; Van Hazel, G; Virdee, PS; Wasan, HS; Wolstenholme, J, 2020) |
| "Mice orthotopically injected with colorectal cancer cells, LNA-siRNA-2 treatment not only inhibited the tumor growth but also blocked liver and lung metastasis." | ( Chang, KC; Chen, RY; Hsieh, HP; Huang, YC; Hung, LY; Lai, CH; Lai, YC; Lee, JC; Lin, BW; Liu, YW; Tsai, SJ; Yen, CJ, 2020) |
| "Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single-agent programmed cell death protein 1 (PD1) inhibitor therapy." | ( Anders, RA; Azad, NS; De Jesus-Acosta, A; Donehower, RC; Durham, JN; Ferguson, AK; Huang, CY; Jaffee, EM; Laheru, D; Le, DT; Murphy, AG; Nauroth, JM; Osipov, A; Rodriguez, C; Rozich, NS; Thomas, DL; Thompson, ED; Yarchoan, M; Zheng, L; Zhu, Q, 2020) |
| "DOT1L is a potential marker for colorectal cancer and EPZ004777 may be a potential drug for the treatment of colorectal cancer." | ( Cui, H; Dong, Z; Lei, Q; Li, L; Yang, J; Yang, L, 2019) |
| "Untreated colorectal tumors contain a population of quiescent/slow cycling cells with stem cell features (quiescent cancer stem cells, QCSCs) characterized by a predetermined mesenchymal-like chemoresistant phenotype." | ( Baiocchi, M; Boe, A; Careccia, S; Ciardi, A; Colace, L; Contavalli, P; D'Andrea, V; De Angelis, ML; De Maria, R; Francescangeli, F; Giuliani, A; Guardiola, O; Haas, TL; La Torre, F; Medema, J; Minchiotti, G; Pagliuca, A; Salaris, F; Signore, M; Tcheremenskaia, O; Zeuner, A, 2020) |
| "Advanced colorectal cancer has a high mortality rate since conventional treatments have limited therapeutic effects and poor prognosis with high risks of metastasis and recurrence." | ( Cai, L; He, H; Liang, R; Liu, L; Pan, H; Zhang, S; Zhou, H, 2020) |
| "Tumor development on chemically-induced colorectal cancer model also significantly inhibited by LYW-6 treatment." | ( Chen, S; Guan, L; Lai, M; Li, J; Liu, Z; Wang, H; Yu, W, 2020) |
| "For RAS/RAF wild-type metastatic colorectal cancer, patients may receive 5-fluorouracil-based chemotherapy plus either bevacizumab or an anti-epidermal growth factor receptor (EGFR)." | ( Baba-Hamed, N; Bignon-Bretagne, AL; Bouche, O; Buecher, B; Coriat, R; des Guetz, G; Dior, M; Doat, S; Galais, MP; Gornet, JM; Goujon, G; Granger, V; Henriques, J; Lievre, A; Locher, C; Manfredi, S; Metges, JP; Michel, P; Mineur, L; Obled, S; Palmieri, LJ; Pernot, S; Phelip, JM; Rousseau, B; Saban-Roche, L; Smith, D; Soularue, E; Tougeron, D; Trouilloud, I; Vernery, D; Vitellius, C, 2020) |
| "Patients with metastatic colorectal cancer (mCRC) beyond second line treatment have a poor prognosis." | ( Cao, M; Zhang, J; Zhou, M, 2020) |
| "We used human and mouse colorectal cancer cell lines, organoids, mouse syngeneic colorectal cancer tumor graft models, and colorectal cancer tissues from patients who received radiotherapy." | ( Alvarado, DM; Chen, B; Ciorba, MA; Iticovici, M; Kau, NS; Parikh, PJ; Park, H; Thotala, D, 2020) |
| "Many studies in colorectal cancer (CRC) use murine ectopic tumor models to determine response to treatment." | ( Bullard, EA; Fahr, MJ; Greening, GJ; Hale, LN; Muldoon, TJ; Mundo, AI; Rajaram, N, 2020) |
| "The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment." | ( An, L; Fang, G; Hong, D; Shi, Y; Su, S; Wang, Z; Wei, Y; Zang, A; Zhang, J, 2020) |
| "In patients with colorectal cancer an accurate diagnostic work-up is mandatory in order to perform the most specific treatment." | ( Guney, IB; Kucuker, KA; Teke, Z; Yalav, O, 2020) |
| "Furthermore, clinical colorectal cancer data set analysis showed that down-regulation of SMPD1 was associated with resistance to chemotherapy regimens that include 5-FU." | ( Akao, Y; Bandu, R; Jung, JH; Kim, KP; Komura, K; Lee, HM; Lee, KY; Lee, MY; Taniguchi, K, 2020) |
| "Lacosamide was introduced in 18 colorectal cancer patients with evidence of clinically significant acute, painful OXAIPN after infusion of the third course (T1) of oxaliplatin-based chemotherapy (FOLFOX4) and was maintained until completion of all 12 courses (T4)." | ( Anastopoulou, GG; Argyriou, AA; Bruna, J; Kalofonos, HP; Kalofonou, F; Litsardopoulos, P; Psimaras, D, 2020) |
| "Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents." | ( Bossi, G; Fratantonio, D; Piastra, V; Pranteda, A; Stramucci, L, 2020) |
| "Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy." | ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020) |
| "In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn." | ( Fujikawa, T; Takahashi, R, 2021) |
| "Thirty metastatic colorectal cancer patients without RAS and BRAF mutations were prospectively enrolled and treated with cytotoxic agents and EGFR blockade as first-line therapy." | ( Iwai, T; Koizumi, M; Kuriyama, S; Matsuda, A; Ohta, R; Shinji, S; Takahashi, G; Takeda, K; Ueda, K; Yamada, T; Yokoyama, Y; Yoshida, H, 2020) |
| "The treatment of human colorectal cancer (CRC) cells through suppressing the abnormal survival signaling pathways has recently become a significant area of focus." | ( Chao, CY; Chen, C; Chiang, EI; Kuo, YH; Lin, CC; Pai, MH; Tang, FY, 2020) |
| "Metastatic colorectal cancers (MCRCs) with microsatellite stability (MSS) are resistant to immunotherapy with programmed cell death protein 1 (PD-1) and programmed death-ligand 1 inhibitors." | ( Chevalier, D; Fakih, M; Lau, C; Saluja, J; Sandhu, J; Wang, C, 2020) |
| "Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate." | ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020) |
| "We enrolled postoperative colorectal cancer (CRC) patients administered with adjuvant capecitabine plus oxaliplatin (CapeOX) and metastatic CRC patients receiving CapeOX." | ( Ariizumi, H; Fujita, KI; Hirasawa, Y; Hisamatsu, A; Ikusue, T; Ishida, H; Ishiguro, T; Kobayashi, K; Kubota, Y; Matsumoto, N; Ohkuma, R; Sekido, M; Shimada, K; Toshima, H; Tsunoda, T, 2020) |
| "Chemotherapeutic drugs for colorectal cancer(CRC) which is currently the third most lethal cancer globally, are administered intravenously (iv) due to their low oral bioavailability resulting from their physicochemical properties." | ( Aktaş, Y; Benito, JM; Bilensoy, E; Ünal, S, 2020) |
| "Patients with metastatic colorectal cancer treated with REG or FTD/TPI as a salvage-line therapy from May 2014 to December 2017 were included." | ( Hatachi, Y; Kato, T; Kotaka, M; Ogata, M; Ogata, T; Satake, H; Tsuji, A; Yasui, H, 2020) |
| "Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group." | ( Abe, T; Akazawa, N; Hirashima, T; Ichikawa, H; Kakita, T; Kobayashi, M; Komura, T; Oikawa, M; Okada, T; Otake, S; Sato, R; Tsuchiya, T; Yazawa, T, 2020) |
| "Fifty patients with metastatic colorectal cancer were prospectively followed-up during the first 4 cycles of fluoropyrimidine-based treatment to assess AEs." | ( Chinchilla, R; Ramos-Esquivel, A; Valle, M, 2020) |
| "The enterocyte subtype of colorectal cancer (CRC) responds favorably to oxaliplatin-based adjuvant treatment for stage III CRC." | ( Barzi, A; Berger, MD; Cao, S; Lenz, HJ; Matsusaka, S; Miyamoto, Y; Okazaki, S; Schirripa, M; Suenaga, M; Yamaguchi, T; Yamamoto, N; Zhang, W, 2021) |
| "Patients with colorectal cancer receiving moderate-emetic-risk chemotherapy (MEC) were enrolled in this prospective single-arm study with intravenous palonosetron 0." | ( Endo, I; Ichikawa, Y; Ishibe, A; Kunisaki, C; Nakagawa, K; Ota, M; Suwa, H; Suwa, Y; Suzuki, S; Takei, S; Watanabe, J; Watanabe, K; Yamanaka, T, 2020) |
| "The IVICA trial randomized anaemic colorectal cancer patients to receive either oral (OI, control) or intravenous (IVI, treatment) iron prior to their elective operation." | ( Acheson, AG; Brookes, MJ; Dickson, EA; Keeler, BD; Kumar, A; Ng, O, 2020) |
| "Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients." | ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020) |
| "The study includes the total of 60 colorectal cancer metastases operated patients, divided into two groups of 30 patients: the group of patients who were treated with "bevacizumab plus FOLFOX IV" protocol as a neoadjuvant therapy - prior to liver metastases surgery and the control group, patients with the liver resection done without previous neoadjuvant chemotherapy." | ( Gmijovic, M; Pecic, V; Stojanovic, M, 2020) |
| "Here we investigated the colorectal cancer cell lines HT29, HCT116, SW48 and Caco-2 to provide a preclinical rationale for FTD/TPI-based chemoradiation treatment." | ( Brinker, A; Burdak-Rothkamm, S; Christiansen, S; Frenzel, T; Horn, M; Petersen, C; Rieckmann, T; Rothkamm, K; Schumacher, U; Stein, A, 2020) |
| "The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists." | ( Artac, M; Ates, O; Beypinar, I; Demir, H; Eren, T; Ergun, Y; Korkmaz, M; Sakalar, T; Sakin, A; Taskoylu, BY; Turhal, S, 2021) |
| "Most colorectal cancers are microsatellite-stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies." | ( Nusrat, M, 2020) |
| "The liver metastases of colorectal cancer (CRC) can be surgically treated in selected cases, with continuously improving results." | ( Haglund, C; Hagström, J; Isoniemi, H; Peltonen, R; Sorsa, T; Tervahartiala, T, 2021) |
| "RAS signaling is a promising target for colorectal cancer (CRC) therapy, and a variety of selective inhibitors have been developed." | ( Kawachi, H; Koshikawa, N; Kusama, D; Muroi, A; Nagayama, S; Natsume, Y; Noda, T; Okamoto, T; Ooki, A; Osumi, H; Sakahara, M; Shinozaki, E; Takano, H; Takeuchi, K; Ueno, M; Yamaguchi, K; Yamanaka, H; Yao, R, 2020) |
| "A considerable proportion of metastatic colorectal cancer patients who received active chemotherapy in this population-based study received only one line of therapy." | ( Abdel-Rahman, O; Koski, S; Mulder, K, 2021) |
| "RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat group." | ( Allen, WL; Bardelli, A; Campbell, A; Di Nicolantonio, F; Evergren, E; Harrison, T; Javadi, A; Kennedy, R; Khawaja, H; Longley, DB; Majkut, J; McArt, D; O'Reilly, P; Rehm, M; Roberts, JZ; Sansom, OJ; Scott, CJ; Van Schaeybroeck, S; Vitale, N, 2020) |
| "Key Words: Chemotherapy, Cetuximab, Colorectal cancer, Metastatic tumor, Surgery." | ( Hong, L; Kong, Y; Xu, X, 2020) |
| "We identified patients with metastatic colorectal cancer who were treated with raltitrexed-based systemic therapy after developing serious adverse events with fluoropyrimidine-based treatment in a large Canadian province from 2004 to 2018." | ( Batra, A; Cheung, WY; Hannouf, MB; Rigo, R, 2021) |
| "Raltitrexed in patients with colorectal cancer who were previously treated with fluoropyrimidine-based systemic therapy is effective and well-tolerated." | ( Batra, A; Cheung, WY; Hannouf, MB; Rigo, R, 2021) |
| "A total of 60 colorectal cancer patients were enrolled in study and were randomized to be treated with or without SGB therapy." | ( Chen, Y; Kang, Z; Li, S; Su, C; Zeng, J; Zhu, G, 2021) |
| "In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown." | ( Antista, M; Antoniotti, C; Bergamo, F; Calareso, G; Clavarezza, M; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Greco, FG; Lonardi, S; Manca, P; Morano, F; Murialdo, R; Pagani, F; Palermo, F; Pietrantonio, F; Prisciandaro, M; Racca, P; Raimondi, A; Randon, G; Rimassa, L; Smiroldo, V; Tampellini, M; Tomasello, G; Vaiani, M; Zaniboni, A, 2021) |
| "Peritoneal carcinomatosis from colorectal cancer (CRC) has a poor prognosis with median survival and clinical responses that are worse than for other metastatic sites, and even more so in pretreated patients proposed for regorafenib therapy." | ( Fé, A; Rosati, G, 2021) |
| "mtBRAF Colorectal Cancer (CRC) is resistant to the approved BRAF inhibitors, although combinatorial treatment co-targeting BRAF and EGFR/MEK is offering a promising prospect." | ( Chatziioannou, A; Kontogianni, G; Kosmidou, V; Koumaki, K; Kritsi, E; Pahitsa, F; Papadodima, O; Pintzas, A; Souliotis, VL; Zervou, M, 2021) |
| "Treatment for patients with metastatic colorectal cancer (mCRC) typically involves multiple lines of therapy with eventual development of treatment resistance." | ( Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y, 2021) |
| "Microsatellite-stable (MSS) colorectal cancer (CRC) tends to be poorly immunogenic, with limited treatment options." | ( Bendell, JC; Falchook, GS; Hamada, K; Makris, L; Patel, MR, 2021) |
| "A subset of colorectal cancer (CRC) with a mesenchymal phenotype (CMS4) displays an aggressive disease, with an increased risk of recurrence after surgery, reduced survival, and resistance to standard treatments." | ( Barra, G; Belli, V; Blauensteiner, B; Cardone, C; Ciaramella, V; Ciardiello, D; Ciardiello, F; Corte, CD; Cuomo, A; De Falco, V; Franco, R; Giunta, EF; Marino, FZ; Martinelli, E; Martini, G; Matrone, N; Mohr, T; Morgillo, F; Napolitano, S; Poliero, L; Selvaggi, F; Sibilia, M; Troiani, T; Vitiello, PP, 2021) |
| "For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX)." | ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| "One of the main problems of colorectal cancer is not the treatment of the primary tumor but the metastatic stage." | ( Al Sabbagh, C; Boudy, V; Mignet, N; Pimpie, C; Pocard, M; Roy, P; Seguin, J, 2021) |
| "Human colorectal cancer cells (HCT-116 and LOVO) were cultured and treated with anlotinib alone or combined with cisplatin (DDP)." | ( Jia, ZX; Li, A; Li, Z; Wu, HJ; Xie, YN; Yang, ZB; Zhang, HM; Zhang, XM; Zhang, Z, 2021) |
| "In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events." | ( Denda, T; Esaki, T; Fukuoka, S; Hatachi, Y; Kajiwara, T; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Niisato, Y; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Yamazaki, K, 2021) |
| "Microsatellite-stable (MSS) colorectal cancers are characterized by low mutation burden and limited immune-cell infiltration and thereby respond poorly to immunotherapy." | ( Ballesteros-Merino, C; Bernard, B; Duhen, T; Fox, BA; Newell, P; Rajamanickam, V; Ross, D; Samson, K; Tran, E, 2021) |
| "MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy." | ( Carballido, E; Imanirad, I; Kim, DW; Kim, RD; Martinez, M; Mehta, R; Schell, MJ; Strosberg, J; Tan, E; Yu, J; Zhou, JM, 2021) |
| "In clinical trials of metastatic colorectal cancer, progressive disease after second-line therapy is often defined according to Response Evaluation Criteria in Solid Tumors criteria." | ( Bekaii-Saab, TS; Grothey, A; Prager, GW; Yoshino, T, 2020) |
| "Little is known about the delivery of colorectal cancer treatment in India and its associated costs." | ( , 2021) |
| "Stage II/III colorectal cancer patients receiving capecitabine adjuvant chemotherapy were randomly allocated to receive either EVOSKINPSMC or physiological saline treatments for their hands and feet." | ( Chen, R; Chen, S; Chen, X; Hong, C; Huang, Z; Ke, C; Lei, J; Liu, H; Lu, W; Lv, H; Su, R; Sun, Z; Tan, X; Wei, Y; Yang, P, 2021) |
| "Despite recent advances in therapy, colorectal cancer remains a leading cause of death in affected people." | ( Babaei, E; Ebrahimi, M; Feizi, MAH; Neri, F, 2021) |
| "The treatment and prognosis of advanced colorectal cancer (CRC) remain a challenging clinical research focus." | ( Huang, Q; Jiang, Z; Li, B; Li, C; Li, D; Liang, R; Sun, J; Wang, Z; Yang, M; Zhao, H, 2021) |
| "It is used to treat metastatic colorectal carcinoma." | ( Ates, UC; Comert, B; Ergun, B; Gezer, S; Ugur, L; Yakar, N, 2021) |
| "In the treatment of metastatic colorectal cancer (mCRC), there is a need for a treatment option in patients who have received regorafenib (RGR) therapy and progressed, especially in patients fit enough to receive a new therapy." | ( Doğan, M; Eraslan, E; İlhan, A; Öksüzoğlu, ÖB; Yildiz, F, 2021) |
| "We retrospectively examined 67 colorectal cancer patients treated with anti-EGFR antibody drugs for the first time." | ( Asaka, J; Chiba, T; Kimura, T; Kudo, K; Matsuura, Y; Nihei, S; Tairabune, T; Takahashi, H; Ujiie, H, 2021) |
| "The treatment of colorectal cancer is limited by high recurrence rate and multidrug resistance." | ( Cheng, Y; Han, X; Ma, X; Mo, F; Wang, H; Zeng, H; Zhao, Y; Zheng, Y, 2021) |
| "Patients with BRAF-mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and epidermal growth factor receptor (EGFR) inhibitors." | ( Hiraide, S; Ishioka, C; Komine, K; Takahashi, M; Yamada, H; Yoshida, Y, 2021) |
| "CONCLUSIONS TDM in colorectal cancer can reduce toxicity, improve efficacy and clinical outcome, and can be routinely used in 5-FU-based chemotherapy." | ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021) |
| "Developing effective treatments for colorectal cancers through combinations of small-molecule approaches and immunotherapies present intriguing possibilities for managing these otherwise intractable cancers." | ( Begley, KL; Chen, X; Evers, BM; Gao, T; Guo, L; He, D; Kril, LM; Lee, EY; Liu, C; Liu, X; Sviripa, VM; Wang, C; Watt, DS; Xie, Y; Zhang, W, 2021) |
| "In 2017, colorectal cancer with peritoneal metastases was additionally diagnosed and treated with 8 cycles of capecitabine due to its antitumor activity against both malignancies." | ( Debus, J; Fuxius, S; Giesel, FL; Haberkorn, U; Kratochwil, C; Lindner, T; Rathke, H, 2021) |
| "Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated." | ( Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M, 2021) |
| "The primary cause of colorectal cancer (CRC) recurrence is increased distant metastasis after radiotherapy, so there is a need for targeted therapeutic approaches to reduce the metastatic-relapse risk." | ( Kim, A; Kong, JS; Lee, H; Lee, SS, 2021) |
| "Tumor hypoxia is a common feature in colorectal cancer (CRC), and is associated with resistance to radiotherapy and chemotherapy." | ( Chen, CT; Guan, SS; Liao, TZ; Lin, KL; Liu, SH; Peng, CL; Shih, YH; Wang, YC; Weng, MF; Wu, CT; Yeh, CH, 2021) |
| "A total of 48 consecutive patients with colorectal cancer (CRC) with hepatic metastasis were retrospectively reviewed, and factors such as metastatic tumor vascular microenvironment, chemotherapy response and hepatic resection, were analyzed." | ( Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M, 2021) |
| "The complexity in colorectal cancer treatment leads to new research in combination therapy to overcome multidrug resistance in cancer and increase apoptosis." | ( Desai, D; Shende, P; Ture, N, 2021) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled." | ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021) |
| "Five-year survival rates for advanced colorectal cancer are still low, highlighting the need for novel targets in colorectal cancer therapy." | ( Arnold, C; Boengler, K; Brunner, T; Christmann, M; Demuth, P; Fahrer, J; Huber, M; Linnebacher, M; Rasenberger, B; Seiwert, N; Wittmann, S, 2022) |
| "To overcome this problem, patients with colorectal cancer are treated with chemotherapy for a short time, followed by a less aggressive maintenance regimen of the chemotherapy drug 5-fluorouracil and the targeted therapy drug bevacizumab." | ( Cui, K; Gurary, EB; Kim, TW; Lerman, N; Taieb, J; Yoshino, T, 2021) |
| "Chemotherapy as part of colorectal cancer management can cause death to immunologically active tumor cell, but also it has immune suppressive effect." | ( Riwanto, I; Tendean, M, 2021) |
| "Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated." | ( Dagenborg, VJ; Dueland, S; Flatmark, K; Goscinski, MA; Hofsli, E; Larsen, SG; Lund-Iversen, M; Sorbye, H; Steigen, SE; Torgunrud, A, 2022) |
| "Furthermore, AB4 treatment eliminated colorectal cancer stem cells by promoting apoptotic cell death in 5-FU resistant colorectal cancer cells." | ( Duan, XW; He, X; Hou, XL; Li, HQ; Liao, GB; Liu, W; Tang, J; Wang, JX; Yan, HZ; Yu, SY, 2021) |
| "Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event." | ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023) |
| "Microbial dysbiosis is a colorectal cancer (CRC) hallmark and contributes to inflammation, tumor growth, and therapy response." | ( Andren, A; Bell, HN; Das, NK; Fearon, ER; Goyert, J; Gygi, SP; Huang, W; Kerk, SA; Kuljanin, M; Lyssiotis, CA; Mancias, JD; Miller, SL; Rebernick, RJ; Shah, YM; Singhal, R; Solanki, S; Todd, PK, 2022) |
| "Most patients affected with colorectal cancers (CRC) are treated with 5-fluorouracil (5-FU)-based chemotherapy but its efficacy is often hampered by resistance mechanisms linked to tumor heterogeneity." | ( Bersuder, E; Brigand, C; Chenard, MP; Delhorme, JB; Duluc, I; Freund, JN; Gross, I; Martin, E; Rohr, S; Terciolo, C; Vlami, O, 2022) |
| "Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy." | ( Alonso-Marañón, J; Cantero-Recasens, G; Espinosa, L; Garrido, M; Iglesias, M; Lobo-Jarne, T; Malhotra, V, 2022) |
| "Several serious attempts to treat colorectal cancer have been made in recent decades." | ( Brunetti, O; Chamani, E; Derakhshani, A; Franchina, T; Gholipour, F; Hoshyar, R; Larki, P; Nomiri, S; Rezaei, Z; Safarpour, H; Salmani, F; Santarpia, M; Silvestris, N; Tabrizi, NJ; Tavakoli, T, 2022) |
| "Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival." | ( Boerma, D; Constantinides, A; de Hingh, IHJT; Elias, SG; Huitema, ADR; Koster, J; Kranenburg, O; Laoukili, J; Nienhuijs, SW; Raats, DAE; Rinkes, IHMB; van Grevenstein, HMU; van Schelven, SJ; van Wettum, J; Volckmann, R; Wassenaar, ECE; Wiezer, RJ, 2022) |
| "Effective treatment of colorectal cancer is important to improve the quality of life for patients, which however remains a great challenge in the clinic." | ( Chen, D; Chen, W; Li, Y; Su, L; Wu, S; Xu, C; Zhang, C; Zhang, Q, 2022) |
| "The treatment of colorectal cancer liver metastases has seen significant improvement in recent years and, for certain patients, the long-term survival and even cure are possible." | ( Naher, SK; Samoon, Z; Sjoquist, KM; Zalcberg, J, 2022) |
| "It is used for metastatic colorectal cancer (mCRC) treatment." | ( Alandağ, C; Karaman, E; Yüce, E, 2022) |
| "We investigated the medical records of colorectal cancer patients who received chemotherapy from 2015 to 2020." | ( Chang, WJ; Hyun, MH; Kim, JH; Kim, YH; Lee, S; Lim, AR; Park, JH; Park, KH, 2022) |
| "Patients with colorectal cancer (CRC) undergo surgery, as well as perioperative chemoradiation or adjuvant chemotherapy primarily based on the tumor-node- metastasis (TNM) cancer staging system." | ( Chang, PK; Chen, CY; Chou, YC; Hsu, CH; Hu, JM; Hu, PH; Lai, PY; Lin, HC; Lin, YJ; Su, JQ; Sun, CA; Wu, JJ; Yang, T, 2022) |
| "Most of Stage II/III colorectal cancer (CRC) patients can be cured by surgery alone, and only certain CRC patients benefit from adjuvant chemotherapy." | ( Jonnagaddala, J; Li, X; Xu, XS; Yang, S; Zhang, H, 2022) |
| "Patients with metastatic colorectal cancer who switched from capecitabine to S-1, given as monotherapy or in combination with other agents, were identified in a Dutch prospective cohort study (2016-2021)." | ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Chemotherapy resistance of colorectal cancer stem cells (CRC-SCs) has become a major challenge in clinical treatment of cancer." | ( Liu, C; Wang, JL; Wu, DZ; Xin, L; Yuan, YW, 2022) |
| "Monitoring the therapeutic response of colorectal cancer (CRC) patients is crucial to determine treatment strategies; therefore, we constructed a liquid biopsy-based approach for tracking tumor dynamics in non-metastatic (nmCRC) and metastatic (mCRC) patients (n = 55)." | ( Barták, BK; Dank, M; Fodor, T; Igaz, P; Kalmár, A; Molnár, B; Nagy, ZB; Szigeti, KA; Takács, I; Valcz, G; Zsigrai, S, 2022) |
| "iron treatment in surgical colorectal cancer (CRC) patients in clinical practice." | ( Knudsen, T; Kroijer, R; Ploug, M; Qvist, N, 2022) |
| "The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade." | ( Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG, 2022) |
| "Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil." | ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| "Among colorectal cancer (CRC) patients, pre-existing diabetes is suggested to influence poor prognosis, but the impact on adjuvant chemotherapy implementation is largely unknown." | ( Goto, A; Higashi, T; Imai, K; Inoue, K; Iwasaki, M; Kanehara, R; Katanoda, K; Kobayashi, S; Noda, M; Ohashi, K; Saito, E; Taguri, M; Watanabe, T, 2022) |
| "Understanding the mechanisms of colorectal cancer (CRC) progression is critical for developing innovative treatment strategies." | ( Deng, J; Han, L; Li, Y; Shi, J; Wang, H; Yan, Y; Zhao, H; Zhao, L; Zou, F, 2022) |
| "Chemoresistance is a main obstacle for colorectal cancer treatment." | ( Li, J; Liu, J; Liu, K; Luo, F, 2022) |
| "Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0." | ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022) |
| "More and more patients with advanced colorectal cancer (CRC) have benefited from surgical resection or ablation following neoadjuvant chemoradiotherapy (nCRT), but nCRT may be ineffective and have potential risks to some patients." | ( Ding, C; Dong, Z; Gong, B; Jin, S; Liu, S; Xie, W; Xu, C; Xu, L; Zhang, R; Zhao, Y; Zheng, Y, 2022) |
| "Survival of patients affected by colorectal cancer peritoneal metastases (CRC-PM) can be improved with combined complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | ( Brigand, C; Delhorme, JB; Diab, S; Liu, D; Rohr, S; Romain, B; Sauvinet, G; Séverac, F, 2022) |
| "Moreover, E2 fraction potentialized colorectal cancer cells to 5-FU treatment." | ( Borie, N; Chazee, L; Devarenne-Charpentier, E; El Btaouri, H; Hammami, M; Martiny, L; Remy, S; Renault, JH; Toumi, I; Yatouji, S, 2023) |
| "Despite advances in colorectal cancer (CRC) treatment, most advanced CRC patients who experience disease progression after chemotherapy, targeted therapy, and immunotherapy face a situation in which there is no available medicine." | ( Dong, H; He, L; Hu, L; Hu, Y; Liu, H; Shi, M; Su, Y; Tian, Y; Wang, C; Wang, H; Wen, C; Xiang, N; Yang, X, 2022) |
| "To optimize the pretreatment method of colorectal cancer tissue samples for metabolomics research based on solid-phase nuclear magnetic resonance (NMR)." | ( Deng, P; Han, Y; Huang, H; Jiang, H; Liang, H; Liu, H; Lu, CD; Peng, J; Wang, L; Wang, Y; Yang, G, 2022) |
| "We retrospectively investigated 167 colorectal cancer patients who had been treated with panitumumab for three cycles or more." | ( Aoyama, T; Ishikawa, H; Sato, J; Shikamura, Y; Shino, M; Tanaka, R, 2022) |
| "The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy." | ( Buchanan, CM; Deva, S; Kolekar, S; Shepherd, PR; Shih, JH; Tran, KB; Wang, Q, 2022) |
| "For patients with colorectal cancer, minimally invasive surgical methods, particularly laparoscopic methods, are now the preferred course of therapy." | ( Chen, Y; Xi, D; Zhang, Q, 2022) |
| "In treating colorectal cancer, surgical techniques and adjuvant treatments have advanced over the past century, but relatively less attention has been given to improve health-related quality of life (HRQOL)." | ( Choi, CM; Chung, S; Jo, MW; Kim, CW; Kim, H; Kim, JC; Kim, KW; Kim, YI; Ko, Y; Lee, HJ; Lee, JW; Lee, Y; Lim, SB; Park, IJ; Yoon, YS; Yu, CS; Yun, SC, 2022) |
| "We retrospectively analyzed data of 190 colorectal cancer patients who had undergone laparoscopic surgery between October 2020 and May 2021 at Samsung Medical Center, Seoul, Korea, with (n=74) or without intraoperative DEX (n=85) administration." | ( Ahn, HJ; Chung, YJ; Lee, JE; Lee, JY; Park, HJ; Sim, WS, 2022) |
| "A total of 178 patients with metastatic colorectal cancer (mCRC) and 87 patients with pancreatic cancer were treated with FOLFIRI, FOLFOX, FOLFOXIRI, modified FOLFIRINOX, or gemcitabine plus nab-paclitaxel." | ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "The outcomes of treatment of metastatic colorectal cancer (mCRC) is still unsatisfactory." | ( Hassan, MA; Khalil, KA; Mahmoud, IA; Musallam, HS, 2022) |
| "Four colorectal cancer patient derived xenograft (PDX) models were treated with AZD0156, irinotecan, or 5FU alone and in combination for assessment of tumor growth inhibition (TGI)." | ( Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW, 2022) |
| "A cohort of metastatic colorectal cancer patients 60 years or older who received treatment with regorafenib combined with PD-1 inhibitors was included in our analysis." | ( Chen, B; Chen, X; He, Y; Huang, J; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, H; Zhao, J, 2022) |
| "Ferroptosis is a promising colorectal cancer (CRC) treatment strategy; however, its value in prognosis remains at an exploratory stage." | ( Guo, J; Guo, S; Li, S; Liu, L; Zhang, T; Zhao, W, 2023) |
| "(2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6−9 months and >12 months." | ( Cao, X; Chen, X; Fan, J; Li, Z; Liu, Y; Luo, Y; Wang, X; Xie, P; Yu, Q, 2023) |
| "Increased colorectal cancer rates were seen for patients who received subdiaphragmatic radiation therapy (rate ratio [RR], 2." | ( Aleman, BMP; Aznar, MC; Cutter, DJ; Darby, SC; Geurts, YM; Janus, CPM; John, KM; Krol, ADG; Ntentas, G; Ramroth, J; Roberti, S; Roesink, JM; Schaapveld, M; Shakir, R; van der Maazen, RWM; van Leeuwen, FE; Zijlstra, JM, 2023) |
| "We report 2: Cases of advanced colorectal cancer that developed nephrotic syndrome after ramucirumab(RAM)administration." | ( Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H, 2022) |
| "LLR for liver metastasis of colorectal cancer can be safely performed at multiple sites or multiple times, and good treatment results have been obtained, so it was considered to be an effective treatment method." | ( Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y; Yanagisawa, K, 2022) |
| "We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine." | ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022) |
| "For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (p < 0." | ( Aizawa, F; Goda, M; Hamano, H; Ishida, S; Ishizawa, K; Izawa-Ishizawa, Y; Kajizono, M; Maruo, A; Niimura, T; Sakaguchi, S; Ushio, S; Yagi, K; Zamami, Y, 2023) |
| "The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years." | ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023) |
| "Not all RAS wild-type metastatic colorectal cancer (mCRC) patients experience the same benefit from anti-epidermal growth factor receptor (EGFR) treatments." | ( Araz, M; Artaç, M; Demirkıran, A; Demirkıran, D; Eryılmaz, MK; Karaağaç, M; Kılınç, F; Koçak, MZ; Korkmaz, M, 2023) |
| "In this study, colorectal cancer (CRC) cells were treated with either- a low sub-toxic dose (LD; 30 µM) or a ten times higher acute dose (HD; 300 µM) of cisplatin, and thereafter, the cellular response was mapped through RNA sequencing followed by transcriptomic analysis." | ( Chatterjee, S; Chowdhury, R; Chowdhury, S; Daiya, A; Dave, R; Mandloi, A; Mukherjee, S; Saini, H; Sharma, H, 2023) |
| "Outcomes in colorectal cancer treatment are historically worse in Black people and residents of rural areas." | ( Elmore, M; Nolan, N; Richmond, BK; Thompson, S; Tobin, EC, 2023) |
| "Moreover, TIMP-2 in colorectal cancer patient serum undergoing 5-Fu-based chemotherapy could indicate their drug resistance status, and its efficacy is higher than CEA and CA19-9." | ( Hu, G; Li, Y; Lu, Z; Shen, L; Tao, F; Tao, K; Xu, C; Zhang, G; Zhu, R, 2023) |
| "Advanced metastatic colorectal cancers (CRCs) are regarded as a challenge in clinical cancer therapy." | ( Du, B; Liu, X; Luan, X; Zhang, W; Zhuang, C, 2023) |
| "The high incidence and mortality of colorectal cancer (CRC) and the lack of adequate diagnostic molecules have led to poor treatment outcomes for colorectal cancer, making it particularly important to develop methods to obtain molecular with significant diagnostic effects." | ( Feng, S; Huang, K; Liu, B; Su, R; Wang, D; Xing, F; Zheng, R, 2023) |
| "vicina (AFPR) in treating colorectal cancer (CRC) and to further reveal its active ingredients and key targets." | ( He, JH; Lai, KD; Li, DM; Li, Y; Liu, LM; Liu, YC; Su, QB; Wang, B; Wei, DM; Wei, GN; Wei, J; Xie, JX; Zhu, FC, 2023) |
| "Generic oxaliplatin is widely used in colorectal cancer chemotherapy; however, studies on the adverse events of generic drugs are limited." | ( Fujita, Y; Fujiyama, J; Fukunaga, T; Tada, H; Tani, N; Watanabe, N, 2023) |
| "Precise and early screening of colorectal cancer (CRC) is one crucial yet challenging task for its treatment, and the analysis of multi-targets of CRC in a single assay with high accuracy is essential for pathological research and clinical diagnosis." | ( Chen, C; Chen, W; Hou, W; Kong, D; Li, T; Liu, C; Ma, Z; Mao, W; Shen, W; Tang, S; Yao, Y; Zhang, J, 2023) |
| "MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathological response to 5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy in LARC." | ( Caramés, C; Cristóbal, I; García-Foncillas, J; Luque, M; Madoz-Gúrpide, J; Rojo, F; Santos, A; Sanz-Álvarez, M, 2023) |
| "Untreated colorectal cancer cells outcompeted CD8+ T cells for tryptophan, leading to impaired CD8+ T-cell function." | ( Chen, H; Du, W; Hong, X; Huang, X; Su, W; Sun, D; Sun, T; Wang, J; Xiong, H; Yan, T; Yang, C; Yu, T; Zhou, C, 2023) |
| "38 patients with metastatic colorectal cancer are being selected in 6 centers in France, and will be followed for 2 regorafenib treatment cycles, or for approximately 56 days." | ( Artru, P; Arvis, P; Bourgeois, V; Coriat, R; Kremliovsky, M; Manfredi, S; Palma, MD; Sibaud, V; Trouilloud, I, 2023) |
| "This review discusses the treatment of colorectal cancer with conventional methods, highlighting the drawbacks of standard medicine and exploring innovative options based on the use of diatomite-based drug delivery systems." | ( De Stefano, L; Rea, I; Tramontano, C, 2023) |
| "The gold standard drug for colorectal cancer (CRC) treatment, 5-Fluorouracil (5-FU), induces pharmacological tolerance in long-term management." | ( Barredo-Vacchelli, GR; Birocco, AM; Blachman, A; Calabrese, GC; Camperi, SA; Cenci, G; Curcio, S; Gianvincenzo, PD; Moya, S; Rodriguez, JA; Sosnik, A, 2023) |
| "The standard of care for patients with colorectal cancer and liver metastases, who fail to respond to systemic chemotherapy has not yet been established." | ( Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Jimbo, R; Kobayashi, Y; Sano, T; Sato, R; Sato, T; Yokoyama, J, 2023) |
| "Forty-six patients with colorectal cancer and unresectable liver metastases, who received systemic chemotherapy beyond the third line at our hospital between July 2014 and April 2020 were analyzed." | ( Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Jimbo, R; Kobayashi, Y; Sano, T; Sato, R; Sato, T; Yokoyama, J, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "After that, the SW480 colorectal cancer cell line was treated with different concentrations of SM and the SM-Sn complex." | ( Abbasinia, H; Heshmati, M; Najjar, N; Sadeghi, H; Yousefi, M, 2023) |
| "The most common site of metastasis in colorectal cancer (CRC) is the liver and liver metastases occur in more than 50% of patients during diagnosis or treatment." | ( Cai, H; Cao, H; Fan, Z; Gao, Y; Huang, T; Liu, H; Pan, H; Rong, D; Sun, G; Tang, W; Wang, Y; Zhao, S, 2023) |
| "The incidence rate of colorectal cancer (CRC) has been increasing and poses severe threats to human health worldwide and developing effective treatment strategies remains an urgent task." | ( Chang, CH; Chen, GW; Hsieh, YH; Lee, TH; Lin, CL; Ong, AZ; Sun, WC; Wang, SW; Yeh, YH; Yu, CL, 2023) |
| "When used to the treatment of colorectal cancer, the BOS-CH-HSA-TPGS NPs show promise as a sustained-release therapy with improved therapeutic effects by addressing the challenges of poor solubility, poor permeability, and toxic side effects." | ( Bhattacharya, S; Hatware, K; Jain, A; Manthalkar, L; Phatak, N; Shah, D; Sreelaya, P, 2023) |
| "The incidence rate of colorectal cancer (CRC) has been increasing significantly in recent years, and it is urgent to develop novel drugs that have more effects for its treatment." | ( Cui, H; Dong, Z; Li, J; Liu, C; Lü, M; Shen, Y; Sun, W; Wang, Z; Yang, Y; Zhang, X; Zhu, Y, 2023) |
| "CPT-11 is one of the drugs employed in colorectal cancer treatment and has faced challenges in the form of resistance." | ( Chang, YC; Chen, MC; Ho, TJ; Hsieh, DJ; Huang, CY; Jassi, C; Kuo, CH; Kuo, WW; Li, CC; Wang, TF, 2023) |